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Daptomycin	 is	a	bactericidal	antibiotic	of	 last	 resort	 for	 serious	 infections	caused	by	methicillin-
resistant	Staphylococcus	aureus	(MRSA).	Although	resistance	is	rare,	treatment	failure	can	occur	in	
>20%	of	cases	and	so	there	is	a	pressing	need	to	identify	and	mitigate	factors	that	contribute	to	
poor	therapeutic	outcomes.	Work	described	 in	this	 thesis	 revealed	that	 loss	of	 the	Agr	quorum-
sensing	 system,	 which	 frequently	 occurs	 in	 clinical	 isolates,	 enhanced	 S.	 aureus	 survival	 during	
daptomycin	 treatment.	Wild-type	 S.	 aureus	 was	 killed	 rapidly	 by	 daptomycin	 but	 Agr-defective	
mutants	 survived	 antibiotic	 exposure	 by	 releasing	 membrane	 phospholipid,	 which	 bound	 and	
inactivated	 the	antibiotic.	Although	wild-type	bacteria	also	 released	phospholipid	 in	 response	 to	
daptomycin,	Agr-triggered	secretion	of	small	cytolytic	toxins,	known	as	phenol	soluble	modulins,	
prevented	antibiotic	inactivation.	Phospholipid	release	by	S.	aureus	occurred	via	an	active	process	
that	 appears	 to	 involve	 the	 VraUTRS	 regulon,	 and	 was	 inhibited	 by	 the	 β-lactam	 antibiotic	
oxacillin,	 which	 slowed	 inactivation	 of	 daptomycin	 and	 enhanced	 bacterial	 killing.	 Subsequent	
work	revealed	that	next-generation	lipid	biosynthesis	 inhibitors	completely	blocked	phospholipid	
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Sir	 Alexander	Ogston	 first	 discovered	 the	 bacterium	Staphylococcus	 aureus	 in	 the	 year	 1880	 by	
microscopic	examination	of	the	pus	from	an	abscess	that	formed	in	a	surgical	wound.	Because	this	





and	 characterised	 a	 pure	 culture	 of	 the	 bacterium.	 It	 was	 discovered	 that,	 although	 S.	 aureus	
preferentially	 grows	 via	 aerobic	 respiration,	 it	 is	 also	 a	 facultative	 anaerobe	 that	 can	 grow	 in	
anaerobic	 or	 microaerobic	 conditions3.	 Given	 its	 production	 of	 the	 carotenoid	 pigment	
staphyloxanthin,	 which	 resulted	 in	 golden	 colonies,	 Rosenbach	 revised	 the	 name	 of	 the	
staphylococci	species	as	Staphylococcus	aureus1,2.		
Based	 on	 taxonomic	 classification	 by	 16s	 rRNA	 sequences,	 S.	 aureus	 belongs	 to	 the	
firmicutes	 phylum,	 and	 the	Micrococcaceae	 family	 that	 includes	 all	 Gram-positive	 cocci,	 and	 is	
placed	 within	 the	 genus	 Bacillus-Lactobacillus-Streptococcus	 cluster4	 To	 date,	 128	 species	 of	 S.	




dominant	 lineages	 associated	with	 the	 colonisation	 and/or	 infection	of	 humans,	with	 additional	
lineages	linked	to	animal	infections7,8.	These	lineages	differ	in	the	presence	of	genes	that	encode	
regulators	 or	 virulence	 factors	 such	 as	 surface	proteins.	Approximately	 15-20%	of	 the	S.	 aureus	
genome	 consists	 of	 mobile	 genetic	 elements	 (MGEs),	 which	 are	 acquired	 by	 horizontal	 gene	
transfer9.	 MGEs	 are	 diverse	 and	 include	 pathogenicity	 islands,	 the	 staphylococcal	 cassette	
chromosome,	plasmids	and	transposons,	many	of	which	are	 important	contributors	of	antibiotic	
resistance	(e.g.	the	low-affinity	penicillin-binding	protein	PBP2a	encoded	by	the	mecA	gene),	host	




Because	of	 the	 thick	 peptidoglycan	 cell	wall	 and	 single	membrane,	S.	 aureus	 retains	 the	
Gram	 stain	 and	 is	 identified	 as	 a	 Gram-positive	 bacterium.	 S.	 aureus	 is	 spherical	 in	 shape	 and	
produces	 both	 catalase	 and	 coagulase,	 which	 is	 useful	 as	 a	 rapid	 diagnostic	 test3.	 Further	
diagnostic	approaches	exploit	the	ability	of	S.	aureus	to	grow	at	high	salt	concentrations,	enabling	
discrimination	 from	 other	 members	 of	 the	Micrococcaceae	 family.	 Diagnostic	 samples	 can	 be	
grown	on	mannitol	 salt	 agar	 (MSA)	plates10,	which	 contain	a	high	 (7.5%)	 salt	 concentration	and	







of	 peptidoglycan,	 lipoteichoic	 acids	 and	 wall	 teichoic	 acids,	 which	 are	 anchored	 to	 the	
phospholipid	membrane	 by	 diacylglycerol11	 and	 covalently	 anchored	 to	 the	 peptidoglycan	 layer	
respectively12	 (Fig	1.1).	Lipid	 II	 is	a	polyisoprenoid,	which	 is	anchored	 in	the	bacterial	membrane	
and	 is	 central	 to	 the	 assembly	 of	 peptidoglycan	 subunits	 on	 the	 cytoplasmic	 side	 of	 the	
membrane.	 Lipid	 II-linked	peptidoglycan	 precursors	 assemble	 at	 the	 division	 septa	 and	 form	an	
important	target	of	vancomycin13,14.	The	outermost	surface	of	many	strains	of	S.	aureus	is	coated	
with	a	polysaccharide	capsule14,15.		
The	 peptidoglycan	 consists	 of	 glycan	 chains	 composed	 of	 alternating	 amino	 sugars	
including	N-acetylglucosamine	and	N-acetylmuramic	acid.	Additionally,	stem	pentapeptides	(L-Ala-






S.	 aureus	 encodes	 4	 penicillin	 binding	 proteins	 (PBPs),	 of	 which	 PBP1,	 PBP2	 and	 PBP3	
belong	 to	 the	high	molecular	weight	 class	of	PBPs,	whereas	PBP4	belongs	 to	 the	 low-molecular	
weight	class	of	PBPs.	PBP1	has	a	transpeptidase	(TPase)	function	which	links	the	penultimate	D-Ala	
to	 a	 glycine	 acceptor	 in	 the	 nascent	 cell	 wall14,18.	 This	 mono-functional	 TPase	 is	 essential	 for	
		 24	
important	for	cell	division	and	survival.	PBP2	has	a	transglycosidase	(TGase)	function	which	 links	






charged	 D-alanine25.	 By	 contrast,	 LTAs	 are	 glycerol	 phosphate	 polymers	 linked	 to	 a	 glycolipid	
terminus	in	the	cytoplasmic	phospholipid	membrane25.	Teichoic	acids	are	involved	in	cell	division	
and	function	as	a	barrier	to	host	antimicrobial	peptides	and	antibiotics.	For	example,	the	positively	
charged	D-alanine	 residues	 of	 teichoic	 acids	 repel	 positively	 charged	 antimicrobial	 peptides26,27.	
WTAs	extend	beyond	 the	peptidoglycan	 layer,	whereas	 fully	 extended	 LTAs	may	not	be	 able	 to	
pass	the	peptidoglycan	layer12.		
The	 S.	 aureus	 cell	 membrane	 is	 composed	 of	 three	 major	 phospholipids:	
phosphatidylglycerol	(PG),	cardiolipin	(CL)	and	lysyl-PG	(LPG).	Both	PG	and	CL	have	a	net	negative	
charge	and	make	up	72.1%	±8.0	and	12.4%	±	6.5	of	the	total	quantity	of	membrane	phospholipids	
















present	 for	 >	 154	days;	 30%	of	 individuals	 are	 identified	 as	 intermittent	nasal	 carriers	where	S.	
aureus	 nasal	 colonization	 is	 present	 for	 approximately	 4-14	 days,	 and	 50%	 of	 individuals	 are	
identified	 as	 non-carriers	where	 S.	 aureus	nasal	 colonization	 is	 present	 for	 <	 4	 days.	 Persistent	
carriers	are	colonized	by	a	higher	load	of	S.	aureus,	which	often	results	in	a	higher	risk	of	acquiring	
infection	because	of	seeding	from	the	nasal	cavity29,31–36.			




between	 the	ages	of	9-19	years,	before	again	declining	during	adulthood29,31–35.	 The	 route	of	S.	
aureus	transmission	from	the	environment	to	the	anterior	nares	is	believed	to	occur	via	the	hand,	
which	 is	 the	main	 vector	 of	 transmission37.	 The	 source	 of	 S.	 aureus	 colonization	 in	 neonates	 is	
most	likely	due	to	transmission	from	the	mother29,31,34,37–39.	
The	 carriage	 state	 is	 dependent	on	multiple	host	 and	bacterial	 factors.	Host	 factors	 that	
have	 been	 shown	 to	 be	 associated	with	 higher	 carriage	 rate	 include	 ethnicity,	 age	 and	 specific	
patient	groups	such	as	those	with	diabetes	mellitus,	individuals	undergoing	haemodialysis	or	last	
stage	renal	dialysis,	those	infected	with	HIV	and	patients	with	S.	aureus	skin	infection.	
Bacterial	 factors	 that	 influence	 the	 rate	 of	 carriage	 include	 the	 cell	 surface	 associated	
bacterial	 ligands	 that	mediate	 attachment	 to	 receptors	 in	 the	 nasal	 niche29,31,40.	 Some	 of	 these	
ligands	 include	cell	wall	 teichoic	acid,	 lipoteichoic	acid	and	 fibronectin	binding	proteins	 that	are	
able	to	bind	to	the	glycoproteins	and	proteoglycans	found	on	host	epithelial	and	mucosal	surfaces	
29,31,33,34.	 In	 addition,	 clumping	 factor	 B	 enables	 bacterial	 adhesion	 to	 the	 squamous	 type	 of	
epithelial	cells	found	in	the	lining	of	the	respiratory	tract40,41.		
Although	carriage	is	asymptomatic,	persistent	carriers	are	more	likely	to	acquire	infections.	





While	S.	aureus	 is	primarily	a	commensal	organism	it	 is	also	a	very	versatile	pathogen3,43.	 	 It	can	
infect	a	 large	number	of	different	anatomical	 sites	and	cause	a	wide	range	of	different	 types	of	
infection,	 including	 skin	 and	 soft	 tissue	 infections	 (SSTIs),	 pneumonia,	 bacteremia,	 infective	
endocarditis	 (IE),	bone	and	joint	 infections	such	as	osteomyelitis	and	septic	arthritis,	and	central	
nervous	system	(CNS)	 infections	 including	meningitis	 (Fig	1.2)3,43,44,45.	These	 infections	can	range	
from	mild	and	superficial	to	invasive	and	life-threatening3,43,46,47.	
Skin	 is	 the	 first-line	 of	 defence	 against	 infection,	 providing	 a	 physical	 barrier	 to	 bacteria	
that	 prevents	 entry	 into	 deep	 tissues	 and	 dissemination	 to	 distal	 sites	 within	 the	 body44,46,48.	
However,	S.	aureus	 is	one	of	 the	 leading	causes	of	SSTIs,	which	 is	 the	most	 frequent	 form	of	S.	
aureus	 infection29,44,46,48.	 The	 clinical	 manifestations	 of	 SSTIs	 present	 in	 various	 forms,	 ranging	
from	 uncomplicated	 and	 superficial	 to	 complicated	 SSTIs	 that	 involve	 bacterial	 invasion	 of	 the	
deeper	 layers	of	 the	skin	and	underlying	soft	 tissues46.	Uncomplicated	SSTIs	are	cutaneous,	self-
limiting	and	can	be	resolved	effectively	by	the	primary	immune	defence	against	S.	aureus,	which	is	
the	 neutrophil	 (polymorphonuclear	 leukocyte)	 and	 without	 the	 need	 for	 antibiotic	
treatment44,46,48.	 These	 SSTIs	 are	 clinically	 presented	 as	 impetigo,	 which	 is	 more	 frequent	 in	
children,	furuncles	(boils)	and	folliculitis	(inflammation	of	the	skin	surrounding	the	hair	shaft).	The	
clinical	manifestation	of	 complicated	 SSTIs	 often	 includes	 large	 abscesses	 and/or	 cellulitis44,46,48.	
Abscesses	are	essentially	a	mixture	of	neutrophils,	host	cell	debris	and	bacteria	surrounded	by	a	












Complicated	 SSTI	 (cSSTI)	 can	 develop	 into	 necrotizing	 fasciitis,	 which	 is	 rare	 but	 life-
threatening.	 It	most	often	occurs	 in	middle-aged	patients	with	comorbidities	 including	diabetes,	
hepatitis	C,	AIDS	or	 intravenous	drug	users44,46,48.	 In	addition,	S.	aureus	SSTIs	can	cause	systemic	
manifestations	such	as	toxic-shock	syndrome	(TSS)	which	is	mediated	by	the	S.	aureus	toxin	toxic-
shock	 syndrome	 toxin-1	 (TSST-1),	 and	 Staphylococcal	 scalded	 skin	 syndrome	 (SSSS),	 which	 is	
mediated	by	S.	aureus	exfoliative	toxin	and	typically	occurs	in	very	young	children44,46,48.	
Although	 the	 skin	 provides	 a	 barrier	 to	 infection,	 S.	 aureus	 can	 exploit	 wounds	 or	
indwelling	medical	devices	as	an	access	point	to	the	deeper	tissues.	S.	aureus	is	highly	effective	at	
colonising	 the	 inert	 surfaces	 of	 indwelling	 medical	 devices	 including	 prosthetic	 heart	 valves,	
prosthetic	joints	and	intravenous	catheters,	which	typically	leads	to	the	formation	of	biofilms	that	
protect	 the	pathogen	from	host	 immune	defences	and	antibiotics49,50.	These	devices,	along	with	





infections	 are	 of	 an	 acute	 type,	 with	 a	 rapid	 onset	 of	 disease.	 Most	 superficial	 infections	 are	
successfully	 treated	 using	 antibiotic	 therapy	 and	 typically	 resolve	 within	 7	 days	 of	 onset52.	
However,	S.	aureus	 invasive	infections	can	take	on	a	persistent	course,	particularly	in	the	case	of	
osteomyelitis	or	IE52.	
The	 S.	 aureus	 strains	 that	 colonise	 wounds	 and	 catheters	 are	 most	 often	 derived	 from	
colonization	 sites	 such	 as	 the	 anterior	 nares	 and	 hands42.	 For	 example,	 frequent	 carriers	 of	 S.	
aureus	are	more	vulnerable	than	non-carriers	to	acquiring	S.	aureus	bacteremia	(SAB)42.	However,	






One	 of	 the	 most	 serious	 types	 of	 staphylococcal	 infections	 is	 bacteraemia,	 with	 S.	 aureus	
responsible	for	20	to	50	cases/100,000	population	per	year,	with	mortality	rates	between	16%	and	
30%51,52,54,55.	 One	 of	 the	 reasons	 for	 the	 high	mortality	 rate	 is	 that	 S.	 aureus	 bacteremia	 (SAB)	
frequently	 results	 in	bacterial	 seeding	 into	host	 tissues,	 leading	 to	a	diverse	 range	of	 secondary	
infections	 such	 as	 infective	 endocarditis	 (associated	 with	 4.3%	 -	 39%	 cases	 of	 SAB),	 vertebral	
osteomyelitis	 (10%	of	cases),	 septic	arthritis	 (24%	of	cases),	 tissue	abscesses	 (18%	of	cases)	and	




for	many	days.	Although,	 the	definition	of	persistent	bacteremia	varies,	 it	 is	 typically	defined	as	
the	 duration	 of	 bacteremia,	 which	 is	 greater	 than	 3	 or	 7	 days52.	 In	 addition	 to	 persistent	
bacteremia,	 there	 are	 other,	 longer	 lasting	 infections.	 For	 example,	 when	 an	 individual	 first	
develops	 osteomyelitis	 or	 a	 skin	 infection	 it	 is	 termed	 as	 acute	 infection.	 However,	 this	 can	
become	a	 persistent	 infection	 if	 it	 lasts	 for	more	 than	 7	 days,	 and	 chronic	 if	 it	 lasts	 for	 several	
weeks.	Recurrent	infections	are	defined	as	having	a	couple	or	more	episodes	of	severe	infections	
within	a	year.	
This	 phenomenon	 is	 important	 because	 the	 greater	 the	 duration	 of	 culture-positive	








Therefore,	 the	 timely	 administration	 of	 appropriate	 antibiotic	 therapy	 that	 sterilizes	 the	
bloodstream	 is	 essential	 in	 preventing	 or	 reducing	 the	 incidence	 of	 secondary	 infections	 and	
therefore	 mortality.	 This	 principle	 has	 been	 validated	 by	 several	 clinical	 studies,	 which	















the	 antibiotic	 susceptibility	 profile	 of	 the	 causative	 organism,	 antibiotics	 such	 as	 linezolid,	




by	 MRSA	 strains	 the	 empirical	 antibiotic	 treatment	 includes	 oral	 antibiotics	 such	 as	 TMP-SXT,	
clindamycin,	 tetracycline	 (doxycycline-minocycline)	 or	 linezolid,	 which	 is	 given	 for	 5-10	 days.	
However,	for	hospitalized	patients	with	more	serious	infections	antibiotics	including	vancomycin,	
daptomycin	or	 linezolid	are	given	 intravenously	 for	14	days66	 to	prevent	bacterial	dissemination	
into	the	bloodstream.		
Because	 many	 S.	 aureus	 can	 develop	 a	 persistent	 or	 relapsing	 course56,57,	 treatment	 is	
often	 given	 for	 several	 days	 or	 even	 weeks,	 particularly	 when	 infection	 involves	 MRSA	 strains	
resistant	 to	 first-choice	drugs.	 This	 is	 particularly	 true	 for	patients	with	osteomyelitis	 caused	by	
MRSA,	which	 are	 typically	 treated	with	 vancomycin	 or	 daptomycin	 for	 a	minimum	 of	 8	weeks.	
Where	 infection	has	already	developed	a	chronic	course,	an	additional	1-3	months	of	treatment	
































Penicillin	 G	 in	 1940	marked	 the	 beginning	 of	 the	 antibiotic	 era	 and	 dramatically	 improved	 the	
prognosis	of	patients	with	bacterial	infections73.		
Penicillin	 G	 (benzyl	 penicillin)	 was	 the	 first	 mass-produced	 β-lactam	 antibiotic,	 which	 is	
synthesised	by	the	members	of	the	Penicillium	genus	of	fungi	(P.	rubens)74,75.	The	β-lactam	ring	of	
Penicillin	 G	 is	 structurally	 similar	 to	 the	 terminal	 D-alanyl-D-alanine	 (D-Ala	 D-Ala)	 amino	 acid	
residues	of	the	peptidoglycan	precursors	N-acetylglucosamine	and	N-acetylmuramic	chains.	These	
peptidoglycan	precursors	are	cross-linked	by	transpeptidases	known	as	penicillin-binding	proteins	














hindrance76.	 However,	 as	 for	 Penicillin,	 resistance	 to	 methicillin	 emerged	 soon	 after	 its	
introduction,	giving	rise	to	strains	known	as	Methicillin-Resistant	S.	aureus	(MRSA)	(Fig	1.3).	Since	
then,	MRSA	has	become	a	global	concern,	with	a	recent	report	estimating	that	53	million	people	






the	 cause	 of	 methicillin	 resistance,	 which	 was	 not	 due	 to	 a	 β-lactamase80,85.	 Horizontal	 gene	
transfer	of	a	mobile	genetic	element	termed	Staphylococcal	Cassette	Chromosome	mec	(SCCmec),	
most	 likely	 from	 Staphylococcus	 sciuri	 or	 Staphylococcus	 fleuretti,	 to	 S.	 aureus	 conferred	
resistance	 towards	methicillin.	 The	 SCCmec	 element	 harbors	 the	mecA	 gene,	which	 encodes	 an	
alternative	 penicillin-binding	 protein	 known	 as	 2a	 (PBP2a)86.	 β-lactam	 antibiotics,	 including	
methicillin,	target	one	or	more	of	the	4	PBPs	produced	by	S.	aureus,	blocking	the	cross-linking	of	
the	peptidoglycan	chains	essential	for	cell	wall	synthesis.	However,	PBP2a	has	a	very	low	affinity	
for	 β-lactam	 antibiotics,	 enabling	 it	 to	 continue	 to	 function	 in	 the	 presence	 of	 the	
antibiotic72,76,80,87.	Whilst	 the	 emergence	 of	MRSA	was	 not	 recognized	 until	 the	 introduction	 of	









which	 harbor	 different	 combinations	 of	mec	 gene	 and	 ccr	 gene	 complexes	 and	 carry	 multiple	
genes	 conferring	 antibiotic	 resistance72,81,89,90.	 HA-MRSA	 strains	 are	 frequently	 isolated	 from	
patients	 who	 have	 a	 weakened	 immune	 system	 or	 other	 health	 problems	 including	 HIV	 and	
diabetes	 mellitus91.	 By	 contrast,	 the	 smaller	 type	 IV	 element	 is	 present	 in	 highly	 virulent	
community-associated	MRSA	 (CA-MRSA)	strains	such	as	USA300,	which	 infect	otherwise	healthy	
individuals92.	 It	 is	 thought	 that	 the	 smaller	 type	 IV	 element	mitigates	 the	 fitness	 costs	 seen	 in	















the	 growth	 of	 the	 bacterium,	 and	 is	 rapidly	 bactericidal101,102.	 S.	 aureus	 acquired	 resistance	 to	
gentamicin	 either	 by	 producing	 aminoglycoside-modifying	 enzymes103	 or,	 because	 gentamicin	
requires	 an	 electrochemical	 gradient	 to	 enter	 the	 cell	membrane	 and	 reach	 its	 target	 site104,	S.	


























the	 selection	 of	 the	 first	 vancomyin-resistant	 S.	 aureus	 (VRSA)	 isolate	 in	 2002.	 Resistance	 was	
mediated	by	the	acquisition	of	the	vanA	operon,	via	horizontal	gene	transfer	from	a	vancomycin	
resistant	Enterococcus	faecalis	(VRE)	strain14,118.	The	vanA	operon	encodes	an	alternative	terminal	
peptide	 D-Ala	 D-lac,	 which	 is	 not	 recognized	 by	 vancomycin	 and	 enables	 the	 cross-linking	 of	
peptidoglycan	precursors	and	the	synthesis	of	the	cell	wall80,119.	The	presence	of	vanA	enables	S.	






infections	 caused	 by	multi	 drug-resistant	MRSA	 and	 VISA	 strains28,120.	 It	 is	 the	 only	 lipopeptide	
antibiotic	used	clinically	and	was	approved	 for	 the	treatment	of	S.	aureus	bacteremia	and	right-









and	RNA,	 leading	 to	bacterial	 cell	 death	without	 lysis28,120,124,125,126,127.	 The	use	of	 daptomycin	 is	




Daptomycin	resistance	or	 'non-susceptibility'	has	been	 identified	sporadically	 in	S.	aureus	
and	typically	arises	during	treatment.	As	for	the	emergence	of	VISA,	acquisition	of	the	daptomycin	
non-susceptible	(DNS)	phenotype	arises	via	mutations	in	various	genes,	which	lead	to	a	small	but	
clinically	 significant	 increase	 in	MIC.	 The	 best	 characterized	 route	 to	 the	DNS	 phenotype	 is	 the	
acquisition	 of	 gain-of-function	mutations	 in	 the	multiple	 peptide	 resistance	 factor	 (mprF)	 gene,	
which	 encodes	 a	 phosphatidylglycerol	 lysyltransferase28,126,130–132.	 These	 mutations	 result	 in	
increased	 lysyl-phosphatidylglycerol	 content	 in	 the	 membrane.	 The	 mechanism	 by	 which	 this	
reduces	daptomycin	susceptibility	is	unclear	but	proposed	to	either	repel	the	antibiotic	or	stabilize	
the	membrane28,131–133.	An	additional	route	to	the	DNS	phenotype	is	via	mutations	that	result	 in	
increased	 expression	of	 the	dlt	 operon,	which	 results	 in	 the	 addition	of	D-alanine	 esters	 to	 the	
teichoic	 acids	 of	 the	 cell	 wall134.	 As	 for	 mprF	 mutations,	 it	 is	 not	 clear	 how	 this	 decreases	
susceptibility	 but	 it	 may	 involve	 repulsion	 of	 daptomycin	 by	 the	 positively-charged	 teichoic	
acids28,126,130–132.	 In	addition,	DNS	strains	exhibit	changes	 in	the	cytoplasmic	membrane,	cell	wall	
stress	stimulon	and	altered	membrane	potential,	all	of	which	have	been	hypothesized	to	reduce	
the	 ability	 of	 daptomycin	 to	 depolarize	 the	 membrane134,135.	 However,	 to	 date,	 no	 dedicated	
daptomycin	resistance	mechanism	has	been	identified	in	S.	aureus136.		
Although	the	DNS	phenotype	is	rare,	daptomycin	treatment	failure	occurs	in	up	to	30	%	of	
staphylococcal	 infections	 including	 cSSTI,	 right-sided	 infective	 endocarditis	 and	 osteomyelitis136.	













Calcium	 enables	 the	 negatively	 charged	 daptomycin	 to	 bind	 to	 the	 negatively	 charged	
phosphatidylglycerol	 and	 insert	 into	 the	 cell	 membrane	 of	 Gram-positive	 bacteria.	 Each	
daptomycin	 molecule	 binds	 to	 two	 calcium	 ions	 in	 successive	 steps	 during	 this	 binding	 and	
insertion	 process139.	 After	 insertion,	 the	 daptomycin-calcium	 complexes	 oligomerise	 in	 the	
membrane,	which	is	necessary	for	bactericidal	activity.	This	leads	to	changes	in	membrane	fluidity,	
formation	of	membrane	blebs	and	 is	 thought	to	 induce	the	formation	of	pores	consisting	of	6-8	
daptomycin	molecules,	 which	 in	 turn	 results	 in	 potassium	 ion	 efflux,	membrane	 depolarization	
and	bacterial	cell	death132.		
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factors,	 the	 expression	 of	 which	 are	 coordinated	 by	 a	 quorum-sensing	 system	 known	 as	 the	
Accessory	 gene	 regulator	 (Agr)140–142.	 It	 was	 first	 identified	 via	 a	 transposon	 screen,	 when	 a	
mutant	with	a	 transposon	 inserted	between	 the	purB	and	 ilv	 genes,	was	 found	 to	be	unable	 to	
produce	 toxins	 such	 as	 α-	 toxin	 (Hla),	 β-	 toxin	 (Hlb),	 γ-	 toxin	 (Hlg),	 toxic	 shock	 syndrome	 toxin	
(TSST-1),	 but	 had	 strong	 production	 of	 Staphylococcal	 protein	A	 (SpA)	when	 compared	 to	wild-
type	S.	aureus143.	
Soon	 after	 this,	 Peng	 et.	 al.	 (1988)	 characterised	 the	 Agr	 quorum-sensing	 system	 by	
identifying	 agrA,	which	 is	 the	 response	 regulator	 of	 the	 agr	 operon144.	 Thereafter,	 Janzon	 and	
Arvidson,	 (1990)	and	Novick	et	al.	 (1993)	 identified	genes	 that	are	 regulated	by	 the	agr	 operon	
including	 the	 hld	 gene	 which	 is	 embedded	 within	 the	 regulatory	 RNA	 component	 of	 the	 agr	





Together,	 the	 studies	 described	 above	 revealed	 that	 the	 Agr	 quorum-sensing	 system	 is	
encoded	by	the	agr	operon,	which	consists	of	two-divergent	promoters,	P2	and	P3	that	transcribe	
RNAII	 and	 RNAIII	 respectively	 (Fig	 1.5).	 RNAII	 encodes	 the	 quorum-sensing	 system	 and	 RNAIII	
comprises	 a	 regulatory	 RNA	 molecule,	 which	 is	 the	 primary	 effector	 of	 the	 system,	 and	 also	




signaling	 molecule,	 known	 as	 auto-inducing	 peptide	 (AIP).	 AgrD	 encodes	 a	 pro-peptide	 that	
contains	 a	 N-terminal	 amphipatic	 leader	 sequence	 that	 directs	 it	 to	 AgrB,	 which	 is	 a	
transmembrane	 bound	 endopeptidase	 protein	 (Fig	 1.5).	 The	 type	 I	 signal	 peptidase	 SpsB	 along	
with	 AgrB	 cleaves	 the	 N-terminal	 of	 the	 propeptide	 and	 the	 C-terminal	 of	 the	 propeptide	
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divergent promoters, P2 and P3; P2 comprises a 4-gene operon (agrBDCA) encoding the 
quorum-sensing circuit, which regulates expression of the regulatory RNA molecule 
(effector molecule) RNAIII from P3 [27] (Figure 1). 
 
Expression of RNAIII leads to the production of cytolytic toxins (e.g. α-haemolysin, δ-
haemolysin), leukocidins (e.g. Panton-Valentine leukocidin) and decreased surface protein 
(e.g. staphylococcal protein A and fibronectin-binding proteins A and B) expression. In 
addition, AgrA directly regulates expression of the Phenol soluble modulin class of 
cytolytic toxins, and >80 genes involved in metabolism [30–32].  
The transmembrane P2 product AgrB is required for processing of the propeptide 
AgrD to produce the quorum signal molecule, autoinducing peptide (AIP). The AIP 
molecule functions as a specific ligand for the corresponding sensor kinase AgrC. AgrC 
possesses an extracellular N-terminal domain and seven transmembrane domains. 
Binding of AIP induces a conformational change within the cytoplasmic helix that links the 
sensor and kinase domains of AgrC, enabling autophosphorylation. Together, AgrC and 
AgrA comprise a classical two component signal transduction system, where ligand bound 
AgrC phosphorylates and activates the DNA-binding response regulator AgrA [27]. 
Activated AgrA dimers bind to the agr intergenic region (agr-IR) between P2 and P3 and 
trigger expression from these promoters [27]. 
The agr operon is regulated by numerous other global regulators, which converge 




Figure	1.5.	Accessory	gene	 regulatory	quorum	sensing	 system	 regulates	 toxin	production	 in	S.	
aureus		
The	Agr	 operon	 controls	 the	 cell	 density-dependent	 virulence	 factor	 expression	 in	 S.	 aureus.	 In	
brief,	the	P2	promoter	encodes	the	production	of	the	signaling	molecule	AIP.	As	the	cell	density	
increases,	the	signaling	peptide	activates	the	AgrC-AgrA	two	component	signaling	system,	where	
the	 ligand	 bound	 AgrC	 phosphorylates	 and	 activat s	 the	 DNA-binding	 response	 regulator	 AgrA.	
Activated	AgrA	dimers	bind	to	the	agr	 intergenic	region	(agr-IR)	and	triggers	expression	from	P2	
and	 P3	 promoters.	 	 Expression	 of	 RNAIII	 leads	 to	 the	 production	 of	 cytolytic	 toxins	 (e.g.	 α-
haemolysin,	δ-	haemolysin),	leukocidins	(e.g.	Panton-Valentine	leukocidin)	and	decreased	surface	






formed	between	 the	 cysteine	 amino	acid	 and	 carboxyl	 group149.	 	 The	N-terminal	 tail	 of	 the	AIP	
molecule	 subsequently	binds	 to	and	activates	 the	histidine-kinase	of	 the	 transmembrane	bound	
AgrC142,148,149.	 AgrC	 possesses	 an	 extracellular	 N-terminal	 domain	 and	 seven	 transmembrane	
domains.	 Binding	 of	 AIP	 to	 the	 second-transmembrane	 loop	 induces	 a	 conformational	 change	
within	 the	 cytoplasmic	helix	 that	 links	 the	 sensor	 and	kinase	domains	of	AgrC.	 This	 enables	 the	
autophosphorylation	 of	 the	 histidine	 residue	 within	 the	 histidine-kinase	 domain	 of	 AgrC154,155.	
Subsequently,	 this	autophosphorylation	enables	 the	activation	and	dimerization	of	 the	 response	
regulator	 AgrA	 by	 the	 transfer	 of	 its	 phosphate	 group	 to	 the	 conserved	 aspartate	 amino	 acid	








phosphorylated	 AgrA	 binds	 to	 the	 agr-IR,	 driving	 increased	 transcription	 of	 agr,	 leading	 to	 an	
exponential	 increase	 in	 Agr	 activity165.	 In	 addition	 to	 driving	 the	 quorum-sensing	 circuit,	 the	
binding	 of	 phosphorylated	 AgrA	 to	 the	 agr-IR	 drives	 transcription	 from	 the	 agr-P3	 promoter,	
which	 leads	 to	 the	 production	 of	 the	 regulatory	 RNA	 molecule	 RNAIII,	 which	 also	 encodes	 δ-
toxin142,146,162.	
The	 RNAIII	 transcript	 is	 514	 nucleotides	 in	 length	 and	 contains	 14	 hairpins,	 and	 3	 other	




that	 are	 required	 to	 initiate	 translation146,166,167.	 For	 example,	 the	 production	 of	 α-haemolysin	
(Hla)	is	dependent	upon	the	binding	of	the	5’	region	of	RNAIII	to	the	hla	mRNA,	which	relieves	a	






production	 of	 cytolytic	 toxins	 that	 are	 required	 to	 release	 nutrients	 and	 destroy	 host	 immune	
cells.	 However,	 although	 RNAIII	 is	 the	 principal	 effector	molecule	 of	 the	 Agr	 system,	 AgrA	 also	
contributes	to	the	phenotype	of	the	cell	by	directly	triggering	the	expression	of	a	small	group	of	
cytolytic	 toxins	 known	 as	 the	 phenol	 soluble	 modulins	 (PSMs)	 by	 binding	 to	 their	 promoter	




IV.	 Each	 type	 produces	 a	 different	 AIP	 molecule	 (AIP1-4)172.	 Depending	 on	 the	 combination,	
mismatched	 AIP	 and	 AgrC	 types	 can	 result	 in	 inhibition	 of	 Agr	 activity	 or	 only	 weak	
activation167,172.	 This	 is	because	binding	of	 the	 cognate	AIP	 to	AgrC	 induces	a	 counter-clockwise	




The	 regulation	 of	 virulence	 factor	 expression	 via	 a	 quorum-sensing	 system	 enables	 S.	
aureus	to	produce	the	required	virulence	factors	at	the	optimal	point	in	infection,	and	across	the	
whole	population.	This	 is	 important	because	 the	production	of	virulence	 factors	 is	metabolically	
costly	and	may	be	counter-productive	if	toxins	or	proteases	are	produced	at	inappropriate	stages	
of	 infection	or	 in	a	heterogeneous	manner.	For	example,	during	 the	earliest	 stages	of	 infection,	
when	there	are	few	S.	aureus	cells,	and	Agr	activity	 is	 low,	surface	proteins	are	produced.	These	
enable	 bacterial	 adhesion	 to	 host	 surfaces	 or	 indwelling	 medical	 devices,	 and	 support	 biofilm	
formation.	 Some	 of	 these	 surface	 proteins,	 such	 as	 protein	 A,	 also	 enable	 evasion	 of	 the	 host	
immune	response174,49.	However,	once	colonization	 is	established,	the	staphylococcal	population	
starts	to	replicate,	leading	to	an	increase	in	cell	density	and	Agr	activity175.	This	results	in	the	loss	
of	 surface	 proteins	 and	 the	 expression	 of	 toxins	 and	 proteases	 that	 liberate	 nutrients	 from	 the	
host,	 enable	biofilm	dispersal,	 tissue	 spread	and	 the	production	of	 leukocidins	 that	 kill	 immune	
cells142,167,176,177,178,179.		
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Whilst	 quorum-sensing	 systems	 primarily	 reflect	 population	 density,	 Agr	 also	 enables	 S.	
aureus	to	detect	enclosure	within	the	phagosome	of	neutrophils	or	other	immune	cells	by	acting	
as	a	diffusion	sensing	system180,181.	Once	within	a	phagocytic	vacuole,	Agr	expression	is	activated	




PSMs,	 Luk	 AB/GH	 and	 LukED	 toxins178,190–193.	 In	 addition,	 due	 to	 nutrient	 limitation	 within	 a	
phagosome	 the	 stringent	 response	 is	 trigerred,	which	 then	 leads	 to	 the	 expression	 of	 PSMs192.	
These	 toxins	 lyse	 the	 neutrophils,	 which	 then	 enables	 S.	 aureus	 to	 escape.	 However,	 the	
mechanism	by	which	these	toxins	lyse	the	neutrophils	from	inside	is	yet	unknown.	There	are	two	
proposed	 hypothesis,	 (i)	 bacteria	 lyse	 the	 phagosome	 and	 then	 lyse	 the	 cell193	 and	 (ii)	 the	
production	of	toxins	induces	programmed	cell	death	of	the	neutrophil194.		
The	 contribution	 of	 Agr	 quorum-sensing	 to	 pathogenesis	 and	 the	 establishment,	 and	
progression	 of	 various	S.	 aureus	 infections,	 including	 SSTIs,	 bacteremia,	 IE,	 osteomyelitis,	 septic	
arthritis,	 abscess	 formation	 and	 pneumonia	 has	 been	 demonstrated	 in	 several	 in	 vivo	 animal	
infection	models164,195–201	(as	will	be	described	in	section	1.7	and	table	1.1).	
1.5.1 Regulation	of	the	Agr	system	by	other	transcription	factors	
Whilst	Agr	enables	S.	aureus	 to	 regulate	virulence	 factor	production	 in	a	cell	density	dependent	
manner142,	the	system	is	fine-tuned	via	regulatory	control	by	several	two-component	systems	that	
detect	and	 respond	 to	diverse	environmental	 stimuli142,167,202–204.	 These	 regulators	 can	 influence	
Agr	 either	 by	 binding	 directly	 to	 the	 agr-IR	 or	 indirectly	 by	 modulating	 the	 activity	 of	 other	
regulators	do	bind	directly	to	the	agr-IR202–204.	To	date,	the	global	regulators	CodY,	SrrA,	SarX	and	
SarR	have	been	shown	to	bind	directly	to	the	agr-IR	and	repress	the	expression	of	the	agr	operon	
whereas,	 Rsp,	 SarA,	 MgrA	 and	 SarZ	 bind	 directly	 to	 the	 agr-IR	 and	 activate	 agr	 transcription.	
However,	 several	 of	 these	 regulators	 also	 modulate	 the	 staphylococcal	 phenotype	 by	 directly	








which	 repress	Agr	activity,	whilst	 SarU,	 SarV,	ArlR,	CcpA,	ClpXP	and	CvfA	 indirectly	enhance	agr	




S.	 aureus	 expresses	 20	 different	 surface	 proteins,	 which	 are	 typically	 secreted	 by	 the	 Sec	
translocon	and	covalently	linked	to	the	peptidoglycan	cell	wall	by	the	sortase	enzyme	that	cleaves	
and	 anchors	 the	 proteins	 via	 the	 LPXTG	motif49,208–211	 (Fig	 1.6).	 Several	 belong	 to	 the	microbial	
surface	components	recognizing	adhesive	matrix	molecules	(MSCRAMM)	family	of	proteins212,213.	
However,	 although	 the	S.	 aureus	 cell-surface	MSCRAMM	proteins	 are	 tethered	 to	 the	 cell	wall,	
several	other	adhesins	are	decorated	on	and/or	secreted	from	the	cell	surface	and	are	termed	as	
secreted	 expanded	 repertoire	 adhesive	 molecules	 (SERAM).	 Examples	 from	 the	 SERAM	 family	
include	extracellular	fibrinogen	binding	(Efb),	extracellular	matrix	binding	(Emb)	and	extracellular	




evasion	 (as	 described	 in	 section	 1.6.1)	 and/or	 biofilm	 formation,	 which	 is	 associated	 with	
persistent	 infections49.	 A	 good	 example	 of	 this	 are	 the	 fibronectin-binding	 proteins	 A	 and	 B	
(FnBPA/B),	which	mediate	adhesion	of	S.	aureus	to	fibronectin,	fibrinogen	and	elastin,	some	or	all	
of	 which	 are	 exposed	 in	 surgical	 wounds,	 coat	 implanted	 medical	 devices	 and	 line	 the	
endothelium214–218,219,220.	 The	 engagement	 of	 fibronectin	 on	 host	 cell	 surfaces	 by	 FnBPA	 and/or	
FnBPB	 results	 in	 the	 clustering	 of	 α5β1	 integrins,	 triggering	 a	 signaling	 cascade,	 actin	
rearrangement	 and	 uptake	 of	 the	 bacterium	 into	 a	 vacuole219,221.	 Once	 inside	 the	 host	 cell,	 S.	
aureus	 can	 persist,	 protected	 from	 antibiotics	 and	 immune	 surveillance222–228.	 	 Alternatively,	 S.	
aureus	releases	cytolytic	toxins	via	Agr	activation,	leading	to	apoptosis	and	death	of	the	host	cell,	
which	 may	 contribute	 to	 bacterial	 dissemination	 216,229,222,223,230.	 For	 staphylococci	 attached	 to	






























glucose	promotes	proteinaceous	biofilms,	whilst	 salt	 stress	 leads	 to	biofilms	containing	PIA.	The	
polysaccharide	PIA	is	positively	charged,	which	then	enables	S.	aureus	to	adhere	to	inert	surfaces	
237,238,239.		
In	addition	 to	 infection,	 several	 surface	proteins	are	also	 required	 for	nasal	 colonization,	
including	 ClfB,	 SasG,	 iron-regulated	 surface	 determinant	 A	 (IsdA),	 serine-aspartate	 repeat-
containing	 protein	 E	 (SdrE),	 as	 well	 as	 wall-teichoic	 acid	 (WTA)240–243.	 IsdA	 not	 only	 adheres	 to	
epithelial	cells,	it	also	binds	to	haemoglobin,	extracts	and	transports	haem	across	the	cell	wall	and	
membrane	and	then	into	the	cytoplasm	where	haemoxygenases	releases	the	iron49,244,245.	





complement	 system49,247,248.	 During	 S.	 aureus	 infection	 fibrinogen	 is	 deposited	 at	 the	 site	 of	
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infection	to	immobilize	the	microbes.	The	cell-surface	associated	protein	ClfA	evades	this	immune	




thrombin,	disrupting	complement	activation	and	 thereby	 reducing	 the	opsonophagocytosis	of	S.	
aureus253,49,254.	 Therefore	 both	 ClfA	 and	 SdrE	 contribute	 to	 immune	 evasion	 by	 disrupting	
complement	activation.	
In	addition	 to	 the	multi-functional	nature	of	many	surface	proteins,	 there	 is	also	a	 lot	of	
functional	 redundancy	 with	 several	 different	 proteins	 binding	 to	 the	 same	 host	 proteins	 or	
contributing	 to	 the	same	function	 (Fig	1.6).	For	example,	both	FnBPs	and	ClfA/B	bind	 fibrinogen	
enabling	 the	 colonization	 of	 wounds	 and	 cardiac	 vegetations,	 leading	 to	 SSTIs	 and	 infective	
endocarditis	respectively216,229.	Fibrinogen	is	also	bound	by	the	secreted	adhesin	Eap,	which	also	
binds	 fibronectin,	 vitronectin,	 prothrombin	 and	 ICAM-1211.	 Eap	 also	 triggers	 TNFα	 release	 from	
immune	cells,	which,	 in	turn,	enhances	the	adhesion	of	S.	aureus	 to	endothelial	cells	via	the	cell	
surface	associate	protein	SpA255.	
By	 contrast	 to	 fibrinogen,	 S.	 aureus	 encodes	 a	 single	 cell-surface	 protein	 that	 binds	
collagen-rich	tissue,	known	as	the	collagen	adhesin	(Cna),	which	was	associated	with	virulence	in	a	










system,	 prevention	 of	 phagocytosis	 and	 neutrophil	 killing.	 During	 invasion	 and	 replication	 of	 S.	
aureus	 in	 host	 tissues,	 the	 bacteria	 release	 products	 including	 lipoproteins,	 peptidoglycan	 and	
formyl-peptides	 that	 act	 to	 produce	 inflamatory	 signals	 (chemoattractants	 and	 cytokines)	 and	
recruit	 immune	cells186,260.	However,	S.	aureus	subverts	neutrophil	extravasation	and	chemotaxis	
by	 secreting	 staphylococcal	 superantigen-like	 proteins	 (SSL)	 which	 bind	 to	 various	 neutrophil	
receptors	and	disrupt	their	function260.	For	example,	SSL3	binds	to	TLR-2	and	blocks	immune	cell	
recognition	 of	 S.	 aureus	 lipoproteins261,262.	 In	 addition,	 formyl-peptide	 receptor-like	 1	 inhibitor	
(FLIPr)	 and	 formyl-peptide	 receptor-like	 1	 inhibitor-like	 (FLIPrL)	 bind	 and	 inhibit	 the	 neutrophil	




Complement	 activation	 and	 phagocytosis	 is	 a	 central	 component	 of	 the	 innate	 host	
defence	 system.	 Complement	 is	 composed	 of	 >30	 proteins	 and	 is	 activated	 by	 three	 pathways	
including	classical,	lectin	and	alternative	pathway.	All	the	three	routes	converge	in	the	assembly	of	
the	 C3	 convertase	which	 cleaves	 C3	 into	 C3a	 and	C3b266.	 C3b	 covalently	 binds	 to	 the	S.	 aureus	
surface	and	C3a	is	released	as	a	chemoattractant	for	phagocytes.	This	deposition	of	complement	
components	 on	 the	 surface	 of	 S.	 aureus	 is	 known	 as	 opsonisation	 and	 is	 required	 to	 promote	
recognition,	 phagocytosis	 and	 subsequent	 killing	 by	 host	 phagocytes260,266.	 S.	 aureus	 is	 able	 to	
block	 this	 by	 secreting	 inhibitory	 factors	 that	 interfere	 with	 the	 opsonisation	 of	 bacteria.	 For	
example,	 SSL10	 sequesters	 immunoglobulins	 to	 block	 their	 ability	 to	 promote	 complement	
activation	 i.e.	 SSL10	blocks	 IgG1	 from	binding	 to	 Fcγ	 receptor	of	 professional	 phagocytes	which	
results	 in	 the	 inhibition	 of	 phagocytosis	 of	 IgG1-opsonised	 S.	 aureus	 by	 immune	 cells	 267,268.	
Meanwhile,	 the	 Staphylococcal	 binder	 of	 immunoglobulin	 (Sbi)	 blocks	 the	 complement	 classical	
pathway	 activation	 by	 interfereing	 with	 C1q	 binding	 to	 immunoglobulin	 and	 thus	 evading	
opsonophagocytosis269,270.	 Staphylococcal	 complement	 inhibitor	 (SCIN)	 blocks	 all	 three	




factor	 C3,	 which	 compromises	 opsonisation	 because	 the	 cleavage	 product	 C3b’	 and	 C3a’	 are	
inactive	 and	 are	 degraded	 by	 host	 proteins272–274.	 S.	 aureus	 is	 also	 able	 to	 inactivate	 the	
complement	factor	C3b	and	IgG	molecules	that	are	bound	to	the	surface	of	opsonised	cells	that	





immune	 evasion	 by	 not	 eliciting	 the	 adaptive	 immune	 response	 as	 the	 binding	 prevents	
opsonisation	 and	 phagocytosis	 of	 S.	 aureus	 277.	 Also,	 as	 mentioned	 previously	 cell-surface	
associated	proteins	 including	BbP	and	SdrE	evade	 the	 immune	 response	by	bind	 to	C4b	binding	
protein	and	Factor	H	and	prevent	the	activation	of	the	complement	system	246.		
Despite	 these	 myriad	 of	 immune	 evasion	 system,	 S.	 aureus	 is	 often	 phagocytosed	 by	
neutrophils,	 where	 it	 is	 killed	 and	 degraded	 by	 various	 toxic	 products	 including	 ROS	 such	 as	
hydrogen	 peroxide	 and	 superoxide,	 proteases	 and	 antimicrobial	 peptides186,260.	 However,	 S.	
aureus	 is	 able	 to	 resist	 neutrophil-killing	 by	 expressing	 several	 enzymes	 and	 inhibitors.	 For	
example,	 the	 S.	 aureus	 synthesised	 carotenoid	 pigment	 staphyloxanthin,	 along	 with	 catalase	
(KatG)	 and	 alkylhydroperoxide	 reductase	 (AhpC),	 provides	 resistance	 to	 ROS278,279.	 Similarly,	
superoxide	 dismutases	 (SodA	 and	 SodM)	 are	 antioxidants	 that	 protect	 against	 oxidative	 stress	
caused	 by	 superoxides280.	 S.	 aureus	 is	 also	 able	 to	 resist	 killing	 by	 antimicrobial	 peptides	 by	
secreting	 Aur	 which	 cleaves	 the	 peptides,	 and	 by	 modyfying	 phosphatidylglycerol	 in	 the	
membrane	 with	 lysine,	 or	 promoting	 the	 D-alanylation	 of	 teichoic	 acids,	 which	 neutralizes	 the	
negative	charge	of	the	cell	surface	that	attracts	cationic	antimicrobial	peptides26,260,281.	
Typically,	S.	aureus	invasion	of	host	tissues	triggers	the	infiltration	of	neutrophils	at	the	site	
of	 the	 lesion.	 This	 causes	 the	 neutrophils	 to	 release	 their	 DNA	 commonly	 known	 as	 NETs	






One	of	the	most	 important	mechanisms	of	 immune	evasion	that	S.	aureus	deploys	 is	 the	
multifunctional	 surface	protein	known	as	SpA.	Because	SpA	binds	 to	 immunoglobulin	molecules	
including	 IgG,	 IgA,	 IgD,	 IgM	and	IgE	with	high	affinity	and	other	 ligands	 including	TNF	receptor	1	
(TNFR1)	 and	von	Willebrand	 factor	 (VWF),	 it	 is	 able	 to	display	a	number	of	 immunosuppressive	
traits260,284,285.	 In	 particular,	 SpA	 binds	 to	 the	 Fc	 fragment,	 which	 results	 in	 the	 bacteria	 being	
coated	with	 IgG	molecules	 that	 are	 bound	 in	 the	 incorrect	 orientation	 to	 be	 recognised	 by	 the	
neutrophil	Fc	receptor260,285,286.	This	interaction	between	SpA	and	IgG	also		prevents	the	activation	
of	the	complement	system	via	the	classical	pathway	which	leads	to	the	evasion	of	phagocytosis	by	




In	 addition	 to	 expressing	numerous	 cell-surface	 associated	proteins,	S.	 aureus	 also	 produces	 an	
even	 greater	 number	 of	 different	 secreted	 virulence	 factors,	 including	 haemolysins,	 cytolysins,	
leukocidins,	 exfoliative	 toxins	 and	 superantigens,	 in	 addition	 to	 secreted	 lipases,	 proteases,	
nucleases	 and	 coagulase	 that	 lyse	 host	 cells,	 enable	 bacterial	 dissemination,	 degrade	 host	
macromolecules,	liberate	nutrients	and	dysregulate	the	immune	system		(Fig	1.7)287–289.		
As	 described	 in	 section	 1.5,	 the	 vast	 majority	 of	 these	 secreted	 virulence	 factors	 are	
regulated	 by	 RNAIII158.	 However,	 the	 precise	 array	 of	 toxins	 expressed	 and	 the	 quantities	
produced	 is	 typically	dependent	on	 the	 type	of	S.	aureus	 strain.	 For	example,	CA-MRSA	 isolates	
have	increased	expression	of	Agr	and	thus	elevated	levels	of	secreted	toxin	production	relative	to	
HA-MRSA	isolates	with	large	type	I-III	SCCmec	elements.	CA-MRSA	isolates	are	also	associated	with	
the	 expression	 of	 the	 Panton	 Valentine	 Leukocidin	 (PVL),	which	 is	 typically	 absent	 in	 HA-MRSA	











As	 described	 above	 for	 surface	 proteins,	 the	 secreted	 virulence	 factors	 of	 S.	 aureus	 are	 often	
multifunctional	or	exert	their	effects	on	multiple	targets.	This	is	exemplified	by	α-haemolysin	(Hla),	





Hla	was	 identified	via	 the	 isolation	of	a	 transposon	mutant	 that	 lacked	the	ability	 to	 lyse	
red	blood	cells	when	grown	on	Colombia	blood	agar	containing	erythrocytes	from	rabbits306.	This	
toxin	 lyses	 rabbit	 erythrocytes	 at	 nM	 concentrations	 and	 human	 erythrocytes	 at	 μM	
concentrations	of	protein296,307,308.	Hla	exists	as	a	33	kDa	monomer,	until	it	binds	to	the	membrane	
of	 specific	 host	 cells,	 at	 which	 point	 it	 oligomerises	 and	 forms	 a	 14	 Å	 beta-barrel	 heptameric	
pore307,309.	 This	 pore	 disrupts	membrane	 organization,	 leading	 to	 potassium	 ion	 efflux,	 calcium	
influx,	membrane	depolarization,	and	cell	death310–313.	In	addition	to	the	host	cell	membrane,	Hla	
can	also	bind	to	ADAM10	receptors	 in	the	membranes	of	epithelial	cells.	ADAM10	is	responsible	
for	 maintaining	 cell-cell	 adhesion314.	 However,	 the	 binding	 of	 Hla	 to	 ADAM10,	 leads	 to	 the	
cleavage	of	E-cadherin,	resulting	in	degradation	of	the	adhesion	junctions	and	finally	detachment	
of	the	basal	membrane,	which	separates	the	epithelium	from	the	underlying	connective	tissues314.	




The	 β-haemolysin	 (Hlb)	 toxin	 is	 a	 sphingomyelinase	 that	 degrades	 the	 sphingomyelin	 in	






more	 important	 for	 infections	 in	 animals	 since	 many	 human	 isolates,	 including	 the	 CA-MRSA	
USA300	lineage	have	a	prophage	(ΦSa3)	inserted	with	the	hlb	gene,	that	results	in	complete	loss	
of	 expression	of	 the	 toxin289,315,319–321,322–324.	However,	 exposure	 to	oxidative	or	 other	 genotoxic	
stresses	may	 trigger	 loss	of	 the	phage	ΦSa3	and	enable	S.	aureus	 to	produce	a	 functional	 toxin	







toxins	 (β1	 and	 β2),	 which	 are	 44	 amino	 acids	 long	 and	 negatively	 charged.	 PSM-Mec,	 which	 is	
encoded	on	type	II,	III	or	VIII	SCCmec	elements,	is	most	similar	to	PSMα.	However,	although	PSM-
Mec	 is	 positively	 regulated	 by	 the	 Agr	 quorum-sensing	 system,	 the	 binding	 of	 the	 activated	
response	regulator	AgrA	to	the	promoter	sequence	upstream	of	 the	psm-mec	promoter	has	not	
been	directly	demonstrated328,158.	By	contrast	to	the	other	PSMs,	psm-mec	RNA	binds	specifically	









As	 described	 above,	 the	 key	 host	 defence	 against	 S.	 aureus	 is	 the	 neutrophil,	 which	
phagocytosis	 S.	 aureus	 and	 exposes	 it	 to	 a	 cocktail	 of	 reactive	 oxygen	 species,	 antimicrobial	
peptides	 and	 enzymes.	 PSMs	 have	 a	 formylated	 methionine,	 which	 is	 detected	 by	 the	 formyl	
peptide	receptor	on	the	surface	of	neutrophils,	leading	to	an	inflammatory	response.	However,	as	
described	previously,	the	Agr	system	enables	S.	aureus	to	detect	enclosure	within	the	phagocytic	
vacuole.	 This	 triggers	 the	 expression	 of	 PSMs,	 which	 lyse	 the	 phagocytic	 vacuole	 and	 enable	
bacterial	 survival176,294.	 The	 production	 of	 PSMs	 contributes	 to	 the	 initiation	 and	progression	 of	
SSTIs	and	bacteremia	as	shown	in	animal	models	of	these	infections294.		
In	 addition	 to	 pathogenesis,	 the	 pronounced	 amphipathic	 nature	 of	 PSMs	 gives	 these	
peptides	a	characteristic	surfactant-like	property,	which	enables	the	toxins	to	structure	biofilms.	S.	







from	 biofilms176,177.	 This	 dispersal	 of	 biofilms	 by	 PSMs	 appears	 to	 be	 a	 key	 mechanism	 of	 the	
systemic	dissemination	of	biofilm	infections176,332.	In	addition,	it	has	been	reported	that	PSMs	can	





Human	 isolates	of	 S.	 aureus	 produce	5	different	 types	of	 bi-component	 leukocidins,	 including	2	
forms	of	γ-haemolysin	(HlgAB	and	HlgCB),	PVL,	LukED	and	LukAB/GH.	By	contrast,	animal	isolates	
produce	 a	 single	 bi-component	 leukocidin	 known	 as	 LukMF’178,190,335,336.	 Leukocidins	 function	 as	
receptor-mediated	 toxins	 that	 lyse	 several	 different	 types	 of	 leukocytes	 including	 monocytes,	
macrophages	and	neutrophils	by	forming	beta-barrel	pores	 in	the	cell	membrane190	 	 (Table	1.1).	
Each	leukocidin	is	composed	of	2	components:	the	class	F	component	and	the	class	S	component.	
HlgB,	LukF,	LukD,	LukF’	and	LukA/G	belong	to	the	F	component	class	and	HlgA,	HlgC,	LukS,	LukM,	
LukE,	 LukB/H	 belong	 to	 the	 S	 component	 family288.	 Both	 components	 are	 required	 to	 lyse	 the	
targets	 cells	 and	 function	most	 effectively	when	 the	 S-	 and	F-components	 combine	within	 their	





the	 leukocidins	 during	 S.	 aureus	 infection	 has	 been	 difficult	 to	 assess	 using	 animal	 models	 of	
infection.	 For	 example,	 the	 PVL	 and	 LukAB/GH	 toxins	 are	 capable	 of	 lysing	 human	 and	 rabbit	
target	cells	but	not	mice179,342.	Therefore,	 studies	 in	mice	do	not	 reflect	 the	 function	of	 the	PVL	
toxins	in	humans.	Furthermore,	because	the	production	of	leukocidins	is	very	much	dependent	on	




































































Many	 staphylococcal	 infections	 are	 believed	 to	 be	 facilitated	 by	 a	 combination	 of	 different	
cytolytic	 toxins.	 However,	 S.	 aureus	 also	 produces	 several	 toxins	 that	 are	 associated	 with	 very	
specific	conditions.	A	clear	example	of	this	is	the	TSST-1	toxin.	Typically,	foreign	antigens	that	are	
processed	 and	 presented	within	major	 histocompatibility	 complex	 (MHC)	 class	 II	molecules	 are	
presented	 to	 T	 cells.	 Upon	 interaction	with	 the	 T	 cell	 receptor	 (TCR),	 the	 T-cells	 are	 activated,	
releasing	 cytokines	 and	 replicating178.	 However,	 superantigens	 such	 as	 TSST-1	 bind	 to	 the	 Vβ	
region	 of	 the	 TCR,	 resulting	 in	 non-specific	 activation	 of	 20-50%	 of	 the	 T-cells	 in	 the	 host.	 This	
massive	activation	of	host	T-cells	 leads	 to	 the	production	of	pathological	 concentrations	of	pro-
inflammatory	 cytokines,	 resulting	 in	 the	 life-threatening	 condition	 toxic	 shock	 syndrome359.		
Furthermore,	this	process	results	in	the	destruction	of	the	T-cells,	preventing	the	development	of	
immunity	 towards	S.	aureus	 infection360,361.	Remarkably,	 the	onset	of	 toxic	 shock	does	not	even	
require	 infection	 since	 bacteria	 that	 have	 colonized	 tampons	 can	 trigger	 the	 condition	 in	
menstruating	woman362.	
Another	 example	 is	 the	 enterotoxins,	 SeA-E,	 G-J	 and	 R-T,	 that	 are	 responsible	 for	 food	
poisoning	that	 results	 in	diarrhea	and	emesis288.	S.	aureus	 typically	encodes	5-6	enterotoxins	on	
mobile	genetic	elements	that	are	believed	to	function	similarly	to	superantigens363,364.		
Finally,	infections	including	bulbous	impetigo	and	SSSS	are	caused	by	exfoliative	toxins	ETA	
and	 ETB	 that	 exfoliate	 the	 skin	 either	 locally	 (impetigo)	 or	 systemically	 (SSSS)365.	 S.	 aureus	
exfoliative	toxins	are	serine	proteases	that	function	by	cleaving	the	protein	desmoglein-1,	which	is	
found	 throughout	 the	 layers	 of	 the	 skin	 and	 is	 required	 to	maintain	 the	 cell-to-cell	 adhesion	of	
keratinocytes	that	make	the	outermost	layer	of	the	skin366.	When	desmoglein-1	is	cleaved	by	the	











persistent	 bacteremia	 cases	 than	 in	 resolving	 bacteremia	 cases	 (39%	 -	 75%)369,	370,371.	 	 Similarly,	
Butterfield	et	al.	(2011)	observed	a	higher	rate	(68%)	of	agr-defective	isolates	associated	with	>72	
h	 of	 in	 hospital	 length	 of	 stay	 compared	 to	 a	 lower	 rate	 (16%)	 of	 agr-dysfunctional	 isolates	
associated	 with	 <72	 h	 of	 in	 hospital	 length	 of	 stay	 due	 to	 invasive	 staphylococcal	 infection372.	
Similarly,	Moise	et	al.	(2009)	found	a	significantly	higher	frequency	of	mixed	and	non-haemolytic	
strains	 (76%)	compared	 to	a	 lower	 frequency	 (24%)	of	agr-dysfunctional	 strains	 in	patients	with	
persistent	 bacteremia367.	 In	 keeping	 with	 this,	 loss	 of	 Agr	 is	 also	 associated	 with	 mortality.	





suppressed	 in	 MRSA	 strains	 with	 high	 mecA	 expression	 and	 VISA	 strains,	 most	 likely	 due	 to	
changes	 in	 the	 cell	wall	 that	 prevent	 engagement	 of	 AIP	with	 AgrC14,375–379	 .	 A	 recent	 study	 by	
Laabei	 et.	 al.,	 (2015)	 demonstrated	 the	 association	 between	 Agr-dysfunctional	 strains	 with	
invasive	 S.	 aureus	 infections	 including	 bacteraemia	 and	 pneumonia380.	 However,	 this	 study	 also	
showed	 that	 Agr-dysfunction	 is	 not	 always	 due	 to	 mutations	 within	 the	 Agr	 locus	 but	 other	
mutations	elsewhere	in	the	genome.	For	example,	mutations	caused	by	a	premature	stop	codon	in	
the	 transcriptional	 regulator	 gene	 repressor	 of	 surface	 proteins	 (rsp)207	 resulted	 in	 reduced	Agr	
activity	 and	 has	 been	 implicated	 in	 the	 progression	 of	 fatal	 bacteraemia205,381–384.	 Therefore,	 it	




The	 association	 of	 persistent	 bacteremia	with	 loss	 of	 Agr	 function	 is	 paradoxical	 since	 it	
abrogates	 the	 production	 of	 numerous	 cytolytic	 toxins,	 including	 leukocidins,	 which	 can	 kill	
immune	 cells.	 Therefore,	 it	 would	 be	 expected	 that	 Agr	 activity	 promotes	 survival	 in	 the	
bloodstream,	 rather	 than	 the	 clinical	 evidence	 that	 suggests	 loss	 of	 Agr	 activity	 promotes	
survival193.	This	raises	an	important	question:	what	advantage	does	loss	of	Agr	function	confer	to	
S.	aureus	during	persistent	bacteremia?		
During	 bacteraemia	 S.	 aureus	 faces	 two	 serious	 threats:	 the	 immune	 system	 and	
antibiotics.	 Both	 the	 host	 immune	 system	 and	 antibiotic	 treatment	 are	 essential	 in	 clearing	
invasive	S.	aureus	infections.	Previous	work	in	our	laboratory	and	from	others	has	shown	that	agr-
defective	bacteria	are	indeed	more	susceptible	to	killing	by	neutrophils	 in	blood	than	those	with	
intact	 agr	 operons186,374,385,386.	 However,	 whilst	 immune	 cells	 from	 healthy	 individuals	 appear	
effective	 at	 clearing	 infections	 caused	 by	 agr-defective	 S.	 aureus	 strains186,374,385,	 persistent	
bacteremia	is	often	associated	with	patients	with	a	weakened	immune	system,	such	as	the	elderly,	
patients	 receiving	 cancer	 chemotherapy	 or	 those	 with	 renal	 failure43	 .	 This	 suggests	 that	 Agr-
dysfunction	may	 confer	 an	 advantage	 to	 S.	 aureus	 exposed	 to	 antibiotics,	 rather	 than	 immune	
cells.	However,	the	evidence	for	this	is	limited,	with	just	a	few	studies	suggesting	a	link	between	
Agr-dysfunction	 and	 antibiotic	 susceptibility387–389.	 For	 example,	 Sakoulas	 et.	 al.,	 (2002)	
demonstrated	that	agr	null	strains,	but	not	wild-type	bacteria,	which	were	grown	in	sub-inhibitory	
concentrations	 of	 vancomycin,	 showed	 a	 small	 decrease	 in	 vancomycin	 susceptibility388,	
suggesting	 that	 loss	of	Agr	 enables	 resistance	development.	 In	 another	 study,	 Paulander	et.	 al.,	
(2012)	 demonstrated	 that	 in	 the	 presence	 of	 sub-lethal	 concentrations	 of	 antibiotics	 including	






















Staphylococcus	 aureus	 strains	 used	 are	 listed	 in	 Table	 2.1	 and	 were	 routinely	 cultured,	 unless	
otherwise	 stated,	 in	 Tryptic	 Soy	Broth	 (TSB)	or	 on	Tryptic	 Soy	Agar	 (TSA).	Mueller-Hinton	Broth	
(MHB)	was	used	in	some	susceptibility	assays	and	Columbia	Blood	Agar	(CBA)	supplemented	with	






by	 S.	 aureus	 and	 previous	 work	 has	 established	 it	 has	 a	 fully	 functioning	 Agr	 system390,391,392.	
USA300	 was	 selected	 because	 it	 is	 representative	 of	 strains	 responsible	 for	 the	 majority	 of	
community-associated	MRSA	infections	in	the	USA,	exhibits	strong	Agr	activity	and	is	resistant	to	
the	frontline	antibiotic	flucloxacillin322,393,394.	It	was,	therefore,	an	appropriate	model	organism	for	












































































































































Tryptone	 (pancreatic	 digest	 of	
casein)	 (17.0	 g),	 papaic	 digest	
of	 soybean	 (3.0	 g),	 dextrose	




Pancreatic	 digest	 of	 casein	
(15.0	 g),	 papaic	 digest	 of	




Beef	 infusion	 solids	 (2.0	 g),	
starch	 (1.5	 g),	 casein	
hydrolysate	(17.5	g)	
For	S.	aureus	MIC	assays	




g),	 starch	 (1.0	 g),	 NaCl	 (5.0	 g),	
agar	(15.0	g)	
S.	 aureus	 growth	 medium	 to	
differentiate	between	Agr+	and	





















dilution	 in	 fresh	 TSB	 up	 to	 1/32	 of	 the	 undiluted	 supernatant.	 The	 undiluted	 and	 diluted	
supernatants	 (400	 μl)	 were	 then	 mixed	 with	 400	 μl	 of	 2%	 defibrinated	 sheep	 blood	 (E&O	
Laboratories	Limited)	in	PBS	(VWR).	Supernatant	and	blood	mixtures	were	incubated	statically	at	
37oC	for	1	h,	after	which	intact	blood	cells	were	removed	by	centrifugation	at	500	x	g	for	10	min.	
The	 degree	 of	 haemolysis	 (red	 blood	 cell	 lysis)	 was	 determined	 by	 measuring	 A450392.	 Blood	


















with	 100	µl	 phage	Φ11	 suspension	 and	 incubated	 at	 37oC	 for	 3	 h	with	 shaking	 (180	 rpm)	 until	
complete	 lysis	was	 observed	 by	 comparison	 to	 a	 blank	 (CY	 broth	with	 CaCl2	 and	MgCl2),	 and	 a	
culture	without	phage.		
Lysed	 bacterial	 debris	 was	 removed	 by	 centrifugation	 (17,000	 x	 g,	 3	 min)	 and	 filtration	
through	 a	 0.22	 µm	 syringe	 filter	 to	 enable	 recovery	 of	 phage	 containing	 DNA	 from	 donor	 cells	
(phage	lysate	A).	The	above	steps	were	repeated	but	instead	of	fresh	lysate,	phage	lysate	A	(100	
µl)	was	added	to	the	1	ml	aliquots	of	the	donor	cells.	Following	incubation	at	37oC	for	3	h	leading	
to	 complete	 lysis,	 the	 phage	 lysate	 was	 centrifuged	 and	 filtered	 as	 described	 above.	 This	 was	
termed	phage	lysate	B	and	stored	at	4oC	until	subsequent	use.	
Recipient	bacteria	(SH1000	wild-type)	were	grown	to	stationary	phase	in	TSB	containing	1	
mM	CaCl2	and	MgCl2,	and	1	ml	was	mixed	with	100	µl	of	 the	phage	 lysate	before	 incubation	at	
37oC	 for	 20	 min.	 Sodium	 citrate	 (2	 ml,	 1%)	 was	 then	 added	 and	 the	 bacteria	 recovered	
immediately	 by	 centrifugation	 (17,000	 x	 g,	 3	 min).	 Bacterial	 pellets	 were	 resuspended	 in	 TSB	
containing	0.5%	sodium	citrate	and	incubated	at	37oC	for	1	h	before	plating	onto	TSA	containing	
sodium	citrate	(0.5%)	and	erythromycin	(10	µg	ml-1).		The	plates	were	then	incubated	at	37oC	for	
48	 h	 to	 allow	 growth	 of	 transductants.	 Colonies	 were	 picked	 and	 passaged	 3	 times	 on	 to	 TSA	







Locus	 Gene	 Forward	primer	 Reverse	primer	
SAUSA300_1512	 pbp3	 CAACACAATCGGAAATGTTGG CCGATTTTCGATAACAGTTG 
SAUSA300_0918	 diacylglycerol	glucosyltransferase	 GTGCAAATGCACAAGTAG CAGTTATTGTGATACCACCAG 
SAUSA300_1169	 ftsK	 GTCGGAAAGAAACCAAG CTCTGCATCAAACACTC 








Colony	 PCR	 was	 performed	 to	 efficiently	 identify	 and	 confirm	 successful	 transduction	 by	 using	
oligonucleotide	primers	that	amplified	the	transposon-targeted	gene.	Primers	were	synthesized	by	
Sigma-Aldrich	and	are	detailed	in	Table	2.3.	PCR	was	carried	out	using	PhusionR	High-Fidelity	DNA	
polymerase	 (NEB)	 because	 of	 its	 high	 sensitivity	 and	 tolerance	 for	 the	 presence	 of	 inhibitors	
released	 from	 lysed	 bacteria.	 Potential	 transductants	 were	 picked,	 resuspended	 in	 10	 µl	 of	
Molecular	Biology	Grade	Nuclease-Free	water	and	2	µl	spotted	onto	TSA	containing	erythromycin	
as	 described	 above.	 The	 remaining	 8	µl	 was	microwaved	 on	 full	 power	 for	 3	min	 in	 an	 800	W	
microwave.	The	microwave-treated	cells	were	pelleted	(17,000	x	g,	3	min)	and	1	µl	or	5	µl	of	the	
supernatant	was	added	to	the	PCR	reaction	as	detailed	in	Table	2.4	to	provide	template	DNA.	PCR	
was	 carried	 out	 in	 0.2	ml	 thin-walled	 PCR	 tubes	 (Greiner)	 in	 a	 PTC-200	 Peltier	 Thermal	 Cycler.	
Controls	 without	 DNA	 were	 used	 to	 check	 for	 contamination	 of	 reagents.	 The	 thermocycling	
conditions	used	for	PCR	are	detailed	in	Table	2.5.	For	colony	PCR	the	initial	denaturation	step	at	
98oC	was	extended	to	10	min	instead	of	the	usual	30	sec	-	5	min,	which	is	typically	used	when	the	
















Reaction	phase	 Temperature	 Duration	 Number	of	cycles	
Initial	denaturation	 98°C	 10	min	 1	
Denaturation	 98°C	 10	sec	 30	
Annealing	 54-62°C	 20	sec	 30	
Extension		 72°C	 15-30s	per	Kb	 30	
Final	extension	 72°C	 5	min	 1	














2.9 Determination	 of	 antibiotic	 minimum	 inhibitory	 and	 bactericidal	
concentrations	(MIC/MBC)	












The	MBC	 is	 defined	 as	 the	 lowest	 concentration	 of	 antibiotic	 required	 for	 a	 >1000-fold	
reduction	 in	 CFU	 counts	 compared	 to	 the	 inoculum403,404.	 To	 determine	 the	 MBC	 value	





This	 assay	 was	 performed	 to	 measure	 the	 rate	 at	 which	 staphylococcal	 strains	 were	 killed	 by	
various	antibiotics	including	daptomycin	(20	μg	ml-1)	with	CaCl2	(0.5	mM),	gentamicin	(10	μg	ml-1),	
vancomycin	(10	μg	ml-1)	or	cloxacillin	(1.25	μg	ml-1),	or	the	antimicrobial	peptides	nisin	(20	μg	ml-1)	
or	 melittin	 (50	 μg	 ml-1).	 These	 antibiotic	 concentrations	 represented	 at	 least	 5	 x	 MIC	 and	 a	
previous	 study	 by	 Johnson	 and	 Levin	 (2013)	 demonstrated	 that	 these	 were	 sufficient	 for	
bactericidal	 antibiotics	 to	 kill	 stationary-phase	 S.	 aureus405.	 Furthermore,	 all	 antibiotic	
concentrations	 used	 fall	 within	 previously	 described	 free	 serum	 concentrations	 determined	 in	
humans	or	animals	that	had	received	clinically-relevant	therapeutic	doses405–410.	All	antibiotics	and	
peptides	 used	 in	 these	 assays	 were	 purchased	 from	 Sigma-Aldrich,	 with	 the	 exception	 of	
daptomycin	(TOCRISTM).	
Staphylococcal	strains	were	grown	to	stationary-phase	in	3	ml	TSB	with	shaking	(180	rpm)	
at	 37°C	 in	 30	 ml	 universal	 tubes	 as	 described	 above.	 They	 were	 subsequently	 adjusted	 to	 a	
concentration	of,	 ~1	 x	108	bacteria	ml-1	 in	 fresh	TSB	before	each	antibiotic	was	added.	Cultures	
were	 then	 incubated	 at	 37°C	with	 shaking	 (180	 rpm)	 and	 bacterial	 viability	 determined	 by	 CFU	
counts	every	2	hours	until	8	h.	Some	experiments	involved	additional	measurements	at	16,	24	and	
48	 h.	 Stationary	 phase	 bacteria	 were	 used	 because	 this	 is	 when	 Agr	 is	 active	 in	 vitro.	 Most	
experiments	used	mono-cultures	of	wild-type	or	agr-mutant	strains,	but	some	utilised	mixtures	of	
wild-type	 and	 agr-mutant	 bacteria,	 with	 the	 inoculum	 maintained	 at	 a	 total	 of	 108	 CFU	 ml-1.	
Because	daptomycin	is	an	anionic	lipopeptide,	calcium	ions	affect	its	structure	and	are	believed	to	
enable	 it	 to	 overcome	 the	 charge-to-charge	 repulsion	 caused	 between	 daptomycin	 and	 the	





All	 experimentation	 involving	 animals	was	 conducted	 in	 accordance	with	 the	 Animals	[Scientific	
Procedures]	Act	1986	outlined	by	the	UK	Home	Office	regulations.	Procedures	were	carried	out	by	
Dr	 Thomas	 Clarke	 (Imperial	 College	 London).	Work	was	 approved	 by	 the	UK	Home	Office	 after	
ethical	approval	from	the	Imperial	College	Animal	Welfare	and	Ethical	Review	Body	(AWERB).		
Six-	to	eight-week-old	female	C57BL/6	mice	(Charles	River,	United	Kingdom)	were	infected	
via	 the	 intraperitoneal	 route	with	2.5	×	 107	CFU	USA300	 LAC	or	 a	 1:1	mixture	of	wild-type	and	
ΔagrA	 mutant	 USA300	 LAC	 (total	 of	 2.5	 ×	 107	 CFU).	 For	 the	 indicated	 experiment,	 wild-type	








on	blood	 agar	 plates.	Wild-type	 and	ΔagrA	mutant	 bacteria	were	differentiated	on	 the	basis	 of	
haemolytic	 activity.	 The	 size	 of	 the	 groups	 used	 was	 determined	 prior	 to	 undertaking	 the	
experiment	 using	 power	 analysis	 based	 on	 in	 vitro	 data411.	 Tubes	 containing	 the	 inocula	 and	
antibiotic	 solutions	 were	 blinded	 prior	 to	 commencing	 the	 experiment.	 Mice	 were	 randomly	
allocated	to	individual	study	group	cages	by	animal	husbandry	technicians	who	were	not	involved	









the	 bacterial	 inoculum	 was	 allowed	 to	 air	 dry	 and	 the	 wells	 were	 filled	 with	 the	 supernatant	
recovered	 from	 cultures,	 which	 had	 been	 processed	 by	 centrifugation	 (17,000	 x	 g)	 and	 filter	
sterilization	 (0.22	 μm	 polyethersulfone	 membrane	 syringe	 filter	 (EMD	 Millipore))	 to	 remove	
bacterial	cells.	Plates	were	 incubated	for	16	h	at	37°C	and	the	zone	of	growth	 inhibition	around	
the	 well	 measured	 at	 4	 perpendicular	 points.	 In	 some	 assays,	 fresh	 daptomycin	 was	 added	 to	
culture	supernatants,	incubated	statically	at	37oC	for	up	to	8	h,	and	then	added	to	wells	in	TSA	as	
described	 above.	As	well	 as	 spent	 culture	 supernatants,	 some	assays	 used	 fresh	 TSB	 containing	
phospholipids	and/or	PSM	peptides	in	addition	to	daptomycin	for	filling	the	wells.		
To	 accurately	 quantify	 daptomycin	 activity,	 a	 standard	 plot	 was	 generated	 for	 each	
experiment	 by	measuring	 the	 zone	 of	 growth	 inhibition	 around	wells	 that	were	 filled	with	 TSB	
supplemented	with	range	of	daptomycin	concentrations.	This	enabled	the	conversion	of	the	size	





phospholipid,	 spent	 culture	 supernatants	 were	 treated	 with	 heat	 (80oC,	 20	 min),	 Triton	 X-100	
(0.1%),	phospholipases	A,	B,	D	(5	U	ml-1),	trypsin	(10	μg	ml-1)	or	proteinase	K	(10	μg	ml-1)	for	16	h	
at	37oC	prior	 to	 the	addition	of	20	µg	ml-1	 fresh	daptomycin	 (all	 reagents	 sourced	 from	Sigma).	




In	 addition	 to	 the	 daptomycin	 activity	 determination	 assay	 described	 above	 (section	 2.12),	 this	
assay	was	used	 to	 confirm	 the	bactericidal	 activity	of	daptomycin	 in	 spent	 culture	 supernatants	














mutant	bacteria	 (exposed	or	not	 to	daptomycin)	were	 swapped	and	used	 to	measure	S.	aureus	
survival	upon	exposure	to	a	 fresh	dose	of	daptomycin	(20	μg	ml-1)	with	CaCl2	 (0.5	mM).	For	this	
assay,	 bacteria	 grown	 in	 TSB	 (3	 ml)	 were	 pelleted	 by	 centrifugation	 (17,000	 x	 g,	 5	 min),	 the	
supernatant	removed	and	filtered	as	described	above,	and	the	bacteria	resuspended	in	an	equal	
volume	of	filter-sterilised	spent	culture	supernatant	from	a	different	strain	before	immediate	use	









concentration	 of	 5	 µg	 ml-1	 in	 the	 wells	 of	 clear	 flat-bottom	 microtitre	 plates	 with	 black	 walls	
appropriate	 for	 fluorescence	 readings	 (Greiner	 Bio-One).	 Fluorescence	 was	 measured	 using	 a	
Tecan	microplate	 reader,	with	excitation	at	565	nm	and	emission	at	660	nm	to	generate	values	
expressed	 as	 relative	 fluorescence	 units	 (RFU).	 Samples	 were	 measured	 in	 triplicate	 for	 each	
biological	 repeat	 and	 TSB	mixed	with	 the	 FM-4-64	 dye	was	 used	 as	 a	 blank.	 	 The	 fluorescence	









Filter-sterilised	 culture	 supernatants	 or	 TSB	 containing	 various	 purified	 lipid	 standards	
and/or	daptomycin	were	extracted	with	1	sample	volume	of	chloroform:methanol	(2:1,	v/v).	The	
samples	 were	 mixed	 by	 vortexing	 and	 then	 centrifuged	 (17,000	 x	 g,	 10	 min)	 to	 separate	 the	
aqueous	and	organic	phases.	The	aqueous	phase	was	removed	and	the	organic	phase	evaporated	
at	ambient	temperature	and	pressure	 in	a	 fume	hood.	Dried	samples	were	then	resuspended	 in	
100	µl	of	chloroform:methanol	(2:1,	v/v).		
Samples	 were	 then	 separated	 by	 one-dimensional	 TLC	 as	 described	 previously414.	 Equal	
volumes	of	lipid	extracts	were	spotted	onto	silica	60	F254	HPTLC	plates	(Merck)	and	migrated	for	
25	min	with	chloroform:methanol:ammonium	hydroxide	(30%)	(65:30:4,	by	volume)414	.	TLC	plates	
were	 allowed	 to	 dry	 by	 evaporation	 before	 lipids	 were	 detected	 using	 iodine	 vapour	 (Sigma-
Aldrich).	 Purified	 lipid	 standards	 included	 phosphatidylglycerol,	 cardiolipin,	 lysyl-
phosphatidylglycerol,	phosphatidic	acid	and	phosphatidylethanolamine.		
All	 standards	 were	 purchased	 from	 Sigma-Aldrich,	 with	 the	 exception	 of	 lysyl-
phosphatidylglycerol	 (Avanti	 Polar	 Lipids).	 To	 enable	 accurate	 identification	 of	 phospholipids	 in	
spent	 culture	 supernatants,	 the	 purified	 lipid	 standards	 were	 added	 to	 TSB	 at	 100	 µM	 and	
daptomycin	 (20	 µg	 ml-1)	 added	 before	 the	 mixtures	 were	 subjected	 to	 the	 same	 extraction	
procedure	used	for	culture	supernatants.		
The	 identity	 and	 relative	 proportions	 of	 lipids	 were	 determined	 as	 described	 previously	
28,415.	Lipids	were	extracted	from	spent	culture	supernatant	into	chloroform:methanol	(2:1	v/v)	as	
described	above.	Samples	were	then	subjected	to	2D	TLC	using	silica	60	F254	HPTLC	plates,	firstly	







0.3	ml	 70%	 perchloric	 acid	 (Sigma-Aldrich)	 at	 150oC	 (using	 a	 heat	 block)	 for	 3	 h.	 The	 digested	
phospholipid	was	 then	 incubated	with	a	detection	 reagent	 (10%	ascorbic	acid,	2.5%	ammonium	
molybdate,	5%	of	70%	perchloric	acid	used	at	a	1:1:8	ratio	by	volume,	all	chemicals	from	Sigma)	at	
37oC	for	2	h.	The	product	was	then	quantified	by	measurement	of	absorbance	at	750	nm	using	a	
microplate	 reader	 (iMARKTM	 BIO-RAD)	 and	 reference	 to	 standards	 of	 known	 phospholipid	







described	 in	 the	 manufacturer’s	 instructions.	 Desthiobiotin	 (100	 µl,	 10	 mM)	 was	 mixed	 with	
daptomycin	 (100	µl,	 6	 mM)	 in	 PBS	 (1	 ml)	 before	 incubation	 at	 room	 temperature	 with	 gentle	
rocking	 for	1	h.	The	 reaction	mixture	was	 then	dialysed	against	H2O	at	4oC	 to	 remove	unbound	
desthiobiotin	using	a	Float-A-Lyser	G2	device	(Spectrum	Labs)	with	a	molecular	weight	cut-off	of	
0.1	kDa.	This	approach	was	chosen	because	the	EZ-link	enables	simple	and	efficient	labelling	of	the	
single	 free	 amine	 (R-NH2)	 group	 of	 daptomycin	 and	 the	 EZ-link	 spacer	 provides	 the	 spacer	 arm	











For	 the	pull-down	assay,	spent	culture	supernatant	 (1	ml)	was	 incubated	with	20	µg	ml-1	





to	 pellet	 any	 beads	 that	 remained	 in	 suspension.	 The	 supernatant	 was	 then	 removed	 and	 the	
pelleted	beads	washed	with	TSB.	An	additional	round	of	centrifugation	and	a	TSB	wash	was	done	
before	 the	 beads	 were	 resuspended	 in	 elution	 buffer	 (100	 µl,	 4	 mM	 biotin)	 (Sigma-Aldrich)	
followed	by	incubation	at	80oC	for	20	min	to	ensure	denaturation	of	the	streptavidin.	TSB	(100	µl)	
was	then	added	to	the	bead/elution	buffer	suspension,	mixed	by	pipetting	and	beads	removed	by	









































































































To	 measure	 the	 relative	 quantity	 of	 daptomycin	 bound	 to	 the	 bacterial	 cells,	 daptomycin	 was	
labelled	with	the	fluorophore	BoDipy	FL	SE	(D2184,	Life	Technologies).	Daptomycin	(50	µl,	50	mg	
ml-1)	was	mixed	with	BoDipy	FL	SE	(100	µl,	10	mg	ml-1)	and	the	reaction	volume	made	to	1	ml	with	
sodium	 bicarbonate	 buffer	 (0.2	M	 pH	 8.5)	 before	 incubation	 at	 37oC	 for	 1	 h.	 	 The	 succinimidyl	
esters	of	the	BoDipy	fluorophore	enabled	labelling	via	the	amine	(R-NH2)	group	of	daptomycin421.		





for	 0-8	 h	 at	 37oC	with	 shaking	 (section	 2.10),	 before	 rounds	of	washing	 in	 TSB.	 BoDipy-labelled	
daptomycin	bound	to	bacterial	cells	(200	µl)	was	detected	and	quantified	with	a	Tecan	microplate	






and	 survival	 over	8	h	measured	as	described	 in	 section	2.10	 for	 the	determination	of	 antibiotic	
bactericidal	activity.	After	8	h	bacteria	were	pelleted	by	centrifugation	(17,000	x	g,	5	min),	washed	
twice	in	TSB	and	resuspended	in	3	ml	fresh	TSB,	before	incubation	at	37oC	with	shaking	(180	rpm)	
for	 16	 h	 to	 stationary	 phase.	 The	 activity	 of	 daptomycin	 in	 the	 culture	 supernatant	 was	
determined	by	 the	 zone	of	 inhibition	assay	as	described	 in	 section	2.12.	 The	 re-grown	bacterial	
populations	 were	 then	 inoculated	 once	 again	 into	 TSB	 containing	 daptomycin	 (20	 μg	ml-1)	 and	
CaCl2	 (0.5	 mM)	 and	 survival	 over	 8	 h	 measured.	 In	 total,	 3	 rounds	 of	 daptomycin	 challenge	
followed	 by	 re-growth	 in	 antibiotic-free	medium	were	 done.	 After	 each	 round,	 the	 daptomycin	






described	 sequences,	 with	 formylated	 methione	 (fM)	 at	 the	 N-termini294:	 	 PSMα1	
fMGIIAGIIKVIKSLIEQFTGK;	PSMα2	fMGIIAGIIKFIKGLIEKFTGK;	PSMα3	fMEFVAKLFKFFKDLLGKFLGNN;	
PSMα4	 fMAIVGTIIKIIKAIIDIFAK;	 PSMβ1	 fMEGLFNAIKDTVTAAINNDGAKLGTSIVSIVENGVGLLGKLFGF;	
PSMβ2	 fMTGLAEAIANTVQAAQQHDSVKLGTSIVDIVANGVGLLGKLFGF.	 In	 addition,	 a	 peptide	
comprised	 of	 the	 reverse	 sequence	 of	 PSMα1	 (PSM-rev;	 KGTFQEILSKIVKIIGAIIGM)	 was	
synthesised.	Unless	otherwise	indicated,	peptides	were	used	in	assays	at	10	µM,	which	was	based	
on	 concentrations	 described	 for	 stationary	 phase	 cultures	 of	 USA300413.	 When	 used	 in	














described	 in	 the	 legend	 and	 indicated	 on	 the	 figure	 (*).	 Non-significant	 differences	 are	 only	




































S.	 aureus	 is	 responsible	 for	 many	 different	 types	 of	 infection,	 ranging	 from	 mild	 to	 lethal,	
superficial	to	invasive.	The	antibiotics	that	are	used	to	treat	S.	aureus	infections	are	guided	by	the	
susceptibility	 of	 the	 isolate.	 Accordingly,	 for	 the	 treatment	 of	 methicillin-sensitive	 S.	 aureus	
(MSSA)	 bacteremia	 the	 antibiotics	 that	 are	 currently	 available	 include	 penicillinase-resistant	
semisynthetic	 penicillins,	 such	 as	 flucloxacillin	 and	 first-generation	 cephalosporins,	 such	 as	




glycopeptide	 vancomycin62.	 Treatment	 of	 MSSA	 bacteremia	 with	 vancomycin	 is,	 however,	
associated	with	poor	clinical	outcomes	including	a	higher	relapse	rate	(31.2%	cases	of	persistent	
MSSA	bacteremia)	compared	to	cefazolin	(5-13%	of	cases)	and	naficillin	(5.3%	of	cases)56,64	;	and	




When	 treatment	 with	 vancomycin	 fails,	 especially	 in	 patients	 with	 a	 high	 inoculum	




2006.	 Daptomycin’s	 mode	 of	 action	 is	 calcium-dependent	 and	 involves	 the	 insertion	 of	 the	
lipophilic	daptomycin	tail	into	the	cytoplasmic	membrane	of	Gram-positive	cells.	This	causes	rapid	
membrane	depolarization	and	potassium	 ion	efflux.	 This	 is	 followed	by	arrest	of	DNA,	RNA	and	
protein	synthesis	resulting	in	bacterial	cell	death28,120.	
Although	 daptomycin	 is	 highly	 bactericidal	 against	 both	 MRSA	 and	 MSSA	 in	 vitro,	
treatment	 failure	 occurs	 in	 up	 to	 30%	 cases.	 In	 rare	 instances,	 this	 is	 due	 to	 the	 emergence	 of	
isolates	with	 a	 ‘daptomycin	 non-susceptible’	 (DNS)	 phenotype,	 typically	 due	 to	 gain-of-function	
mutations	in	genes	involved	in	biosynthesis	of	phospholipids	or	cell	wall	components.		











However,	 whilst	 Agr-dysfunctional	 strains	 are	 associated	 with	 persistent	 infections	 and	



















SH1000	 strains	 (Table	 2.1).	 The	 mutations	 in	 the	 agr	 operon	 of	 USA300	 had	 been	 previously	
constructed	 via	 complete	 deletion	 of	agrA,	 agrC	or	 RNAIII.	 In	 addition,	 these	mutants	 had	 also	
been	 complemented	 with	 a	 copy	 of	 the	 relevant	 gene	 on	 a	 plasmid	 and	 characterized	
phenotypically400,407.	
		 87	
Since	 growth	 rate	 can	 affect	 antibiotic	 susceptibility,	 this	was	measured	 for	 each	 of	 the	
strains	 used	 in	 antibiotic	 susceptibility	 experiments.	 (Fig	 3.1)	 As	 has	 been	 observed	 previously	
there	were	 slight	differences	 in	growth	profile	between	 the	wild-type	and	agr	mutants	at	 some	
time	 points,	 indicating	 that	 Agr	 has	 a	 subtle	 impact	 on	 the	 growth	 of	 S.	 aureus392,399	 (Fig	 3.1).	































































Two	 approaches	were	 used	 to	measure	 antibiotic	 susceptibility.	 Firstly,	 the	minimum	 inhibitory	
concentration	 (MIC)	 was	 determined	 for	 each	 antibiotic	 and	 each	 strain.	 Secondly,	 the	
susceptibility	of	each	strain	to	bactericidal	concentrations	of	each	antibiotic	was	measured.	
In	 each	 case,	 the	 MICs	 of	 vancomycin	 and	 gentamicin	 for	 wild-type,	 ΔagrA,	 and	 ΔagrC	
mutants	in	the	USA300	strain	or	wild-type,	Δagr	and	agrA-	mutants	in	the	SH1000	strain	were	the	
same	(Table	3.1).	However,	for	the	USA300	ΔRNAIII	mutant	the	MIC	was	half	that	of	the	wild-type	
for	 these	 antibiotics.	 Loss	 of	Agr	 function	 in	 SH1000	 strains	 did	 not	 affect	MIC	 values,	with	 the	






previous	 findings426.	 Taken	 together,	 these	 findings	 indicated	 that	 the	 lack	 of	 the	 Agr-quorum	
sensing	system	did	not	significantly	affect	antibiotic	susceptibility	of	S.	aureus	(Table	3.1).		
To	determine	the	antibiotic	killing	kinetics	of	USA300	and	SH1000	strains	and	their	isogenic	
agr	 mutants,	 bacteria	 were	 challenged	 with	 the	 same	 group	 of	 clinically	 relevant	 antibiotics,	
including	cloxacillin,	vancomycin,	gentamicin	and	daptomycin.	The	concentrations	used	for	all	the	
antibiotics	were	within	the	previously	described	free	serum	concentrations	from	studies	in	animals	






























Cloxacillin	 0.25	 0.25	 0.125	 NA	 NA	 NA	 NA	
Vancomycin	 2	 2	 2	 2	 2	 2	 1	
Gentamicin	 2	 2	 2	 2	 2	 2	 1	








Dapt.	 WT	 ΔagrA	 ΔagrC	
ΔagrC	+		
pCN34	agrC	WT	 ΔRNAIII	
TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
Table.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentraGons	for	strains	used	in	this	













TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
USA300	JE2	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔvraT	 ΔvraTpEmpty	 ΔvraTpagrC	 ΔvraU	 ΔvraR	 ΔvraS	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	
USA300	JE2	–	derived	(vra	regulon)	
Medium	+	




















Dapt.	 WT	 ΔagrA	 ΔagrC	
ΔagrC	+		
pCN34	agrC	WT	 ΔRNAIII	
TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
Table.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentraGons	for	strains	used	in	this	













TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
USA300	JE2	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔvraT	 ΔvraTpEmpty	 ΔvraTpagrC	 ΔvraU	 ΔvraR	 ΔvraS	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	
USA300	JE2	–	derived	(vra	regulon)	
Medium	+	





















of	wild-type	 and	agr	mutants,	 indicating	 that	 Agr	 status	 does	 not	 affect	 the	 susceptibility	 of	 S.	
aureus	 to	 bactericidal	 concentrations	 of	 these	 antibiotics	 (Fig	 3.2a-e).	 However,	 in	 the	 case	 of	
daptomycin,	 the	 Agr	 status	 of	 both	 USA300	 and	 SH1000	 had	 a	 large	 and	 significant	 effect	 on	
survival	(Fig	3.3a).	During	the	first	2	hours	of	exposure	of	USA300	strains	to	daptomycin,	a	rapid	
decrease	 in	 CFU	 was	 observed	 in	 both	 the	 wild-type	 and	 ΔagrA,	 ΔagrC	 and	 ΔRNAIII	 mutants.	
However,	by	4	h	the	ΔagrA	and	ΔagrC	mutants	(but	not	the	ΔRNAIII	mutant)	began	to	recover,	and	
the	CFU	count	increased	100-fold	between	4	h	and	8	h.	By	contrast,	viability	of	the	wild-type	and	
ΔRNAIII	 mutant	 continued	 to	 decrease	 up	 to	 8	 h.	 Thus,	 the	 loss	 of	 the	 quorum-sensing	
components	 of	 Agr	 (AgrA	 or	 AgrC),	 but	 not	 the	 regulatory	 RNAIII	 molecule,	 enabled	 S.	 aureus	
USA300	 to	 survive	 exposure	 to	 daptomycin	 (Fig	 3.3a).	 To	 confirm	 that	 inactivation	 of	 Agr	 was	
responsible	 for	 the	 survival	 of	 USA300	 ΔagrA	 and	 ΔagrC	 mutants,	 the	 ΔagrC	 mutant	
complemented	with	a	wild-type	copy	of	the	agrC	gene	and	exposed	to	daptomycin.	Restoration	of	
Agr	 activity	 in	 the	ΔagrC	mutant	 restored	 sensitivity	 to	daptomycin,	whereas	 the	ΔagrC	mutant	
transformed	with	plasmid	alone	was	not	susceptible	to	the	antibiotic	(Fig	3.3b).		
















the	work	that	 involved	animal	procedures.	Mice	were	 inoculated	via	the	 intraperitoneal	route301	
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with	wild-type	USA300	S.	aureus	or	the	ΔagrA	mutant,	and	then	treated	with	daptomycin	or	PBS	
for	 8	 h.	 Subsequently,	 bacterial	 survival	 was	 measured	 by	 recovering	 and	 enumerating	 CFUs.	
Similar	 to	 that	 reported	 previously427,	 daptomycin	 treatment	 reduced	 the	 size	 of	 the	wild-type	
population	15-fold	after	8	h	treatment,	compared	with	mice	treated	with	PBS	alone	(Fig	3.3e).	By	
contrast,	 daptomycin	 treatment	 did	 not	 significantly	 decrease	 the	 size	 of	 the	 ΔagrA	 mutant	









S.	 aureus	 SH1000	 and	 associated	 agr	 mutants	 were	 exposed	 to	 cloxacillin	 (1.25	 µg	 ml-1)	 (a),	
vancomycin	 (10	µg	ml-1)	 (b)	or	gentamicin	 (10	µg	ml-1)	 (c)	 for	8	h	and	survival	measured	by	CFU	
counts.	The	survival	of	USA300	wild-type	and	associated	agr	mutants	in	the	presence	of	identical	
concentrations	of	vancomycin	(d)	or	gentamicin	(e)	was	determined	as	described	for	SH1000.	Data	






























































































Survival	 of	 USA300	 WT	 or	 agr	 mutants	 (a).	 Survival	 of	 the	 ΔagrC	 mutant,	 ΔagrC	 mutant	
transformed	with	pCN34	empty	or	pCN34	containing	the	wild-type	agrC	gene	under	the	control	of	




wild-type	 vs	 ΔagrC	 with	 empty	 plasmid	 P	 <	 0.001	 at	 indicated	 time	 points	 (*).	 There	 was	 no	
significant	 difference	 between	WT	 and	 ΔagrC	 pCN34	 agrC	WT.	 	 Survival	 of	 USA300	WT	 or	 agr	
mutants	over	48	h	(n=3	in	duplicate,	for	WT	vs	ΔagrA	or	ΔagrC	P	<	0.0001	at	indicated	time	points	
(*).	CFU	counts	of	USA300	WT	or	ΔagrA	mutant	after	8	h	in	the	peritoneal	cavity	of	mice,	treated	
with	20	µg	ml-1	daptomycin	 (+)	or	PBS	only	 (-)	 (*	P	<	0.05,	NS	P	>	0.05,	Each	circle	 represents	a	




































































































































3.4 Clinical	 S.	 aureus	 isolates	 with	 dysfunctional	 Agr	 are	 less	 susceptible	 to	
daptomycin	than	isolates	with	a	functional	Agr	system	
To	further	explore	the	clinical	relvance	of	Agr-modulated	daptomycin	susceptibility,	a	collection	of	
20	 independent	 clinical	MRSA	 isolates	 from	bloodstream	 infections	was	 examined.	 Each	 isolate	
was	 plated	 onto	 Columbia	 Blood	 Agar	 and	 Agr	 activity	 inferred	 using	 a	 semi-quantitative	
haemolysis	 assay.	 Since	 haemolysis	 is	 a	 surrogate	 marker	 of	 Agr	 activity368,370.	 Isolates	 were	
defined	 simply	 as	Agr-functional	 (haemolytic)	 or	Agr-dysfunctional	 (non-haemolytic)	 (Fig	 3.4).	 In	













S.	 aureus	 isolates	 (20)	 were	 obtained	 from	 the	 Imperial	 College	 NHS	 diagnostic	 laboratory.	
Because	 haemolysis	 is	 a	 useful	 surrogate	marker	 for	 Agr	 activity,	 strains	were	 assessed	 for	 Agr	
function	 by	 examination	 of	 haemolytic	 activity	 on	 blood	 agar	 plates	 as	 described	 previously10.	
Isolates	that	produced	clear	zones	of	haemolysis	(a)	(representative	image,	n=13)	were	considered	
to	have	 functional	Agr	 systems,	whilst	 those	defective	 for	haemolysis	 (b)	 (representative	 image,	
n=7)	were	considered	to	lack	a	functional	Agr	system10.	The	survival	of	each	isolate	after	exposure	
to	20	µg	ml-1	daptomycin	 for	8	h	was	 then	measured	using	duplicate	 cultures	 in	3	 independent	
assays.	 The	mean	 average	 survival	 for	 each	 isolate	 is	 plotted	 as	 a	 single	 point	 above	 (c).	 Lines	















































Resistance	 to	 daptomycin	 can	 arise	 spontaneously	 and	 typically	 involves	 gain-of-function	
mutations	in	genes	related	to	phospholipid	or	cell	wall	biosynthesis428,28,131.	To	determine	whether	
the	 survival	 of	agr	mutants	 in	 daptomycin	was	 due	 to	 the	 emergence	 or	 presence	 of	 resistant	















USA300	 (a)	 and	 SH1000	 (b)	 wild-type	 and	 agr	 mutant	 strains	 were	 exposed	 to	 20	 μg	 ml-1	 of	
daptomycin	for	8	h.	CFU	were	quantified	on	TSA	only,	TSA	supplemented	with	daptomycin	at	4	μg	
ml-1	 or	 TSA	 supplemented	 with	 20	 μg	 ml-1	 at	 the	 start	 (0	 h)	 and	 end	 (8	 h)	 of	 the	 assay.	 No	
significant	differences	were	found	between	the	number	of	CFU	on	TSA	plates	supplemented	with	






















































3.6 Agr-defective	 mutants	 promote	 survival	 of	 wild-type	 S.	 aureus	 exposed	 to	
daptomycin		
	Since	staphylococcal	 infections	are	often	caused	by	mixed	populations	of	wild-type	bacteria	and	
agr	mutants368,369,380,425,	 it	was	 investigated	how	this	affected	daptomycin	 susceptibility.	Various	
ratios	of	USA300	wild-type	and	ΔagrA	mutant	S.	aureus	were	prepared	(WT	4:1,	2:1,	1:1,	1:2	and	



















or	 mixed	 at	 a	 1:1	 ratio	 (Mix)	 and	 survival	 of	 both	 strains	 measured	 (b).	 Survival	 of	 wild-type	
SH1000	was	significantly	greater	in	mixed	culture	than	mono-culture	(P	<	0.05	by	Student’s	t-test).	

























Since	 the	 ΔagrA	 mutant	 survived	 daptomycin	 in	 vivo	 and	 protected	 wild-type	 bacteria	 from	
daptomycin	in	vitro	it	was	decided	to	test	whether	the	ΔagrA	mutant	also	protected	the	wild-type	
in	vivo.	Mice	were	infected	via	the	intraperitoneal	route	with	a	1:1	mixture	of	wild-type	bacteria	
and	 ΔagrA	 mutant.	 As	 a	 control,	 mice	 were	 also	 infected	 with	 wild-type	 alone	 (as	 before,	 all	
animal	procedures	were	undertaken	by	Dr.	Thomas	Clarke,	CMBI,	Imperial	College	London).	Mice	
were	then	treated	with	daptomycin	for	4	or	8	h,	and	bacterial	survival	measured	by	recovery	and	
quantification	 of	 CFUs.	 As	 described	 previously	 (Fig	 3.3e),	 daptomycin	 significantly	 reduced	 the	
number	 of	 CFU	 in	 mice	 infected	 with	 wild-type	 bacteria	 alone	 (Fig	 3.7a,	 b).	 However,	 in	 mice	
infected	with	 a	mixture	of	wild-type	and	ΔagrA	mutant	bacteria,	 daptomycin	had	no	 significant	
effect	on	the	number	of	CFU	of	either	strain	after	4	or	8	h	treatment	(Fig	3.7a,	b).	
Therefore,	the	presence	of	the	ΔagrA	mutant	in	the	peritoneal	cavity	of	mice	appeared	to	




































































































to	 daptomycin:	 (i)	 S.	 aureus	 degraded	 or	 otherwise	 inactivated	 the	 antibiotic	 or	 (ii)	 S.	 aureus	
adapted	to	the	presence	of	the	antibiotic,	for	example	by	over-expressing	the	mprF	or	dlt	operon	
genes.			
To	 test	 the	 first	 hypothesis,	 the	 activity	 of	 daptomycin	 in	 the	 culture	 medium	 was	
measured	using	 two	assays:	 a	 zone	of	 inhibition	assay	and	a	bactericidal	 assay.	 For	 the	 zone	of	
inhibition	 assay,	 a	 standard	 plot	 of	 the	 size	 of	 the	 zones	 of	 inhibition	 caused	 by	 increasing	
concentrations	 of	 daptomycin	 (0,	 5,	 10	 and	 20	 μg	 ml-1)	 was	 generated.	 For	 this,	 various	
concentrations	 of	 daptomycin	 in	 TSB	were	 added	 to	 10	mm	wells	made	 in	 TSA	plates	 that	 had	
been	overlaid	with	USA300	wild-type,	and	incubated	for	16	h	at	37oC.	Thereafter,	the	size	of	each	
zone	 of	 inhibition	 was	 calculated	 from	 4	 perpendicular	 measurements	 (Fig	 3.8a	 and	 b).	 The	
standard	 plot	 enabled	 the	 size	 of	 the	 zone	 of	 inhibition	 to	 be	 converted	 to	 perecentage	
daptomycin	activity.	
For	the	daptomycin	bactericidal	assay,	wild-type	S.	aureus	(5	x	105	CFU	ml-1)	was	inoculated	
into	 TSB	 containing	 a	 range	 of	 daptomycin	 concentrations	 and	 incubated	 for	 16	 h	 at	 37°C.	
Subsequently,	the	change	in	CFU	counts	for	each	of	those	concentrations	was	determined	after	24	





USA300,	 daptomycin	 activity	 in	 the	 spent	 culture	 supernatant	 decreased	 slowly	 but	 steadily	 by	
50%.	However,	using	the	bactericidal	assay	it	was	found	that	this	level	of	daptomycin	activity	was	
still	sufficient	for	bacterial	killing	as	there	was	a	>1000-fold	decrease	in	the	CFU	counts	from	the	
starting	 bacterial	 inoculum	 (Fig.	 3.9a,	 b	 and	 c).	 By	 contrast,	 the	 activity	 of	 daptomycin	 in	 the	
culture	 supernatants	of	 the	ΔagrA	mutant	was	completely	 lost	by	4	h.	This	 indicated	 that	 there	
was	a	much	more	 rapid	 loss	of	daptomycin	activity	 in	 cultures	of	 the	ΔagrA	mutant.	 In	keeping	
with	this,	we	found	that	the	antibiotic	was	no	longer	bactericidal	(Fig.	3.9a,	b	and	c).		
Similar	findings	were	obtained	with	S.	aureus	SH1000,	where	the	Δagr	mutant	inactivated	




















A	 standard	 plot	 of	 the	 size	 of	 zones	 of	 inhibition	 generated	 by	 TSB	 containing	 various	
concentrations	of	daptomycin	(open	circle)	or	various	concentrations	of	daptomycin	and	0.25	µg	
ml-1	 oxacillin	 (filled	 circles)	 (a).	 The	 plot	 enabled	 zone	 size	 to	 be	 converted	 to	 percentage	
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daptomycin.	 The	 resuspended	 wild-type	 bacteria	 were	 then	 exposed	 to	 a	 fresh	 dose	 of	
daptomycin	at	37oC	 for	8	h.	The	supernatant	 from	the	ΔagrA	mutant	 that	had	been	exposed	 to	
daptomycin	protected	 the	wild-type	 from	daptomycin	 challenge,	whereas	 the	 supernatant	 from	
the	wild-type	did	not	(Fig	3.11a).	This	indicated	that	the	inactivator	was	present	in	the	supernatant	
of	the	agrA	mutant.			
To	 investigate	 whether	 the	 culture	 supernatant	 from	 the	 ΔagrA	 mutant	 exposed	 to	
daptomycin	 protected	 wild-type	 bacteria	 from	 subsequent	 daptomycin	 challenge	 in	 vivo,	 mice	
were	 infected	with	wild-type	bacteria	that	were	resuspended	 in	culture	supernatants	 from	wild-
type	or	agrA	mutant	that	had	been	exposed	to	daptomycin.	Infected	mice	were	then	treated	with	
daptomycin	 for	 8	 h,	 before	 CFU	 from	 the	 peritoneal	 cavity	 were	 recovered	 and	 quantified.	
Similarly	 to	 the	 in	 vitro	 study,	 we	 found	 that	 the	 CFU	 recovered	 from	 the	mice	 that	 had	 been	
infected	with	the	wild-type	resuspended	in	the	culture	supernatant	from	the	ΔagrA	mutant	that	
had	 been	 exposed	 to	 daptomycin	 was	 significantly	 greater	 than	 the	 wild-type	 bacteria	
resuspended	 in	 the	 culture	 supernatant	 from	 the	wild-type	 bacteria	 that	 had	 been	 exposed	 to	
daptomycin	 (Fig	 3.11b).	 Thus,	 in	 keeping	 with	 the	 previous	 data	 (Fig	 3.7b),	 the	 USA300	 ΔagrA	
mutant	 protects	 wild-type	 bacteria	 during	 daptomycin	 challenge	 both	 in	 vitro	 and	 in	 vivo	 (Fig	
3.11a	and	b).		
Together,	 these	experiments	 indicated	 that	daptomycin	was	 inactivated	by	a	 secreted	or	
released	 factor.	 To	 investigate	 whether	 the	 ΔagrA	 mutant	 secreted	 the	 daptomycin-inactivator	
constitutively	or	 in	response	to	daptomycin,	culture	supernatants	from	ΔagrA	S.	aureus	exposed	
or	not	to	daptomycin	were	assessed	for	their	ability	to	inactivate	a	fresh	dose	of	daptomycin	(20	
μg	ml-1)	 (Fig	3.12a).	Culture	supernatant	 from	the	ΔagrA	mutant	exposed	to	daptomycin	 rapidly	
inactivated	 the	 fresh	 dose	 of	 daptomycin	 (Fig	 3.12b,	 c	 and	 d).	 By	 contrast,	 the	 spent	 culture	
supernatant	from	the	ΔagrA	mutant	that	had	not	been	exposed	to	daptomycin	did	not	inactivate	









Figure	 3.11.	 Culture	 supernatant	 from	 the	 USA300	 ΔagrA	 mutant	 exposed	 to	 daptomycin	
protects	the	wild-type	from	a	subsequent	dose	of	the	antibiotic	in	vitro	and	in	vivo		
Wild-type	USA300	was	recovered	by	centrifugation,	washed	once	in	PBS	and	resuspended	in	spent	
culture	 supernatant	 from	either	wild-type	or	ΔagrA	mutant	S.	aureus	 that	had	been	exposed	 to	
daptomycin.	The	 resuspended	wild-type	bacteria	were	 then	challenged	 in	 vitro	 (a)	or	 in	 vivo	 (b)	
with	20	µg	ml-1	daptomycin	for	8	h.	For	a,	n=3	 in	duplicate,	*	P	<	0.01	compared	to	supernatant	








































































Figure	 3.12.	 The	 daptomycin	 inactivator	 is	 secreted	 in	 response	 to	 the	 antibiotic	 but	 not	
constitutively		
Schematic	outlining	the	experimental	protocol	to	study	the	daptomycin	inactivating	ability	of	the	
culture	 supernatant	 (a).	 To	 determine	whether	 the	 daptomycin	 inactivator	was	 secreted,	 spent	
culture	 supernatant	 from	 the	 ΔagrA	 mutant	 exposed,	 or	 not,	 to	 20	 µg	 ml-1	 daptomycin	 was	
assessed	 for	 its	 ability	 to	 inactivate	 a	 fresh	 dose	 of	 daptomycin	 at	 20	 µg	ml-1.	 The	 supernatant	
from	bacteria	that	had	been	exposed	to	daptomycin	rapidly	inactivated	the	fresh	dose	of	antibiotic	
(b,c).	By	contrast,	 supernatant	 from	the	ΔagrA	mutant	 that	had	not	previously	been	exposed	to	
daptomycin	 did	 not	 inactivate	 a	 fresh	 dose	 of	 antibiotic	 (n=3	 in	 duplicate,	 supernatant	 from	
bacteria	not	exposed	to	daptomycin	vs	supernatant	from	bacteria	exposed	to	daptomycin	P	<	0.01	
at	indicated	time	points	(*),	as	determined	by	two-way	ANOVA	with	Dunnett’s	post-hoc	test,	error	
bars	 represent	 the	 standard	 deviation	 of	 the	 mean).	 Therefore,	 the	 daptomycin	 inactivator	 is	
secreted	in	response	to	daptomycin	exposure.	To	confirm	that	daptomycin	was	fully	inactivated	by	
the	 spent	 culture	 supernatant	 from	 the	ΔagrA	mutant	exposed	 to	daptomycin,	 the	 supernatant	
incubated	with	 fresh	daptomycin	was	 then	 incubated	with	wild-type	S.	aureus.	 In	parallel,	wild-
type	S.	aureus	was	incubated	in	spent	culture	supernatant	from	the	ΔagrA	mutant	not	exposed	to	
daptomycin.	 	 There	was	no	 growth	defect	 in	 the	 supernatant	 from	 the	bacteria	 incubated	with	
daptomycin,	confirming	that	the	antibiotic	had	been	fully	inactivated	(d)	(n=3	in	duplicate).	For	c,	
and	d,	error	bars	represent	the	standard	deviation	of	the	mean.	



































































in	 certain	 genes	 associated	 with	 the	 membrane	 and	 cell	 wall.	 Therefore,	 it	 was	 investigated	
whether	 the	ability	of	agr	mutant	S.	aureus	 to	 survive	daptomycin	exposure	 contributed	 to	 the	
emergence	 of	 insensitivity.	 To	 do	 this,	 a	 simple	 in	 vitro	 evolution	 experiment	was	 employed	 to	
select	 for	and	detect	 the	emergence	of	daptomycin	 insensitivity.	S.	aureus	USA300	wild-type	or	
ΔagrA	were	 inoculated	 into	 TSB	 containing	 daptomycin	 (20	 µg	 ml-1)	 and	 incubated	 for	 8	 h	 as	
described	for	killing	experiments	(Fig	3.3).	Bacteria	were	then	recovered	by	centrifugation,	washed	
with	 TSB	 and	 grown	 in	 TSB	 to	 stationary	 phase	before	 being	 re-exposed	 to	 daptomycin	 for	 8	 h	
(experiment	2).	This	procedure	was	 repeated	a	 third	 time	 (experiment	3).	 For	each	experiment,	
the	survival,	daptomycin	activity	and	MIC	at	8	h	were	determined	to	detect	whether	strains	had	
acquired	daptomycin	insensitivity.		
The	 MIC	 of	 both	 wild-type	 and	 ΔagrA	 was	 unchanged	 after	 a	 single	 exposure	 to	
daptomycin	(Fig	3.13a	and	b).	However,	in	keeping	with	a	previous	report432,	the	daptomycin	MIC	
of	both	strains	increased	after	a	second	exposure,	which	reduced	the	killing	rate	(Fig	3.13c	and	d)	
but	 did	 not	 affect	 daptomycin	 inactivation	 by	 the	 ΔagrA	 mutant	 (Fig	 3.13e	 and	 f).	 Despite	
increases	 in	 the	daptomycin	MIC,	 the	ΔagrA	mutant	 completely	 inactivated	daptomycin	 in	 all	 3	
experiments,	 whilst,	 the	 wild-type	 was	 consistently	 unable	 to	 inactivate	 daptomycin,	 despite	
surviving	the	second	and	third	exposure	to	daptomycin.		
Therefore,	 the	 release	 of	 the	 daptomycin-inactivating	 element	 does	 not	 provide	 an	
efficient	route	to	daptomycin	insensitivity.	Rather,	the	emergence	of	insensitivity	is	delayed	in	agr-
mutant	 S.	 aureus	 with	 efficient	 daptomycin	 inactivation.	 This	 suggests	 that	 daptomycin	
inactivation	 may	 enable	 S.	 aureus	 to	 survive	 short-term	 daptomycin	 exposure	 without	 the	






Figure	 3.13.	 The	 recovery	 of	 the	 ΔagrA	 mutant	 exposed	 to	 daptomycin	 is	 not	 due	 to	 the	
emergence	of	resistance,	which	only	occurs	after	repeated	antibiotic	exposure		
S.	aureus	USA300	wild-type	or	ΔagrA	were	inoculated	into	TSB	containing	daptomycin	(20	µg	ml-1)	
and	 incubated	 for	 8	 h	 (experiment	 1).	 Bacteria	were	 then	 recovered	 by	 centrifugation,	washed	
with	 TSB	 and	 grown	 in	 TSB	 to	 stationary	 phase	before	 being	 re-exposed	 to	 daptomycin	 for	 8	 h	
(experiment	2).	This	procedure	was	 repeated	a	 third	 time	 (experiment	3).	 For	each	experiment,	





two-way	 ANOVA	 with	 Dunnett’s	 post-hoc	 test,	 for	 data	 from	 experiment	 1	 vs	 data	 from	
experiments	2	or	3	P	<	0.01	at	the	indicated	time	points	(*).	In	panel	c,	for	the	final	time	point,	the	
data	from	experiment	3	but	not	2	are	significantly	different	from	experiment	1	as	determined	by	












































































































































Gram-positive	 organisms120,433.	 The	 emergence	 of	 daptomycin-resistant	 and	 daptomycin	 non-
susceptible	S.	aureus	isolates	is	rare	and	arises	due	to	spontaneous	mutations	(in	genes	including	
mprF	 and	 dlt)134.	 These	 spontaneously	 resistant	 strains	 exhibit	 changes	 in	 the	 cytoplasmic	
membrane,	cell	wall	stress	stimulon	and	in	membrane	potential,	all	of	which	are	hypothesized	to	
reduce	 the	 ability	 of	 daptomycin	 to	 depolarize	 the	 membrane134,135.	 However,	 although	





agr	 system	 can	 inactivate	 daptomycin,	 enabling	 bacterial	 survival	 and	 growth.	 Daptomycin	
exposure	 resulted	 in	an	 initial	period	of	killing	of	both	 laboratory	 (MSSA	and	MRSA)	and	clinical	
isolates	 followed	 by	 a	 period	 of	 bacterial	 recovery	 that	 coincided	 with	 the	 inactivation	 of	
daptomycin.	 This	 biphasic	 killing	 and	 subsequent	 recovery	 profile	 is	 similar	 to	 that	 observed	 in	
several	previously	 reported	daptomycin	killing	assays429–431.	However,	 the	phenomenon	was	not	
discussed	 and	 the	 contribution	 of	 Agr	 unappreciated.	 During	 extended	 incubation	 with	
daptomycin,	wild-type	strains	were	also	able	to	recover.	However,	this	occurred	at	a	much	slower	




of	an	 inactivator	secreted	or	released	 into	the	culture	supernatant	 in	response	to	the	antibiotic,	
indicating	 it	 is	 a	 specific	 response	 to	 daptomycin,	 rather	 than	 constitutively	 produced.	
Furthermore,	 the	 inactivator	 appears	 to	 be	 specific	 to	 daptomycin	 since	 Agr	 status	 did	 not	
influence	 the	 susceptibility	 of	 S.	 aureus	 to	 other	 antibiotics	 such	 as	 cloxacillin,	 vancomycin	 or	
gentamicin.	This	may	be	due	to	the	fact	that	daptomycin	is	a	lipopeptide	antibiotic	that	targets	the	
phospholipid	 membrane	 of	 the	 cell	 and	 therefore	 functions	 very	 differently	 to	 the	 other	
antibiotics	that	were	tested	100,106,120,435.	





There	 are	 very	 few	 studies	 examining	 the	 bacterial	 factors	 associated	 with	 daptomycin	






fraction	of	 isolates	 that	are	capable	of	 inactivating	daptomycin.	 In	addition,	host	 factors	such	as	
serum	and	oxidants	can	reduce	Agr	activity439,	which	may	enable	wild-type	bacteria	to	efficiently	
inactivate	the	antibiotic	during	certain	types	of	invasive	infection.	
The	 emergence	 of	 daptomycin	 non-susceptible	 or	 resistant	 strains	 is	 rare	 but	 typically	
leads	 to	 treatment	 failure440,428,28,131.	 The	 data	 shown	 here	 do	 not	 indicate	 that	 daptomycin	
inactivation	by	ΔagrA	mutant	S.	aureus	provides	an	efficient	route	to	daptomycin	insensitivity	or	
resistance.	 In	 fact,	 it	 appears	more	 likely	 that	daptomycin	 inactivation	 reduces	 the	 selection	 for	
resistance	 to	emerge.	There	 is	 some	evidence	 that	daptomycin-insensitivity/resistance	confers	a	
fitness	 deficiency441,442.	 Therefore,	 daptomycin	 inactivation	 may	 provide	 short-term	 protection	
against	 daptomycin	 without	 the	 long-term	 costs	 of	 genetic	 changes	 that	 confer	 resistance	 via	
changes	to	the	cell	wall	or	membrane,	as	has	been	described	previously	for	phenotype-switching	
and	gentamicin	resistance443	.	

















sensing	 system	 enabled	 S.	 aureus	 to	 survive	 daptomycin	 challenge	 both	 in	 vitro	 and	 in	 vivo.	
Subsequent	work	revealed	that	the	ΔagrA	mutant	was	able	to	survive	daptomycin	by	secreting	or	
releasing	a	factor	that	inactivated	the	antibiotic.		
In	 general,	 antibiotic	 inactivation	 occurs	 via	 enzymes	 that	 employ	 one	 of	 two	modes	 of	
action:	 hydrolysis	 of	 the	 antibiotic	 or	 addition	 of	 a	 chemical	 group444–446.	 Antibiotics	 that	 are	
inactivated	 by	 hydrolysis	 include	 β-lactams447,	 the	 macrolide	 erythromycin,	 and	 epoxide	
antibiotics	 such	as	 fosfomycin.	Bacterial	enzymes	 such	as	amidases	and	esterases	 inactivate	 the	
antibiotic	 by	 targeting	 and	 hydrolyzing	 the	 chemical	 bonds	 or	 groups	 that	 are	 required	 for	
antibiotic	 activity.	 For	 example,	 β-lactamases	 belong	 to	 a	 group	 of	 amidases	 that	 cleave	 the	 β-
lactam	ring	of	penicillin	and	cephalosporin	antibiotics,	rendering	them	inactive444,448,449.	Similarly,	
macrolide	 esterases	 inactivate	 erythromycin	 by	 targeting	 the	 ester	 bond,	 which	 results	 in	 the	
opening	 of	 the	 macrolide	 ring444,450,	 whereas	 epoxidases	 inactivate	 the	 epoxide	 antibiotic	
fosfomycin	by	opening	the	reactive	fosfomycin	ring	via	hydrolysis451.	
In	 addition	 to	 antibiotic	 cleavage,	 some	 enzymes	 inactivate	 antibiotics	 by	 transfer	 of	 a	
chemical	 group	 onto	 the	 drug.	 Antibiotics	 that	 are	 inactivated	 by	 this	 mechanism	 include	 the	
aminoglycosides,	 chloramphenicol,	 macrolides,	 rifamycins	 and	 fosfomycin.	 The	 enzymes	
responsible	 are	 known	 as	 group	 transferases	 and	 inactivate	 antibiotics	 by	 covalent	 addition	 of	
chemical	moieties	 that	 cause	 structural	 changes	 that	prevent	 the	antibiotic	 from	binding	 to	 the	
target.	 There	 are	 6	 chemical	 strategies	 employed	 by	 group	 transferases	 which	 include:	 (i)	 O-
acylation	and	N-acylation	 (ii)	O-phosphorylation,	 (iii)	 thiol-transfer,	 (iv)	O-nucleotidylation,	 (v)	O-
ribosylation	 and	 (vi)	 O-glycosylation.	 Because	 the	 covalent	 modifications	 require	 co-substrates	
such	 as	 ATP,	 acetyl-CoaA,	 adenine	 dinucleotide	 (NAD+),	 UDP-glucose	 or	 glutathione,	 these	
enzymes	 are	 only	 active	 in	 the	 cytoplasm	 of	 the	 bacterial	 cell444–446,448,449.	 For	 example,	
aminoglycoside	 acetyltransferases	 inactivate	 aminoglycoside	 antibiotics	 via	 N-acetylation	 that	
disrupts	 the	hydroxyl	and	amine	groups	required	for	 the	 interaction	with	the	ribosome444,452.	By	
contrast,	 chloramphenicol	 acetyltransferases	 (CATs)	 are	 trimeric	 enzymes	 that	 employ	 the	 O-
acetylation	strategy	of	covalent	modification444,453.		
Daptomycin	is	comprised	of	13	amino	acids	cyclized	through	an	ester	linkage	between	the	
secondary	hydroxyl	 group	of	 the	 amino	acid	 threonine	 (Thr)	 and	 the	 carboxyl	 of	 the	C-terminal	
kynurenine	 (Kyn)	 amino	 acid	 residues.	 The	 N-terminus	 of	 the	 tryptophan	 (Trp)	 amino	 acid	 is	
attached	 to	 a	 C-10	 fatty	 acyl	 tail.	 The	 daptomycin	 ring	 structure	 and	 fatty	 acyl	 tail	 have	 been	
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demonstrated	 to	 be	 essential	 for	 antimicrobial	 activity	 (Fig	 4.1)434,454,455.	 A	 previous	 report	 by	
D’costa	 et	 al.	 in	 2012	 detailed	 how	 soil	 actinomycetes	 inactivate	 daptomycin	 using	 hydrolytic	
enzymatic	 mechanisms.	 These	 included	 ring	 hydrolysis	 of	 daptomycin	 and	 deacylation	 of	 the	




tail	 occurs	 via	 deacylation	 and	 occurs	 via	 cleavage	 of	 the	N-terminal	 Trp	 amino	 acid	 residue	 of	
hydrolyzed	daptomycin	via	a	protease434.		
In	 addition	 to	 the	 enzymes	 produced	 by	 soil	 bacteria,	 several	 commercially	 available	
proteases	 of	 mammalian	 origin	 including	 bovine-alpha	 chymotrypsin	 and	 Type	 I	 protease	
inactivate	 daptomycin	 by	 general	 hydrolytic	 cleavage434.	 Therefore,	 it	 appears	 that	 daptomycin	
can	be	inactivated	by	several	different	routes	including	proteases	with	broad	target	ranges.	
S.	 aureus	 produces	 several	 different	 proteases,	 including	 serine	 proteases,	 cysteine	
proteases	 and	 metalloproteases.	 These	 secreted	 proteins	 are	 known	 to	 function	 as	 virulence	
factors,	enabling	 the	acquisition	of	nutrients	 from	host	 tissues	and	degradation	of	antimicrobial	










Daptomycin	 consists	 of	 13	 amino	acids.	 The	peptide	 core	 is	 composed	of	 amino	acids	 including	
Gly,	Orn,	Asp,	D-Ala,	Asp,	Gly,	D-Ser,	MeGlu	and	Kyn,	that	forms	an	ester	bond	with	Thr	and	builds	
up	the	10-member	macrolactone	ring	and	three	exocyclic	residues	including	Trp,	D-Asn	and	L-Asp.	
The	N-terminal	 Trp	 is	 attached	 to	 the	 fatty	 acyl	moiety,	which	 consists	 of	 10	 carbon	 atoms	 (n-
decanoyl).	In	addition,	daptomycin	is	a	member	of	the	acidic	lipopeptide	family	and	has	an	overall	
(-3)	charge.	The	bactericidal	activity	of	daptomycin	is	dependent	on	binding	to	calcium	because	it	
causes	a	 conformational	 change	 in	daptomycin	and	 forms	a	bridge	between	 the	cell	membrane	
and	daptomycin.	A	conserved	motif	 is	 responsible	 for	providing	calcium-binding	sites,	which	are	









































































































































Ring	 hydrolysis	 between	 amino	 acids	 4-13	 and	 12	 and	 13	 (indicated	 by	 the	 blue	 spiral	 symbol)	



























































As	 a	 first	 step	 towards	 testing	whether	 S.	 aureus	 inactivated	 daptomycin	 via	 an	 enzyme,	 initial	
experiments	 sought	 to	 characterize	 the	 basic	 properties	 of	 the	 inactivator.	 Firstly,	 proteins	 in	
culture	supernatants	from	the	S.	aureus	USA300	ΔagrA	mutant	previously	exposed	to	daptomycin	
were	 degraded	 by	 treatment	 with	 proteinase	 K,	 a	 serine	 protease	 that	 exhibits	 a	 very	 broad	
cleavage	specificity459	or	 trypsin,	which	cleaves	peptide	chains	at	 the	carboxyl	side	of	 the	amino	
acids	lysine	or	arginine460.	Culture	supernatants	were	also	heat	treated	at	80	oC	for	20	minutes	to	







in	 the	 staphylococcal	 membrane,	 disrupting	 membrane	 organization	 and	 triggering	 membrane	
blebbing	without	lysis28,121,125,462,463.	Therefore,	it	was	hypothesised	that	membrane	phospholipids	
released	 into	 the	extracellular	 space	could	bind	and	 inactivate	daptomycin.	This	hypothesis	was	
supported	 by	 previous	 work	 showing	 that	 pulmonary	 surfactant,	 which	 contains	 phospholipids	
including	PG,	inactivates	daptomycin464,465.	To	test	this	hypothesis,	culture	supernatants	from	the	
S.	 aureus	 USA300	 ΔagrA	 mutant	 previously	 exposed	 to	 daptomycin	 were	 treated	 with	
phospholipases	 A1,	 A2	 and	 D	 or	 0.1%	 Triton	 X-100.	 Each	 phospholipase	 cleaves	 at	 a	 different	
position	on	the	phospholipid	molecule,	with	phospholipase	A1	cleaving	the	acyl	chain	attached	to	
position	 -1	of	 the	glycerol-3-phosphate	 substrate,	phospholipase	A2	cleaves	 the	 fatty	acid	 chain	
attached	to	position	-2	of	the	glycerol-3-phosphate	substrate	and	phospholipase	D	cleaves	at	the	
phosphate	 group	 to	 produce	 phosphatidic	 acid466.	 Triton	 X-100	 is	 a	 detergent	 that	 solubilizes	
phospholipids467.	 Each	 of	 the	 three	 phospholipases	 restored	 the	 activity	 of	 daptomycin	 as	 did	
Triton	 X-100	 (Fig.	 4.3),	 strongly	 indicating	 that	 the	 daptomycin	 inactivator	 found	 in	 the	 culture	
supernatants	of	the	ΔagrA	mutant	was	a	phospholipid.	
Since	 the	 daptomycin	 inactivator	 was	 only	 produced	 by	 the	 S.	 aureus	 ΔagrA	mutant	 in	
response	 to	 the	 antibiotic	 (Fig.	 3.12c),	 culture	 supernatants	 from	 bacteria	 exposed	 or	 not	 to	
daptomycin	were	examined	 for	 the	presence	of	 phospholipids.	 For	 this,	 a	 phospholipid-reactive	
dye	 (FM-4	 -64)468	 was	 used	 to	 detect	 and	 quantify	 phospholipids	 released	 in	 the	 culture	
supernatant	 during	 exposure	 of	 the	 S.	 aureus	 ΔagrA	 mutant	 to	 daptomycin	 (Fig	 4.4).	 In	 the	
		 122	
absence	of	daptomycin,	S.	aureus	 ΔagrA	 released	extremely	 low	 levels	of	phospholipid	 into	 the	
supernatant.	However,	bacteria	exposed	to	the	antibiotic	released	huge	quantities	of	phospholipid	
during	 the	 first	 4	 hours	 of	 exposure,	 after	 which	 the	 rate	 of	 phospholipid	 accumulation	 in	 the	
medium	decreased	significantly.	The	observed	kinetics	of	phospholipid	release	fits	with	the	data	in	
(Fig.	 3.9)	 showing	 that	 daptomycin	 is	 inactivated	 in	 the	 first	 4	 hr	 of	 incubation	 with	 S.	 aureus	




mutant	 that	 had	 been	 exposed	 to	 daptomycin,	 thin-layer	 chromatography	 (TLC)	 was	
employed132,416,131,415.	 Phospholipids	 were	 extracted	 using	 the	 chloroform:methanol	 Bligh-Dyer	
method.	Thereafter,	a	silica-based	TLC	plate	was	spotted	with	the	extracted	lipid	sample	and	run	
in	 chloroform:methanol:30%ammonium	 hydroxide	 (65:30:4	 v/v/v)	 solvent	 to	 separate	 lipids,	
which	 were	 then	 detected	 by	 iodine	 staining.	 The	 identity	 of	 each	 spot	 was	 determined	 by	
reference	 to	 the	 migration	 pattern	 of	 phospholipid	 standards	 purified	 from	 TSB	 containing	
daptomycin	as	described	for	experimental	samples.	These	phospholipid	standards	were	chosen	on	
the	basis	 that	 they	have	previously	been	 reported	 to	occur	 in	 the	staphylococcal	membrane,	or	
that	act	as	precursors	to	those	lipids	that	are	found	in	the	membrane	28,469.	
	 TLC	 analyses	 revealed	 that	 the	 culture	 supernatant	 contained	 PG,	 lysyl-
phosphatidylglycerol	 (LPG)	 and	 cardiolipin	 (CL)	 (Fig	 4.5).	 To	 quantify	 each	 of	 the	 identified	
phospholipids	2D-TLC	was	undertaken	and	 lipids	revealed	by	 iodine	staining.	Thereafter,	each	of	
the	lipid	spots	that	had	been	identified	as	PG,	LPG	and	CL	were	scraped	off	the	plate	and	subjected	
to	 a	 colorimetric	phosphate	quantification	assay.	 This	 revealed	 that	PG	was	 the	most	 abundant	
phospholipid	species	(>70%	of	total	phospholipid),	together	with	smaller	quantities	of	CL	and	LPG	
in	the	culture	supernatant	of	the	ΔagrA	mutant	exposed	to	daptomycin	(Table	4.1	and	Fig	4.5).	










	Daptomycin	 activity	 in	 TSB	 only	 (TSB)	 or	 culture	 supernatant	 from	 USA300	 ΔagrA	 exposed	 to	
daptomycin	and	subsequently	treated	with	heat	(80oC,	20	min),	proteinase	K	(prot.	K,	10	μg	ml-1),	
trypsin	(10	μg	ml-1),	phospholipases	(PLP)	A1,	A2	or	D	(each	at	5	U	ml-1),	or	0.1%	Triton	X-100	(TX-
100)	 (n=4,	 in	 duplicate,	 for	 untreated	 samples	 vs	 phospholipase	 or	 TX-100-treated	 samples	P	 <	













































































































Figure	 4.5.	 Spent	 culture	 supernatant	 from	 ΔagrA	 USA300	 exposed	 to	 daptomycin	 contains	
membrane	phospholipids		
Thin-layer	 chromatography	 (TLC)	 plate	 spotted	with	 chloroform:methanol	 extracts	 from	 culture	
supernatant	of	TSB	only	(TSB),	TSB	containing	daptomycin,	filtered	culture	supernatant	from	the	
agrA	mutant	exposed	to	daptomycin	(agrA),	TSB	containing	daptomycin	and	various	phospholipids	
standards,	 including	 phosphatidylglycerol	 (PG)28,	 cardiolipin	 (CL)28,	 lysyl-phosphatidylglycerol	





Lipids	were	 identified	 by	 reference	 to	 purified	 standards	 and	quantified	 as	 described	 in	 section	












Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	




USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	



















Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	
Other	 0.4±1.6	 0.3±1.4	 6.9±5.1	 6.7±5.0	
	
	
Supplementary	Table	2.	 Identification	and	q antific tion	of	phospholipids	 in	the	culture	supernatant	of	
USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	



















Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	




USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	




























(PA)	or	diacylglycerol	 (DAG).	The	activity	of	daptomycin	was	 then	determined	using	 the	 zone	of	
inhibition	assay	described	previously.	This	revealed	that,	at	concentrations	similar	to	those	found	
in	the	culture	supernatant,	purified	PG	inactivated	daptomycin	in	a	dose-dependent	manner	(Fig	




PG	 alone,	 this	 mixture	 of	 PG,	 LPG	 and	 CL	 also	 efficiently	 inactivated	 daptomycin	 in	 a	 dose	
dependent	manner	(Fig	4.6b).		
To	provide	additional	evidence	that	exogenous	PG	protected	S.	aureus	 from	daptomycin,	
an	MIC/MBC	 assay	 of	 the	wild-type	 and	 the	 ΔagrA	mutant	was	 undertaken	 in	 the	 presence	 of	
purified	 PG,	 LPG	 or	 CL.	 It	 was	 found	 that	 the	 daptomycin	MIC/MBC	 of	 both	 the	 strains	 in	 the	
absence	of	phospholipid	 (1	μg	ml-1)	was	 the	same	 in	 the	 in	 the	presence	of	CL.	By	contrast,	 the	
MIC/MBC	of	both	the	wild-type	ΔagrA	mutant	in	the	presence	of	PG	was	significantly	increased	(8	
μg	ml-1),	whilst	 the	 presence	 of	 LPG	 led	 to	 a	more	modest	 increase	 (4	 μg	ml-1).	 Therefore,	 the	
























































































































































Having	 established	 that	 daptomycin	 was	 inactivated	 by	 released	 phospholipids,	 it	 was	 then	
investigated	 whether	 this	 occurred	 via	 an	 active	 process	 or	 was	 simply	 a	 consequence	 of	
membrane	damage	 caused	by	 the	 antibiotic.	 To	 do	 this,	 key	 cellular	 processes	were	 chemically	
inhibited	before	daptomycin	challenge	and	measurement	of	 released	phospholipids.	Respiration	




resulted	 in	 the	 release	 of	 high	 levels	 of	 phospholipid	 (Fig	 4.7).	 By	 contrast,	 the	 presence	 of	





To	 ensure	 that	 the	 panel	 of	 inhibitors	 used	 did	 not	 interfere	 in	 any	 way	 with	 the	




that	 because	 lysostaphin	 is	 an	 enzyme,	 assays	 done	 at	 4oC	 resulted	 in	 reduced	 cell	 lysis	 and	
therefore	reduced	phospholipid	release	(Fig	4.9a,	b).		
	 In	 conclusion,	 these	 assays	 revealed	 that	 daptomycin-triggered	 phospholipid	



















respiratory	 inhibitors	 2-n-Heptyl-4-hydroxyquinoline	 N-oxide	 (HQNO)	 or	 NaN3,	 or	 antibiotics	


















































Dunnett’s	 post-hoc	 test.	 For	 bacteria	 treated	 with	 daptomycin	 only	 vs	 bacteria	 treated	 with	


































Figure	 4.9.	 Lipid	 release	 due	 to	 heat	 or	 lysostaphin	 treatment	 is	 not	 affected	 by	 inhibition	 of	
protein	synthesis	or	the	respiratory	chain		
The	USA300	ΔagrA	mutant	was	exposed	 to	 to	 lysostaphin	 (a)	 (10	µg	ml-1,	8	h,	37oC)	or	heat	 (b)		
(100oC,	 20	 min)	 in	 the	 presence	 or	 absence	 (CTL)	 of	 the	 following:	 tetracycline	 (Tet),	






















































































stress	 stimulon	 (CWSS),	 regulated	 by	 the	 products	 of	 the	 vraUTSR	 operon111,135,470.	 This	 operon	
encodes	an	inter-membrane	histidine	kinase	two-component	signaling	transduction	system	(TCS).	
Although	VraUTRS	 is	 characterized	 as	 vancomycin	 resistance	 associated,	 it	 detects	 cell	wall	 and	
membrane	damage	caused	by	 several	different	antibiotics,	 including	β-lactams,	vancomycin	and	
daptomycin111,135,470.	 VraS	 is	 the	 inner-membrane	 histidine	 kinase,	 but	 lacks	 a	 characteristic	
sensing	domain471,472.	 It	 responds	 to	 antimicrobial-induced	 cell	wall	 and/or	membrane	 stress	by	
autophosphorylation	 and	 then	 transphosphorylates	 VraR111,471.	 VraR	 is	 the	 cognate	 response	




To	 determine	 whether	 the	 VraUTSR/CWSS	 regulon	 contributes	 to	 the	 release	 of	
phospholipids	in	response	to	daptomycin,	wild-type	S.	aureus,	vraS::Tn	and	vraR::Tn	mutants	from	
the	 USA00	 JE2	 NARSA	 library398	 were	 grown	 under	 Agr-suppressed	 conditions	 (Agr-)	 using	
synthetic	AIP3,	which	blocks	the	type	I	Agr	system	in	USA300385.		
As	expected,	based	on	previous	results,	the	wild-type	bacteria	grown	under	Agr-	conditions	
survived	 exposure	 to	 daptomycin	 (Fig	 4.10a).	 By	 contrast,	 the	 survival	 of	 both	 vraS::Tn	 and	
vraR::Tn	mutants	 grown	 under	 Agr-	conditions	was	 significantly	 reduced	 compared	 to	 the	wild-




characterised	 ΔvraUTSR	 deletion	 mutant	 in	 the	 USA300	 strain111.	 Similar	 to	 the	 vraS::Tn	 and	
vraR::Tn	mutants	it	was	observed	that	the	ΔvraUTSR	mutant	released	significantly	reduced	levels	
of	 phospholipid	 in	 response	 to	 daptomycin,	 which	 in	 turn	 reduced	 the	 rate	 of	 inactivation	 of	
daptomycin	and	enhanced	the	killing	of	the	mutants	(Fig	4.11).	
Overall,	 these	 experiments	 with	 S.	 aureus	 vra	 mutants	 strongly	 indicate	 that	 the	







two-way	ANOVA	and	Dunnett’s	 post-hoc	 test.	 For	WT	Agr-	 bacteria	 treated	with	daptomycin	 vs	





Survival	 (a),	 lipid	 release	 (b)	 and	 daptomycin	 activity	 (c)	 of	 the	 wild-type	 and	 vraUTSR	 mutant	
grown	under	Agr	suppressed	conditions.	Data	 represent	 the	mean	of	n=3	 in	duplicate	and	were	
analysed	 two-way	 ANOVA	 and	 Dunnett’s	 post-hoc	 test.	 For	 WT	 Agr-	 bacteria	 treated	 with	





















































































4.6 A	 partial	 screen	 of	 the	 NARSA	 transposon	 mutant	 library	 reveals	 a	
requirement	 for	 PBP3	and	diacylglycerol	 glucosyltransferase	 in	daptomycin-
induced	phospholipid	release	
Having	 shown	 that	 daptomycin-induced	 phospholipid	 release	 is	 regulated	 by	 VraUTRS,	 it	 was	
decided	 to	 investigate	 the	 mechanism	 by	 which	 phospholipid	 release	 occurs.	 Our	 data	 from	
experiments	 with	 vra	 mutants	 indicated	 a	 role	 for	 cell	 wall	 remodeling,	 and	 previous	 studies	
indicated	 that	 daptomycin	 disrupts	 the	 cell	 membrane	 and	 division	 machinery126.	 Therefore,	 a	
limited	 transposon	 screen	 was	 undertaken	 on	 mutants	 with	 transposon	 insertions	 in	 genes	
involved	in	cell	wall	or	lipid	biosynthesis	or	that	were	involved	in	cell	division	(Table	4.2).	The	wild-
type	S.	aureus	and	 transposon	mutants	were	 incubated	with	daptomycin	at	37oC	 for	8	h	before	
phospholipid	levels	were	quantified.		This	revealed	defective	phospholipid	release	in	two	mutants:	
pbp3::Tn	(penicillin	binding	protein	3	 involved	in	peptidoglycan	synthesis)24	and	SAUSA_0918::Tn	
(diacylglycerol	 glucosyltransferase	 synthase	 involved	 in	 lipid	 metabolism	 and	 lipoteichoic	 acid	
anchoring)473,474	(Fig	4.12a).		
To	 ensure	 that	 the	 phenotypes	 observed	 were	 due	 to	 the	 inserted	 transposons,	 assays	
were	 repeated	 with	 SH1000	 strains	 into	 which	 selected	 transposons	 had	 been	 transduced:	
pbp3::Tn,	 SAUSA_0918::Tn,	 ftsK::Tn	 and	 ftsH::Tn	 (the	 latter	 two	were	 included	 as	 controls)	 (Fig	




type.	 There	was	no	 significant	 growth	defect	 between	 the	wild-type	and	any	of	 the	 transposon	
mutants	(Fig	4.13).	
Overall,	 these	 findings	 indicate	 roles	 for	 cell	 wall	 remodeling	 and	 lipid	 biosynthesis	 in	
daptomycin-induced	 phospholipid	 release.	 These	 insights	 into	 the	 mechanism	 of	 phospholipid	












































(a).	 Lipid	 release	of	SH1000	wild-type	and	mutants	exposed	 to	20	µg	ml-1	daptomycin	over	 time	






































































































































































































































































4.7 The	 cationic	 antimicrobial	 peptides	 (CAMPs)	 nisin	 and	 melittin	 trigger	 the	
release	of	phospholipids	from	the	ΔagrA	mutant	
Daptomycin	 is	 an	 anionic	 lipopeptide,	 which	 has	 a	 positive	 overall	 charge	 in	 the	 presence	 of	
calcium,	 and	 functions	 by	 targeting	 the	 membrane	 phospholipids	 of	 Gram-positive	 bacteria.	
CAMPs	 such	 as	 nisin	 and	melittin	 function	 in	 a	 similar	way	 to	 daptomycin.	 Nisin	 is	 a	 polycyclic	
cationic	 amphiphilic	 antibacterial	 peptide	 belonging	 to	 the	 lantibiotic	 family.	 It	 consists	 of	 34	
amino	acid	residues	and	functions	by	binding	to	the	membrane,	and	induces	pore	formation	in	S.	
aureus475–477.	Melittin	 is	 a	 lytic	 antimicrobial	 peptide	 of	 26	 amino	 acid	 residues.	 It	 binds	 to	 the	
membrane	and	once	it	reaches	a	threshold	it	forms	a	pore478–480.	Because	these	CAMPs	function	in	
a	 similar	 way	 to	 daptomycin	 it	 was	 hypothesised	 that	 phospholipid	 release	 may	 also	 confer	
protection	against	these	and	similar	membrane-acting	antimicrobials.		
To	test	this	hypothesis,	survival	and	phospholipid	release	was	measured	during	incubation	
of	 S.	 aureus	 wild-type	 or	 ΔagrA	 mutant	 with	 nisin	 or	melittin	 at	 37oC	 for	 8	 h.	 Similarly	 to	 the	
survival	 profile	 seen	with	 daptomycin,	 after	 an	 initial	 period	 of	 killing	 (10-fold	 decrease	 in	 CFU	
counts)	by	both	nisin	and	melittin,	the	ΔagrA	mutant	subsequently	recovered	more	rapidly	than	
the	wild-type	 (Fig	 4.14a,b).	 Again,	 as	 seen	 for	 daptomycin,	 both	 CAMPs	 triggered	 phospholipid	




not	 diffuse	 efficiently	 or	 uniformly	 in	 TSA	 plates	 and	 therefore,	 it	was	 not	 possible	 to	measure	
their	activity	using	the	zone	of	inhibition	assay	as	was	done	for	daptomycin.		
To	test	whether	PG	was	responsible	for	mediating	survival	of	the	ΔagrA	mutant	exposed	to	
either	 peptide,	 the	 MIC	 of	 both	 peptides	 was	 determined	 in	 the	 absence	 or	 presence	 of	 the	
phospholipid.	 It	was	found	that	the	presence	of	PG	increased	the	MIC	of	both	nisin	and	melittin	
44-fold	(Fig	4.15).		
Taken	 together,	 these	 data	 indicate	 that	 phospholipid	 release	may	 constitute	 a	 general	












Melittin	 P	 <0.0001	 by	 one-way	 ANOVA	 with	 Tukey	 post-hoc	 test)	 (c)	 but	 triggered	 enhanced	


























































































































































4.8.1 A	 S.	 aureus	 ΔagrA	 mutant	 actively	 releases	 phospholipids	 in	 response	 to	
daptomycin	
The	 work	 described	 in	 this	 chapter	 revealed	 that	 the	 S.	 aureus	 ΔagrA	 mutant	 inactivates	
daptomycin	 via	 a	 novel,	 enzyme-independent,	mechanism.	Daptomycin	 triggered	 the	 release	 of	
phospholipids,	primarily	phosphatidylglycerol,	which	sequestered	daptomycin	and	inactivated	the	
antibiotic	 (Fig	 4.16).	 This	 finding	 is	 in	 keeping	 with	 previous	 reports	 that	 showed	 daptomycin	
challenge	leads	to	membrane	blebbing	in	S.	aureus126	and	that	daptomycin	can	extract	lipids	from	
artificial	 membrane	 vesicles462.	 However,	 the	 release	 of	 phospholipids	 is	 not	 passive	 or	 the	







the	 formation	of	membrane	blebs	may	directly	 provide	 the	 released	 lipids,	 rather	 than	e.g.	 the	
secretion	of	specific	phospholipids.	Of	these	phospholipids,	only	phosphatidylglycerol	 inactivated	
daptomycin	at	the	concentrations	present.	This	is	perhaps	not	surprising	since	this	is	the	target	of	
daptomycin	 is	 the	membrane.	What	 is	more	surprising	 is	 that	daptomycin	appears	to	have	a	 far	
higher	affinity	for	phosphatidylglycerol	monomers	or	micelles	in	the	culture	supernatant	than	the	






















	 The	 finding	 that	 free	 phospholipid	 sequesters	 daptomycin	 and	 enables	 staphylococcal	
survival	 is	 supported	by	a	previous	study	 from	Silverman	et.	al.,	 (2005),	who	demonstrated	that	
pulmonary	 surfactant	 reduces	 the	 activity	 of	 daptomycin,	making	 it	 an	 ineffective	 antibiotic	 to	
treat	pneumonia	caused	by	S.	aureus465.	Pulmonary	surfactant	is	rich	in	phosphatidylcholine	(PC),	
PG,	 cholesterol	 and	 neutral	 lipids	 and	 its	 role	 is	 to	 reduce	 the	 surface	 tension	 at	 the	 air-liquid	







fold	 less	 efficiently	 than	 PG,	 was	 surprising.	 This	 is	 because	 the	 presence	 of	 elevated	
concentrations	of	 LPG	 in	 the	S.	 aureus	membrane	 is	 associated	with	decreased	 susceptibility	 to	
daptomycin130,482,483.	 One	 of	 the	 hypotheses	 to	 explain	 this	 is	 that	 the	 positively	 charged	 LPG	
headgroup	 repels	daptomycin.	However,	 recent	work	has	 shown	 that	 LPG	does	not	 significantly	




charged	head	group	of	LPG	 is	accessible,	whereas	the	LPG	 in	suspension	will	expose	 its	 lipid	tail	






























































































































































4.8.3 	The	 cell	 wall	 stress	 stimulon	 vraUTRS	 is	 involved	 in	 regulating	 the	 release	 of	
phospholipids	in	response	to	daptomycin	
The	release	of	phospholipid	from	the	S.	aureus	ΔagrA	mutant	is	a	specific	response	to	daptomycin	
and	appears	 to	be	 regulated	by	 the	vraUTRS/CWSS	 regulon,	 at	 least	 in	part,	 since	phospholipid	
release	was	impaired	in	a	mutant	lacking	the	vraUTRS	operon.	Whilst	there	was	a	clear	phenotype	
for	the	mutant,	future	experiments	will	involve	complementation	of	the	mutant	with	the	wild-type	




Because	 the	phospholipids	must	 traverse	 the	 cell	wall	 to	be	 released,	 it	 is	not	 surprising	
that	a	regulator	of	cell	wall	biosynthesis	is	important	for	the	release	of	phospholipids	in	response	
to	 daptomycin.	 However,	 the	 mechanism	 by	 which	 these	 phospholipids	 cross	 the	 cell	 wall	 is	
currently	unknown.	To	 investigate	how	the	VraUTRS/CWSS	regulon	modifies	the	cell	wall,	 future	
work	 will	 look	 at	 the	 VraUTRS/CWSS	 regulon	 by	 using	 the	 mutants	 of	 the	 regulon.	 	 However,	
because	some	of	the	genes	are	essential	for	S.	aureus	survival,	chemical	inhibitors,	many	of	which	
are	 antibiotics,	 will	 be	 used	 to	 block	 the	 several	 essential	 steps	 in	 the	 biosynthesis	 of	 the	
peptidoglycan	layer.	If	the	use	of	these	cell	wall	acting	antibiotics	block	lipid	release	it	might	then	
constitute	 a	 useful	 therapeutic	 approach	 to	 improve	 the	 activity	 of	 daptomycin,	 as	 well	 as	
contribute	 towards	enhancing	our	understanding	about	 the	emerging	area	of	membrane	vesicle	
release	in	Gram	positive	bacteria	for	which	our	understanding	is	very	limited.	For	example,	it	has	
been	 hypothesised	 that	 the	 release	 of	 extracellular	membrane	 vesicles	might	 occur	 via	 protein	
channels	 that	may	guide	 the	membrane	vesicles	 towards	 the	extracellular	 space	and/or	pushed	
through	 the	 cell	 wall	 via	 turgor	 pressure	 after	 the	 release	 from	 the	 plasma	membrane	 and/or	
released	by	cell	wall	modifying	enzymes	that	loosen	the	cell	wall	and	increase	the	pore	size11.		















target	 the	 staphylococcal	 membrane	 and	 cause	 pore	 formation.	 In	 addition,	 similarly	 to	
daptomycin,	Therrien	A.	et.	al.	(2016)	demonstrated	that	melittin	can	extract	lipids	from	artificial	









The	 release	 of	 membrane	 phospholipids	 may	 confer	 protection	 against	 antimicrobial	
peptides	 in	addition	 to	daptomycin	and	these	may	have	provided	the	selection	pressure	 for	 the	
evolution	of	the	phospholipid	release	response	to	membrane	damage.	There	is	growing	evidence	
that	 antimicrobial	 peptides	 that	 are	 produced	 by	 almost	 all	 tissues	 play	 an	 important	 role	 in	
human	 immunity492.	 For	 example,	 antimicrobial	 peptides	 such	 as	 human	 β-defensins	 that	 are	
found	on	the	skin	epithelial	surfaces	show	antimicrobial	activity	against	both	Gram-negative	and	
Gram-positive	 bacteria492,493,	 and	 LL-37,	 which	 belongs	 to	 the	 cathelicidin-related	 antimicrobial	
family,	 is	 found	 in	 polymorphonuclear	 leukocytes	 and	 is	 an	 effector	 molecule	 of	 the	 innate	
immunity	 in	 the	 skin457,494,495.	 Since	 LL-37	 and	 β-defensins	 target	 the	 bacterial	 membrane	 and	
cause	 pore	 formation495,	 it	 would	 be	 interesting	 to	 investigate	 whether	 these	 host	 defence	














releasing	 phospholipids,	 which	 sequestered	 the	 antibiotic,	 rendering	 it	 inactive.	 Therefore,	 the	
next	question	to	address	was	why	S.	aureus	lacking	a	functional	Agr	system,	but	not	the	wild-type,	





consists	 of	 agrB,	 agrD,	 agrC	 and	 agrA	 that	 makes	 the	 quorum-sensing	 component	 and	 RNAIII	
which	 is	 the	 effector	 molecule	 of	 the	 Agr	 system140,496.	 Upon	 activation,	 AgrA	 (the	 response	
regulator)	binds	to	the	P2	promoter	region	and	drives	the	expression	of	RNAII	thus	completing	the	
autoactivation	circuit	and	also	binds	to	the	P3	promoter	region,	driving	the	expression	of	RNAIII	
that	regulates	most	of	the	genes	 in	the	Agr	regulon.	 In	addition,	activated	AgrA,	 independent	of	
the	 regulatory	 RNAIII	 factor,	 directly	 binds	 to	 the	 promoters	 and	 induces	 the	 expression	 of	 the	
PSMα	and	PSMβ	peptide	toxins.	AgrA	also	down-regulates	the	expression	of	~90	metabolic	genes	
involved	in	carbohydrate	and	amino	acid	metabolism140,158.	
There	 are	 7	 PSM	 peptide	 genes	 that	 are	 encoded	 at	 three	 different	 locations	 in	 the	





terminus	of	 the	 longer	PSMβ1	–β2	peptides.	This	α-peptide	region	enables	the	formation	of	 the	
amphipathic	α-helix,	which	is	formed	by	all	the	7	peptides	and	confers	a	characteristic	surfactant-
like	 property.	 This	 amphipathic	 characteristic	 enables	 the	 PSMs	 to	 form	 aggregates,	 enable	
bacterial	spread	on	surfaces	and	the	formation	and	dispersal	of	biofilms140,332,497.		
	The	 PSMα	 peptides	 are	 positively	 charged	 and	 cytolytic,	 whilst	 the	 PSMβ	 peptides	 are	
negatively	 charged	 and	 are	 non-cytolytic.	 PSMδ	 is	 neutral	 in	 charge	 and	 moderately	 cytolytic	
158,176,397.	 The	 lytic	 activity	 of	 PSMα	 peptides	 extends	 to	 human	 neutrophils,	 erythrocytes,	
leukocytes,	osteoblasts	and	macrophages140,294,498	and	several	studies	in	animal	models	indicate	an	













PSM	 Amino	acid	sequence	 PepAde	length	 charge	
δ-toxin	 fMAQDIISTIGDLVKWIIDTVNKFTKK	 26	 0	
α1	 fMGIIAGIIKVIKSLIEQFTGK	 21	 +1	
α2	 fMGIIAGIIKFIKGLIEKFTGK	 21	 +2	
α3	 fMEFVAKLFKFFKDLLGKFLGNN	 22	 +1	
α4	 fMAIVGTIIKIIKAIIDIFAK	 22	 +1	
β1	 fMEGLFNAIKDTVTAAINNDGAKLGTSIVSIVENGVGLLGKLFGF	 44	 -2	





By	 contrast	 to	 the	 psm	 genes,	 AgrA	 down-regulates	 the	 expression	 of	 ~90	 genes	 that	
encode	enzymes	 involved	 in	 carbohydrate	 and	amino	acid	metabolism.	However,	 the	 impact	of	
this	regulation	on	bacterial	physiology	is	largely	unexplored.	





Hypothesis	 1.	 Agr	 activity	 prevented	 wild-type	 bacteria	 from	 releasing	 phospholipids	 in	
response	to	daptomycin.		





















5.2 Wild-type	 S.	 aureus	 releases	 membrane	 phospholipids	 in	 response	 to	
daptomycin		
To	determine	whether	Agr	activity	influenced	daptomycin-induced	phospholipid	release,	wild-type	
S.	 aureus	 was	 incubated	 with	 daptomycin	 and	 the	 phospholipid	 released	 in	 the	 culture	
supernatant	was	measured	 every	 2	 h	 (Fig	 5.1).	 By	 contrast	 to	 the	 ΔagrA	mutant,	 the	wild-type	
released	some	phospholipid	in	the	absence	of	daptomycin.	However,	the	quantity	of	phospholipid	
released	by	wild-type	 bacteria	 in	 response	 to	 daptomycin	was	 significantly	 greater	 than	 that	 of	
wild-type	bacteria	in	the	absence	of	daptomycin,	and	similar	to	that	seen	for	the	ΔagrA	mutant	in	
response	to	daptomycin	(Fig	4.4	and	5.1).	This	demonstrated	that	both	wild-type	S.	aureus	and	the	






address	 was	 why	 does	 the	 phospholipid	 released	 from	 the	 wild-type	 bacteria	 not	 inactivate	
daptomycin?	 Since	 PG	 was	 shown	 to	 be	 essential	 for	 the	 inactivation	 of	 daptomycin,	 it	 was	
hypothesized	that	wild-type	bacteria	did	not	release	this	type	of	phospholipid.	To	test	this,	culture	




























































































































































Silica-based	 thin-layer	 chromatography	 (TLC)	 plates	 were	 spotted	 with	 chloroform:methanol	
extracts	 from	TSB	 containing	 daptomycin,	 purified	 PG,	 both	 or	 neither,	 and	 stained	with	 iodine	
vapour	 after	 chromatography	 in	 chloroform:methanol:ammonium	hydroxide	 (65:30:4	 v/v/v)	 (a).	
TLC	of	chloroform:methanol	extracts	from	culture	supernatant	of	wild-type	(WT)	or	ΔagrA	(agrA)	
mutant	 exposed	 or	 not	 to	 daptomycin	 were	 adjusted	 to	 the	 same	 lipid	 concentrations	 and	
processed	 as	 described	 in	 a	 (b).	 The	 migration	 of	 lipids	 in	 the	 extract	 from	 spent	 culture	






























Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	




USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	



















Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	
Other	 0.4±1.6	 0.3±1.4	 6.9±5.1	 6.7±5.0	
	
	
Supplementary	Table	2.	 Identification	and	q antific tion	of	phospholipids	 in	the	culture	supernatant	of	
USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	
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5.4 Most	 of	 the	 phospholipids	 released	 in	 response	 to	 daptomycin	 are	 in	 the	
form	of	monomers	or	small	micelles	and	not	membrane	vesicles		
Since	wild-type	 bacteria	 released	 the	 same	 phospholipid	 species	 and	 in	 similar	 amounts	 to	 the	
ΔagrA	mutant,	the	phospholipid	released	from	the	wild-type	was	unable	to	inactivate	daptomycin.		
Phospholipids	 can	 exist	 in	 different	 physical	 states,	 including	 monomers,	 micelles	 and	
vesicles.	 Previous	 work	 with	 Escherichia	 coli	 suggested	 that	 membrane	 vesicles	 provided	
protection	against	membrane-targeting	antimicrobials	such	as	polymyxin	antibiotics500.	Therefore,	
it	was	 hypothesized	 that	wild-type	 and	 ΔagrA	mutant	 S.	 aureus	might	 release	 phospholipids	 in	
different	physical	states,	which	in	turn	affected	the	efficiency	of	daptomycin	inactivation.	
To	determine	the	physical	form	of	the	lipid	released	by	S.	aureus	exposed	to	daptomycin,	a	
well-characterised	 method	 was	 used	 to	 fractionate	 released	 phospholipids	 in	 vesicles	 and	
monomers/micelles11.	Culture	supernatant	from	the	USA300	wild-type	or	ΔagrA	mutant	exposed	
to	20	µg	ml-1	daptomycin	was	subjected	to	ultracentrifugation	at	150,000	×	g	and	the	amount	of	
lipid	 that	was	 recovered	 as	 a	 pellet	 (vesicles)	was	 compared	with	 that	 remaining	 in	 suspension	
(monomers/micelles)	using	FM-4-64	dye.	This	 indicated	that	25±1%	of	the	 lipid	released	from	S.	
aureus	ΔagrA	 cultures	 exposed	 to	 daptomycin	was	 in	 the	 form	 of	 vesicles,	 compared	with	 just	
12±1%	of	the	phospholipid	released	by	the	wild-type,	(Fig	5.3a).		
To	 determine	 whether	 the	 phospholipid	 vesicles	 were	 responsible	 for	 inactivating	
daptomycin,	 Bodipy-tagged	 daptomycin	 was	 used	 to	 challenge	 S.	 aureus,	 and	 the	 culture	
supernatant	 was	 subsequently	 subjected	 to	 ultracentrifugation	 at	 150,000	 ×	 g	 to	 recover	
phospholipid	 vesicles.	 This	 revealed	 that	 membrane	 vesicles	 were	 associated	 with	 very	 little	
BoDipy-tagged	 daptomycin,	 which	 was	 mostly	 associated	 with	 monomeric/micellular	
phospholipids	in	suspension	(Fig	5.3b).	To	confirm	that	phospholipid	vesicles	were	not	responsible	
for	 inactivating	 daptomycin,	 culture	 supernatant	 from	 the	 ΔagrA	mutant	 was	 fractionated	 into	
vesicles	 and	 monomers/micelles,	 mixed	 with	 daptomycin,	 and	 the	 activity	 of	 the	 antibiotic	
measured.	This	revealed	that	daptomycin	activity	 in	the	presence	of	purified	membrane	vesicles	
was	unaffected.	By	comparison,	daptomycin	that	had	been	incubated	with	the	monomer/micelle	
fraction	was	 significantly	 reduced	 (Fig	5.3c).	 This	 confirmed	 that	phospholipid	 vesicles	were	not	
responsible	for	inactivating	daptomycin,	and	that	phospholipids	in	the	form	of	monomers	and/or	
micelles	 mediated	 inactivation	 of	 the	 antibiotic.	 Furthermore,	 this	 ruled	 out	 differences	 in	 the	
physical	 form	 of	 phospholipids	 as	 an	 explanantion	 for	 why	wild-type	 bacteria	 are	 less	 efficient	
than	ΔagrA	mutant	S.	aureus	at	inactivating	daptomycin.	
		 154	
To	 fully	 determine	 the	 physical	 form	 of	 the	 phospholipid	 that	 inactivated	 daptomycin	 it	








by	 both	 wild-type	 and	 ΔagrA	 mutant	 S.	 aureus	 existed	 as	 monomers	 or	 small	 micelles	 and	
although	 some	 of	 the	 released	 phospholipid	 was	 in	 the	 form	 of	 membrane	 vesicles,	 these	
contained	very	little	daptomycin	and	were	inefficient	at	inactivating	the	antibiotic	(Fig	5.3a-c	and	










Supernatant	 from	 the	 USA300	 wild-type	 or	 ΔagrA	 mutant	 exposed,	 or	 not,	 to	 20	 µg	 ml-1	
daptomycin	was	subjected	to	ultracentrifugation	at	150,000	×	g	and	the	quantity	of	phospholipid	
that	was	recovered	was	compared	with	that	remaining	 in	suspension	using	FM-4-64	dye	(n=3	 in	
duplicate)	 (a).	 Using	 BoDipy-tagged	 daptomycin	 it	 was	 found	 that	 membrane	 vesicles	 were	
associated	with	very	little	daptomycin	(n=3)	(b).	Purified	membrane	vesicles	were	compared	with	
the	remaining	lipid	in	suspension	for	their	ability	to	inactivate	daptomycin	(c).	(n=3,	for	wild-type	








































































































































































which	 was	 confirmed	 by	 mass-spectroscopy	 (Fig	 2.1)	 (Fig	 5.6).	 Thereafter,	 streptavidin-coated	
agarose	 beads501	 were	 used	 to	 pull-down	 the	 biotin-labeled	 daptomycin	 and	 any	 bound	
phospholipid	 released	 from	 the	 wild-type	 or	 the	 ΔagrA	 mutant	 that	 had	 been	 exposed	 to	
daptomycin.		
Daptomycin	 pull	 down	 significantly	 reduced	 the	 concentration	 of	 phospholipid	 in	 the	
culture	supernatant	of	the	ΔagrA	mutant	(Fig	5.7a).		By	contrast,	there	was	no	significant	change	


















































(a)	 to	 desthiobiotinylated-daptomycin	 (b).	 Experimentally-derived	masses	 were	 similar	 to	 those	
predicted	for	each	molecule	(c).	Data	shown	in	panel	b	were	generated	from	analysis	of	a	single	
batch	of	desthiobiotinylated-	daptomycin	that	were	subsequently	used	 in	all	assays.	Unmodified	





Molecule	 Predicted	mass	 Experimental	mass	 MIC	(µg	ml-1)	
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The	 concentration	 of	 lipid	 remaining	 in	 culture	 supernatant	 from	 USA300	 wild-type	 or	 ΔagrA	
mutant	 previously	 exposed	 to	 20	 µg	 ml-1	 daptomycin	 and	 incubated	 with	 or	 without	 biotin-























































































5.6 A	 small	molecule	 in	 the	 culture	 supernatant	 of	wild-type	 bacteria	 prevents	
phospholipid	from	inactivating	daptomycin	
S.	aureus	 releases	phospholipids	 in	 response	 to	daptomycin,	 independently	of	 the	expression	of	
AgrA.	However,	by	contrast	to	those	of	the	ΔagrA	mutant,	phospholipids	released	by	the	wild-type	
S.	 aureus,	which	 has	 a	 functional	 Agr	 system,	 were	 unable	 to	 bind	 and	 inactivate	 daptomycin.	
Because	 AgrA	 triggers	 the	 secretion	 of	 numerous	 products	 including	 metabolic	 products	 and	
toxins	 such	 as	 PSM	 peptides158,176,397,	 it	 was	 hypothesised	 that	 these	 prevented	 the	 binding	 of	
daptomycin	by	phospholipid	released	from	wild-type	bacteria.			
To	test	this	hypothesis,	wild-type	bacteria	and	the	ΔagrA	mutant	were	grown	to	stationary	
phase	and	 the	culture	 supernatants	extracted.	Thereafter,	 the	ΔagrA	mutant	 cells	were	washed	
and	incubated	with	TSB	containing	0,	5%	or	10%	of	the	spent-culture	supernatant	from	the	wild-
type	 bacteria	 and	 daptomycin	 at	 37oC	 for	 8	 h.	 The	 presence	 of	 5%	 or	 10%	 spent	 culture	
supernatant	 from	wild-type	bacteria	 significantly	 reduced	 the	 survival	 of	 the	ΔagrA	mutant	 and	
inactivation	 of	 daptomycin	 compared	 to	 the	 TSB	 only	 condition	 (Fig	 5.8a	 and	 b).	 Therefore,	 in	
support	of	the	hypothesis,	it	was	found	that	spent	culture	supernatant	from	the	wild-type	bacteria	
prevented	the	ΔagrA	mutant	from	inactivating	daptomycin	(Fig	5.8a	and	b).	
To	 characterize	 the	agent(s)	 responsible	 for	disrupting	 the	phospholipid	 sequestration	of	
daptomycin,	 culture	 supernatant	 from	 the	 wild-type	 bacteria	 and	 the	 ΔagrA	 mutant	 were	
fractionated	 using	 a	 centricon	 filter	 into	 >	 or	 <	 3	 kDa.	 The	ΔagrA	mutant	was	 then	 exposed	 to	
daptomycin	 in	 the	 presence	 of	 each	 fraction	 and	 daptomycin	 activity	 determined	 after	 8	 h.	
Daptomycin	was	 inactivated	efficiently	 in	 the	presence	of	 culture	 supernatant	 from	the	>	3	kDa	
fraction.	However,	 the	<	3	kDa	fraction	significantly	 inhibited	the	ability	of	 the	ΔagrA	mutant	 to	
inactivate	 daptomycin	 (Fig	 5.8c).	 Neither	 fraction	 from	 the	 ΔagrA	 mutant	 supernatant	 affected	
daptomycin	inactivation	(Fig	5.8c).	
Next,	 to	determine	 the	 thermal	 stability	of	 the	<	3	kDa	element	 responsible	 for	 interfering	with	
the	 inactivation	of	daptomycin,	 culture	 supernatants	were	heat	 treated	at	80oC	 for	20	minutes.	
The	ΔagrA	mutant	was	then	incubated	with	TSB	supplemented	with	daptomycin	and	10%	of	the	






Figure	 5.8.	 Spent-culture	 supernatant	 containing	 small	 peptides	 from	 wild-type	 S.	 aureus	
prevents	the	agrA	mutant	from	inactivating	daptomycin		
The	 USA300	 ΔagrA	 mutant	 was	 inoculated	 into	 TSB	 containing	 0,	 5	 or	 10%	 spent	 culture	
supernatant	 from	 stationary-phase	 wild-type	 USA300,	 daptomycin	 (20	 µg	 ml-1)	 and	 CaCl2	 (0.5	
mM).	 Bacterial	 survival	 (a)	 and	 daptomycin	 activity	 (b)	 were	 then	 measured	 over	 time.	 Data	
represent	 the	 mean	 of	 3	 independent	 experiments	 done	 in	 duplicate.	 Spent	 wild-type	 culture	
supernatant	significantly	reduced	bacterial	survival	and	daptomycin	inactivation	(for	TSB	without	
WT	supernatant	vs	TSB	with	5%	or	10%	WT	supernatant	P	<	0.01	at	the	indicated	time	points	(*)	
by	 two-way	 ANOVA	 and	 Dunnett’s	 post-hoc	 test).	 To	 characterise	 the	 factor	 responsible	 for	
blocking	 daptomycin	 inactivation,	 culture	 supernatants	 from	 the	 USA300	 wild-type	 or	 ΔagrA	
mutant	 were	 fractionated	 into	 >	 or	 <	 3	 kDa	 (c),	 or	 (d),	 heat	 treated	 (80oC,	 20	 min).	 Treated	
supernatants	were	then	used	at	10%	as	described	above	for	panels	(a)	and	(b).	This	revealed	that	
the	inhibition	of	daptomycin	inactivation	by	the	wild-type	was	due	to	a	heat-sensitive	factor	of	less	
than	3	kDa	 (n=3	 in	duplicate,	 for	wild-type	supernatant	>3	kDa	vs	wild-type	supernatant	<3	kDa	
and	 unheated	 wild-type	 supernatant	 vs	 heated	 wild-type	 supernatant	 P	 <	 0.001	 by	 one-way	
ANOVA	with	Tukey’s	post-hoc	test.).	 In	all	panels	error	bars	 represent	 the	standard	deviation	of	
the	mean.	


















































































































































































5.7 AgrA-triggered	 PSMα	 production	 compromises	 daptomycin	 inactivation	 by	
released	phospholipids	
AgrA	not	only	regulates	the	quorum-sensing	system	but	also	directly	regulates	the	expression	of	7	
small	 peptide	 cytolysins	 known	 as	 phenol	 soluble	 modulins	 (PSMs),	 categorized	 into	 alpha	
(PSMα1-4)	or	beta	(PSMβ1,2)	families,	as	well	as	the	PSMδ	peptide	encoded	by	the	hld	gene	found	
within	 RNAIII140,158.	 Given	 the	 surfactant	 properties	 of	 PSMs	 it	 was	 hypothesised	 that	 these	
cytolysins	prevented	the	sequestration	of	daptomycin	by	phospholipids.	










mutants	 was	 significantly	 greater	 than	 that	 of	 the	 wild-type	 both	 USA300	 and	 SH1000,	 with	 a	
similar	initial	drop	in	CFU	counts,	followed	by	recovery,	as	seen	previously	for	the	ΔagrA	mutants.	
(Fig	5.10a	and	5.11a,	3.3a	and	c).	By	contrast,	survival	of	the	Δpsmβ	mutant	was	similar	to	wild-
















Data	 show	 the	MIC/MBC	 (μg	 ml-1)	 for	 daptomycin	 in	 TSB	 (Tryptic	 Soy	 Broth)	 or	MHB	 (Muller-
Hinton	 Broth)	 determined	 by	 broth	 microdilution	 as	 described	 previously.	 All	 media	 were	
supplemented	 with	 CaCl2	 (0.5	 mM)	 and	 MIC/MBC	 determined	 after	 24	 h	 incubation.	 Data	







Dapt.	 WT	 Δpsmα	 Δpsmβ	 Δpsmαβ	
TSB	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	
Table.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentraNons	for	strains	used	in	this	







	Dapt.	 WT	 Δpsmα	 Δpsmβ	 Δpsmαβ	
TSB	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	
USA300	JE2	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔvraT	 ΔvraTpEmpty	 ΔvraTpagrC	 ΔvraU	 ΔvraR	 ΔvraS	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	
USA300	JE2	–	derived	(vra	regulon)	
Medium	+	
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in	 the	 bactericidal	 activity	 of	 daptomycin	 in	 cultures	 of	 the	 wild-type	 bacteria,	 and	 the	 Δpsmβ	
mutant	 (Fig	 5.10b	 and	 5.11b)	 By	 contrast,	 both	 the	 Δpsmα	 and	 Δpsmαβ	 mutants	 rapidly	
inactivated	 daptomycin,	with	 similar	 kinetics	 to	 that	 seen	 previously	 for	 the	 ΔagrA	mutant	 (Fig	
5.10b	 and	 5.11b),	 confirming	 that	 PSMα	 peptides	 compromised	 the	 ability	 of	 the	 wild-type	 S.	

















































































































































































the	 activity	 of	 the	 antibiotic	 (b)	 in	 culture	 supernatants	 was	 determined	 (in	 both	 cases	 n=3	 in	























































































































SH1000	 wild-type	 (WT),	 agrA	 mutant	 (agr)	 or	 mutants	 lacking	 psmα,	 psmβ	 or	 psmαβ	 were	
incubated	 with	 or	 without	 daptomycin	 for	 8	 h.	 The	 presence	 of	 lipid	 was	 then	 detected	 and	
quantified	in	the	culture	supernatant	from	each	strain	using	FM-4-64	dye	as	described	in	section	
2.16.	Data	represent	the	mean	average	of	3	independent	experiments	done	in	duplicate	(wild-type	



















































determine	 which	 of	 the	 4	 PSMα	 peptides	 inhibited	 the	 inactivation	 of	 daptomycin,	 synthetic	
PSMα1,	α2,	α3,	α4,	β1	and	β2	peptides	were	utilized	(generated	by	Peptide	Protein	Research	Ltd).	
Wild-type	 bacteria,	 the	 Δpsmαβ	 mutant	 or	 the	 Δpsmαβ	 mutant	 supplemented	 with	 either	 a	
mixture	of	PSM	alpha	peptides	(α1-4),	PSM	beta	peptides	(β1-2)	or	PSM	alpha	+	beta	peptides	(α1-
4	+	β1-2)	were	incubated	with	daptomycin	at	37oC	for	8	h.	Each	peptide	was	used	at	10	µM,	since	
this	 approximated	 to	 the	 concentration	 produced	 by	 wild-type	 USA300	 in	 stationary	 phase	
158,176,397.	
As	 expected	 from	 the	 previous	 findings	with	Δpsm	mutants,	 the	 survival	 of	 the	Δpsmαβ	
mutant	 was	 significantly	 greater	 than	 wild-type	 exposed	 to	 daptomycin	 (Fig	 5.13a	 and	 5.14a).	
Similarly,	survival	of	the	Δpsmαβ	mutant	supplemented	with	a	mixture	of	PSMβ1-2	peptides	was	
also	significantly	greater	than	wild-type	(Fig	5.13a	and	5.14a).	By	contrast,	survival	of	the	Δpsmαβ	







the	 Δpsmαβ	 mutant	 supplemented	 with	 a	 mixture	 of	 PSMα1-4	 peptides	 or	 PSMα1-4	 +	 β1-2	
peptides	 (Fig	 5.13b	 and	 5.14b).	 By	 contrast,	 the	 Δpsmαβ	 mutant	 without	 peptides,	 and	 the	
Δpsmαβ	 mutant	 supplemented	 with	 a	 mixture	 of	 PSMβ1-2	 rapidly	 inactivated	 daptomycin	
similarly	 to	 that	 seen	 previously	 for	 the	 ΔagrA	 mutant	 (Fig	 5.13b	 and	 5.14b).	 Therefore,	 as	
observed	 for	 the	 Δpsm	 mutants,	 the	 presence	 of	 PSMα	 peptides,	 but	 not	 the	 PSMβ	 peptides,	






Figure	5.13.	The	effect	of	 synthetic	PSM	peptides	on	 survival	of	USA300	S.	aureus	 exposed	 to	
daptomycin		
To	 determine	whether	 synthetic	 PSMα	 or	 PSMβ	 peptides	 restored	 daptomycin	 susceptibility	 to	
the	 Δpsmαβ	mutant,	 survival	 (a)	 of	 the	 USA300	 psmαβ	mutant	 in	 the	 absence	 or	 presence	 of	
mixtures	of	PSMα	peptides	(α1-4),	PSMβ	peptides	(β1,2)	or	PSMα	and	PSMβ	(α1-4,	β1,2)	during	
exposure	 to	 20	 µg	 ml-1	 daptomycin	 was	 measured.	 The	 survival	 of	 wild-type	 S.	 aureus	 in	 the	
absence	of	peptides	is	included	for	comparison	(n=3	in	duplicate,	for	Δpsmαβ	without	peptides	vs	
Δpsmαβ	 with	 PSMα	 peptides	 P	 <	 0.0001	 at	 the	 indicated	 time	 points	 (*).	 Filled	 triangles	 are	
obscured	 by	 filled	 squares	 and	 filled	 circles.	 The	 activity	 of	 daptomycin	 in	 culture	 supernatants	
from	the	experiment	described	in	(a)	are	shown	in	panel	(b)	(n=3	in	duplicate,	for	Δpsmαβ	without	
peptides	 vs	 Δpsmαβ	 with	 PSMα	 peptides	 P	 <	 0.0001	 at	 the	 indicated	 time	 points	 (*).	 Data	 in	












































































































































































Figure	5.14.	 The	effect	of	 synthetic	PSM	peptides	on	 survival	of	 SH1000	S.	aureus	 exposed	 to	
daptomycin		
To	 determine	whether	 synthetic	 PSMα	 or	 PSMβ	 peptides	 restored	 daptomycin	 susceptibility	 to	
the	SH1000	Δpsmαβ	mutant,	survival	(a)	was	measured	during	exposure	to	20	µg	ml-1	daptomycin	























































































































To	 determine	 the	 effect	 of	 individual	 PSM	 peptides	 on	 daptomycin	 inactivation,	 the	
USA300	 Δpsmαβ	 mutant	 was	 incubated	 with	 daptomycin	 in	 the	 presence	 or	 absence	 of	 each	
synthetic	 PSM	 peptide.	 In	 keeping	 with	 the	 previous	 data	 (Fig	 5.13a	 and	 5.14a),	 the	 Δpsmαβ	





As	 expected	 from	 the	 survival	 data,	 the	 presence	 of	 PSMβ1,	 PSMβ2,	 PSMα3	 or	 PSMα4	
peptides	had	no	effect	on	the	ability	of	S.	aureus	to	inactivate	daptomycin	(Fig	5.15b).	By	contrast,	
the	Δpsmαβ	mutant	 supplemented	with	 the	 PSMα1	peptide	 had	 a	 significantly	 reduced	 rate	 of	
inactivation	of	daptomycin	compared	to	the	Δpsmαβ	mutant	without	the	peptides	(Fig	5.15b).	The	









USA300	Δpsmαβ	was	 incubated	with	20	µg	ml-1	daptomycin	 in	 the	presence	or	absence	of	each	














































































































Although	 the	 data	 described	 above	 demonstrated	 that	 PSMα	 peptides	 delayed	 the	
inactivation	of	daptomycin	without	affecting	the	rate	and	amount	of	phospholipid	release,	it	was	
important	to	rule	out	a	contributory	effect	from	other	AgrA-regulated	genes.	To	do	this,	the	ΔagrA	
mutant	was	 challenged	with	daptomycin	 in	 the	 absence	or	 presence	of	 the	PSMα1	peptide	 (10	
μM)	(Fig	5.16a).	In	these	experiments,	a	second	peptide	was	also	examined,	which	consisted	of	the	




5.16a).	By	contrast,	 survival	of	 the	ΔagrA	mutant	was	diminished	 in	 the	presence	of	 the	PSMα1	
peptide	(Fig	5.16a).	Interestingly,	the	PSM-rev	peptide	had	a	similar	effect	to	the	PSMα1	peptide,	
significantly	reducing	survival	of	the	ΔagrA	mutant	(Fig	5.16a).	Both	peptides	reduced	the	rate	of	
daptomycin	 inactivation	 by	 the	 ΔagrA	 mutant,	 although	 the	 PSM-rev	 peptide	 did	 not	 block	
daptomycin	inactivation	as	efficiently	as	the	PSMα1	peptide	(Fig	5.16b).		
Therefore,	production	of	the	PSMα1	peptide	in	response	to	Agr	activity	by	S.	aureus	is	the	
critical	 determinant	 in	 the	 efficiency	 of	 phospholipid-mediated	 daptomycin	 inactivation.	
Furthermore,	 it	 appears	 that	 PSMα1	 prevents	 the	 inactivation	 of	 daptomycin	 by	






















































































































Haemolysis	 (a)	 and	 surfactant	 (b)	 activity	 were	 determined	 using	 previously	 described	


























































































































5.9 PSMα1	 blocks	 the	 interaction	 of	 phodphatidylglycerol	 with	 daptomycin	 by	
directly	binding	the	phospholipid	
The	 most	 likely	 mechanism	 by	 which	 PSMα1	 inhibited	 the	 inactivation	 of	 daptomycin	 by	
phospholipids	was	by	direct	competition	with	the	antibiotic	for	the	lipid.	However,	an	alternative	
hypothesis	 was	 that	 PSMα1	 interacted	 with	 the	 bacterium	 and	 promoted	 attachment	 of	
daptomycin.	 To	 test	 this,	 a	 cell-free	 system	 using	 spent	 culture	 supernatant	 from	 the	 USA300	
ΔagrA	mutant	exposed	to	daptomycin	was	employed.	The	supernatant	was	mixed	with	additional	
daptomycin	 in	the	presence	or	absence	of	synthetic	PSMα1	or	PSM-rev	peptide.	As	expected,	 in	
the	absence	of	synthetic	peptides,	 the	supernatant	 inactivated	daptomycin	rapidly	 (Fig	5.18).	By	
contrast,	the	presence	of	the	PSMα1	peptide,	and	to	a	lesser	extent	PSM-rev,	significantly	reduced	
the	 inactivation	of	daptomycin	 in	 the	 spent	 culture	 supernatant	 (Fig	5.18).	 This	provided	 strong	
evidence	that	 the	PSMα1	peptide	directly	prevented	the	 inactivation	of	daptomycin	by	 released	
membrane	phospholipids,	rather	than	an	indirect	effect	on	the	bacterial	cells.	
As	a	follow	up	to	this	experiment,	the	ability	of	purified	PG	to	inactivate	daptomycin	was	
measured	 in	 the	 absence	 or	 presence	 of	 the	 PSMα1	 peptide.	 As	 observed	 for	 spent	 culture	
supernatant,	the	presence	of	synthetic	PSMα1	peptide	blocked	the	inhibition	of	the	antibiotic	by	
the	 phospholipid	 (Fig	 5.19).	 This	 again	 indicated	 that	 PSMα1	 competes	 with	 daptomycin	 for	
phosphatidylglycerol.	
As	 a	 final	 confirmation,	 the	 hemolytic	 activity	 of	 PSMα1	 in	 the	 presence	 or	 absence	 of	
spent	 culture	 supernatant	 was	 tested.	 It	 was	 hypothesized	 that	 if	 PSMα1	 bound	 directly	 to	
phosphatidylglycerol	 then	 there	 would	 be	 a	 loss	 of	 hemolytic	 activity.	 In	 support	 of	 this	
hypothesis,	 it	 was	 found	 that	 the	 PSMα1	 toxin	 in	 the	 presence	 of	 the	 released	 membrane	
phospholipids	 from	the	ΔagrA	mutant	was	significantly	 less	haemolytic	 than	PSMα1	toxin	 in	the	
absence	 of	 released	 membrane	 phospholipids	 (Fig	 5.20a).	 This	 assay	 was	 then	 repeated	 with	
purified	 PG	 instead	 of	 the	 culture	 supernatant	 of	 the	 ΔagrA	mutant	 and	 it	was	 found	 that	 the	
PSMα1	toxin	 incubated	with	the	phospholipid	was	significantly	 less	haemolytic	compared	to	the	
PSMα1	 toxin	 incubated	with	 TSB	 only	 (Fig	 5.20b).	 Therefore,	 the	 presence	 of	 PG,	 either	 in	 the	
form	of	 released	membrane	phospholipids	or	purified	 lipid,	 completely	 inhibited	 the	haemolytic	
activity	of	PSMα1,	indicating	direct	binding	of	the	PSMα1	peptide	to	the	phospholipid	(Fig	5.20).			









α1,	PSM-rev	or	neither,	and	a	 fresh	dose	of	daptomycin.	The	activity	of	 the	antibiotic	was	 then	
measured	over	 time.	The	presence	of	 the	peptides	 significantly	 reduced	 the	 rate	of	daptomycin	
inactivation	(*	 indicates	P	<	0.05	compared	with	the	ΔagrA	mutant	without	peptide	by	two-way	




























































































































































































































presence	 or	 absence	 of	 phospholipid	 shed	 from	 the	 ΔagrA	 mutant	 (a)	 or	 purified	 PG	 (b)	 was	
measured.	 In	 both	 panels,	 n=3	 in	 triplicate.	 Data	 were	 analysed	 using	 a	 one-way	 ANOVA	 with	
Tukey’s	post-hoc	test.	Error	bars	represent	the	standard	deviation	of	the	mean.	For	(a)	PSMα1	in	





























































































































5.10 The	 inhibition	of	phospholipid-mediated	daptomycin	 inactivation	by	PSMα1	
enhances	daptomycin-binding	to	S.	aureus	
The	data	presented	so	far	demonstrate	that	PG	binds	and	inactivates	daptomycin,	and	that	PSMα1	
prevents	 this	 by	 binding	 to	 the	 phospholipid.	 Therefore,	 it	 was	 hypothesised	 that	 PSMα1	
enhanced	daptomycin-mediated	killing	of	S.	aureus	by	preventing	the	phospholipid	sequestration	
of	daptomycin	and	enabling	binding	of	the	antibiotic	to	the	bacterium.	To	test	this,	we	first	tagged	
daptomycin	with	 BoDipy	 to	measure	 its	 binding	 to	S.	 aureus	 (Fig	 5.21).	 Thereafter,	wild-type	S.	
aureus,	the	ΔagrA	mutant	and	the	ΔagrA	mutant	supplemented	with	PSMα1	were	incubated	with	
BoDipy-tagged	 daptomycin	 at	 37oC	 for	 up	 to	 8	 h.	 Every	 two	 hours	 bacteria	 were	 harvested,	
washed,	and	resuspended	in	fresh	TSB	to	measure	the	relative	fluorescence	generated	by	the	cell	
bound	 BoDipy-tagged	 daptomycin.	 This	 revealed	 that	 wild-type	 S.	 aureus	 steadily	 accumulated	
daptomycin	over	 time	 (Fig	5.22).	By	contrast,	binding	of	daptomycin	 to	S.	aureus	ΔagrA	mutant	
significantly	decreased	over	 time	compared	 to	 the	wild-type,	presumably	because	 the	antibiotic	
was	 sequestered	 by	 the	 released	 PG	 (Fig	 5.22).	 In	 the	 presence	 of	 PSMα1	 peptide,	 however,	













bodipy-daptomycin	 (a).	 Experimentally-derived	masses	were	almost	 identical	 to	 those	predicted	
for	 each	molecule	 (b).	Data	 shown	 in	 panel	 b	was	 generated	 from	analysis	 of	 single	 batches	 of	
bodipy-	daptomycin	that	were	subsequently	used	in	all	assays.	Data	in	panel	a,	is	representative	of	
at	least	3	independent	analyses.	MICs	of	unmodified	and	modified	daptomycin	were	established	in	




Molecule	 Predicted	mass	 Experimental	mass	 MIC	(µg	ml-1)	































































Binding	 of	 BoDipy-labelled	 daptomycin	 to	 wild-type,	 ΔagrA	 mutant	 or	 ΔagrA	 mutant	 in	 the	
presence	of	PSMα1	(n=3	in	triplicate,	for	WT	vs	agrA	P	<	0.001	at	the	indicated	time	points	(*)).	





































































































5.11 Oxacillin	 promotes	 daptomycin	 activity	 by	 reducing	 daptomycin-induced	
phospholipid	release		
Having	discovered	that	the	ΔagrA	mutant	employs	a	phospholipid	release	mechanism	to	survive	




to	 β-lactam	 antibiotics418,502.	 Although	 the	 underlying	 mechanism	 is	 unclear,	 one	 of	 the	
explanations	 for	 this	 is	 that	 there	 is	 an	 increase	 in	 the	 binding	 of	 daptomycin	 to	 the	 bacterial	




To	test	 this	hypothesis,	 survival	of	 the	ΔagrA	mutant	during	exposure	to	a	sub-inhibitory	
concentration	 of	 the	 β-lactam	 antibiotic	 oxacillin	 (0.25	 µg	 ml-1),	 20	 µg	 ml-1	 daptomycin,	 both	
antibiotics	together	or	neither	was	measured	over	time.	As	expected,	the	ΔagrA	mutant	grew	well	
in	media	without	 antibiotics	 or	 in	media	 supplemented	with	oxacillin	 alone	 (Fig	 5.23a).	Also,	 as	
expected	 from	 previous	 results,	 the	 ΔagrA	 mutant	 exposed	 to	 daptomycin	 alone,	 suffered	 an	
initial	10-fold	decrease	in	CFU	during	the	first	2	hr,	before	recovering.	However,	CFU	counts	of	the	
ΔagrA	mutant	exposed	to	the	combination	of	oxacillin	and	daptomycin	dropped	1000-fold,	before	
slowly	 beginning	 to	 recover	 after	 6	 hr	 (Fig	 5.23a).	 To	 determine	 whether	 oxacillin	 enhanced	
daptomycin-mediated	 killing	 of	 the	 ΔagrA	 mutant	 by	 inhibiting	 the	 release	 of	 phospholipids,	
culture	 supernatants	 from	 the	assays	described	above	were	 recovered	and	mixed	with	FM-4-64	
dye.	 This	 revealed	 that	 the	 phospholipid	 released	 from	 the	 ΔagrA	 mutant	 exposed	 to	 the	
combination	of	oxacillin	and	daptomycin	was	significantly	reduced	compared	to	the	ΔagrA	mutant	
exposed	to	daptomycin	alone	(Fig	5.23b,c).	 In	keeping	with	this	finding,	the	presence	of	oxacillin	
significantly	 delayed	 the	 inactivation	 of	 daptomycin	 by	 ΔagrA	 mutant,	 relative	 to	 the	 rate	 of	
inactivation	of	daptomycin	in	the	absence	of	the	β-lactam	(Fig	5.23b,c).	In	control	experiments	to	
ensure	that	the	presence	of	oxacillin	did	not	affect	the	size	of	the	zone	of	inhibition	produced	by	











found	 that	 wild-type	 S.	 aureus	 was	 killed	 rapidly	 by	 daptomycin	 alone	 (Fig	 5.23d).	 However,	
although	 the	 wild-type	 S.	 aureus	 was	 rapidly	 killed	 by	 the	 combination	 of	 oxacillin	 and	
daptomycin,	 there	was	no	 significant	difference	between	 the	 survival	of	 the	wild-type	S.	aureus	
exposed	 to	 the	 combination	 of	 oxacillin	 and	 daptomycin	 and	 daptomycin	 alone	 (Fig	 5.23d).	
Although	 the	 phospholipid	 released	 by	 the	 wild-type	 S.	 aureus	 exposed	 to	 the	 combination	 of	
oxacillin	and	daptomycin	was	significantly	reduced	compared	to	the	wild-type	S.	aureus	exposed	
to	 daptomycin	 alone	 (Fig	 5.23e),	 this	 did	 not	 affect	 the	 degree	 to	 which	 daptomycin	 was	
inactivated	by	wild-type	bacteria	 (Fig	5.23f).	Therefore,	unlike	 for	 the	ΔagrA	mutant	phenotype,	
oxacillin	 did	 not	 show	 synergy	 with	 daptomycin	 against	 wild-type	 S.	 aureus,	 despite	 reducing	
phospholipid	 release,	 most	 likely	 because	 the	 phospholipid	 release	 mechanism	 is	 already	
compromised	by	the	presence	of	PSMα	peptides		(Fig	5.23d,e,f).		


















































































































































































































































release	 (b)	 and	daptomycin	 activity	 (c)	measured	over	 8	h	 (n=3	 in	duplicate,	 for	 TSB	 containing	
daptomycin	only	vs	daptomycin	+	oxacillin	P	<	0.001	at	the	indicated	time	points	(*).	USA300	wild-
type	 exposed	 to	 0.25	 µg	 ml-1	 of	 oxacillin,	 daptomycin	 (20	 µg	 ml-1)	 or	 both	 antibiotics	 in	
combination	and	survival	(d),	lipid	release	(e)	and	daptomycin	activity	(f)	measured	after	8	h	(n=3	
in	 duplicate,	 for	 TSB	 containing	 daptomycin	 only	 vs	 daptomycin	 +	 oxacillin	 P	 <	 0.001	 at	 the	
indicated	 time	 points	 (*).USA300	wild-type	 and	 ΔagrA	 at	 a	 1:1	 ratio	were	 exposed	 to	 oxacillin,	







vitro,	 it	 was	 next	 investigated	 whether	 this	 combination	 therapy	 could	 improve	 treatment	
outcomes	of	 infection	caused	by	mixed	population	of	S.	aureus	as	seen	 in	vitro	 (Fig	5.23g-i).	For	
this,	 the	 same	 in	 vivo	 murine	 model	 of	 S.	 aureus	 invasive	 infection	 as	 described	 previously	 in	
chapter	 3	was	 used.	Mice	were	 infected	with	 a	 1:1	 ratio	 of	 the	wild-type	 S.	 aureus	 and	 ΔagrA	
mutant	and	treated	 it	with	sub	 inhibitory	concentration	of	the	β-lactam	antibiotic	oxacillin	 (0.25	
µg	ml-1),	20	µg	ml-1	daptomycin,	both	antibiotics	together	or	neither	for	8	h.	As	expected	based	on	
previous	 animal	 studies	 (Fig	 3.7)	 and	 the	 in	 vitro	 experiments	 described	 above,	 there	 was	 no	
significant	difference	in	the	CFU	counts	recovered	from	mice	infected	with	the	mixed	population	
and	 treated	with	daptomycin	only,	 oxacillin	only	or	 not	 treated	 (Fig	 5.24).	 By	 contrast,	 the	CFU	
counts	recovered	from	mice	that	were	 infected	with	the	mixed	population	and	treated	with	the	


























































In	 chapter	 3	 it	 was	 observed	 that	 daptomycin	 is	 more	 bactericidal	 against	 wild-type	 than	 Agr-
defective	mutants.	The	aim	of	 the	work	 in	 this	 chapter	was	 to	explain	 this	phenomenon.	 It	was	
discovered	that	the	release	of	membrane	phospholipids,	including	PG,	in	response	to	daptomycin	
is	 independent	of	 the	Agr	quorum-sensing	 system	and	occurs	 in	both	wild-type	and	agr-mutant	
strains.	 In	 the	 absence	 of	 Agr,	 the	 released	 PG	 binds	 and	 inactivates	 daptomycin.	 However,	 S.	
aureus	with	an	activated	Agr	quorum-sensing	system	compromises	 this	mechanism	by	secreting	
PSMα1	 peptides,	 which	 compete	 with	 daptomycin	 for	 binding	 to	 PG.	 The	 inability	 of	 PG	 to	










daptomycin	may	be	explained	by	these	differences	 in	charge176,397.	 It	 is	also	unclear	why	PSMα1	
was	significantly	more	inhibitory	than	PSMα2,	which	was	more	inhibitory	than	PSMα3	or	PSMα4.	
However,	 it	 is	 well	 established	 that	 the	 cytolytic	 properties	 of	 the	 PSMα	 peptides	 varies176,	

















It	 appears	 paradoxical	 for	 S.	 aureus	 to	 produce	 cytolysins	 (PSMs)	 that	 compromise	 the	
phospholipid	 release	 defence	 mechanism	 that	 protects	 the	 cell	 from	 daptomycin	 and	 CAMPs.		
However,	it	is	essential	to	consider	that	PSMs	are	not	produced	constitutively	by	S.	aureus	and	are	
only	 secreted	when	 the	Agr	quorum	sensing	 system	 is	 activated140,158,176.	 	 This	occurs	when	 the	
bacterial	cells	reach	a	certain	density	threshold	and	is	subject	to	additional	control	by	numerous	
transcription	 factors	 that	 respond	 to	 environmental	 stimuli140,142,158,183,503.	 For	 example,	 during	
times	of	stress	the	alternative	sigma	factor	B	ensures	that	S.	aureus	does	not	activate	the	quorum	
sensing	 system,	 which	 is	 energetically	 costly	 to	 the	 bacteria202,504.	 In	 nutrient	 limiting	
environmental	 conditions,	 in	 particular,	 the	 limitation	 of	 isoleucine	 (an	 amino	 acid	 required	 to	
build	 branched	 chain	 fatty	 acids),	 the	 transcription	 factor	 CodY	 delays	 the	 quorum-sensing	
activation	 until	 the	 bacteria	 are	 in	 a	 nutrient	 rich	 environment202,505,506.	 This	 may	 explain	 why,	








Agr	system,	 in	conjunction	with	the	stringent	response,	 is	activated,	resulting	 in	the	secretion	of	
PSMs	 that	 lyse	 the	 neutrophils	 from	within176,512.	 PSMs	 also	 appear	 to	 play	 an	 essential	 role	 in	
establishing	 biofilms	 and	 biofilm-associated	 infections.	 The	 PSM	 surfactant-like	 property	 and	
colony	spreading	activity	enables	S.	aureus	to	 form	and	disperse	biofilms	on	biological	materials	
such	 as	 implants	 and	 intravenous-catheters140,425,513,514.	 These	 findings	 demonstrate	 a	 clear	 role	










Whilst	 mutations	 can	 affect	 PSM	 production	 indirectly	 by	 reducing	 or	 abrogating	 Agr	
activity,	 mutations	 within	 the	 psm	 locus	 itself	 can	 result	 in	 reduced	 expression	 levels	 or	 the	
expression	 of	 PSM	 variants,	 which	 may	 not	 prevent	 the	 inactivation	 of	 daptomycin	 by	





AIP	 signaling	molecule	 and	 PSM	 toxins.	 Therefore,	 Agr	 is	 active	 in	 only	 a	 subset	 of	 bacteria	 in	
certain	host	niches,	 tissues	and	biofilms509,518,519.	 This	 implies	 that,	during	 infection,	wild-type	S.	
aureus	may	 respond	 very	 differently	 to	 daptomycin,	 depending	 on	 its	 anatomical	 location.	 For	
example,	in	skin	and	soft	tissue	infections	where	Agr	is	active	and	PSMs	are	expressed,	it	would	be	
expected	that	daptomycin	would	be	highly	effective.	By	contrast,	during	invasive	infections,	when	
Agr	activity	 is	absent	or	reduced,	 it	would	be	expected	that	daptomycin	would	be	 less	effective.	
Indeed,	 analyses	 of	 daptomycin	 treatment	 outcomes	 suggest	 that	 the	 antibiotic	 is	 far	 more	
effective	in	combatting	skin	infection	relative	to	bacteraemia520–523,70.	Whilst	treatment	outcomes	











response	 to	 daptomycin	 were	 mainly	 in	 the	 form	 of	 monomers	 or	 small	 micelles,	 rather	 than	
membrane	 vesicles	 secreted	 by	 Gram-negative	 bacteria	 such	 as	 E.	 coli.	 Although	 some	 of	 the	
released	phospholipids	existed	as	membrane	vesicles,	these	contained	very	little	daptomycin	and	
were	inefficient	at	inactivating	the	antibiotic.		
This	was	 surprising	 since	previous	work	 has	 shown	 that	E.	 coli	outer	membrane	 vesicles	
provided	 protection	 against	 membrane-targeting	 antimicrobial	 peptides	 such	 as	 colistin	 and	







5.12.4 	β-lactam	oxacillin	 enhances	 the	 activity	 of	 daptomycin	by	 reducing	phospholipid	
release	
S.	aureus	 encodes	4	PBPs,	of	which	PBP1	and	PBP2	are	essential	 for	building	 the	peptidoglycan	
layer	 required	 for	 cell	 wall	 synthesis	 and	 S.	 aureus	 growth24.	 β-lactam	 antibiotics	 have	 variable	
affinities	 for	each	of	 the	PBPs	but	 the	anti-staphylococcal	penicillin	oxacillin	 targets	all	 4.	MRSA	
strains	encode	an	addition	PBP,	PBP2a,	which	is	has	a	very	low	affinity	for	β-lactam	antibiotics	and	
therefore	confers	resistance24.	
In	 this	 chapter,	 it	 was	 described	 how	 the	 β-lactam	 oxacillin	 enhanced	 the	 activity	 of	
daptomycin	by	reducing	the	release	of	phospholipids	 in	 response	to	daptomycin,	despite	having	





Furthermore,	 these	 data	 are	 in	 agreement	 with	 previous	 work	 showing	 that	 β-lactam	
antibiotics	that	target	PBP1	promote	the	activity	of	daptomycin413,525,	presumably	because	PBP1,	
which	 is	 required	 for	 peptidoglycan	 synthesis,	 occurs	 at	 the	 site	 of	 daptomycin	 insertion	 and	
reduces	 the	 release	 of	 phospholipids.	 There	 is	 also	 evidence	 that	 β-lactam	 antibiotics	 promote	
daptomycin	 activity	 against	wild-type	 S.	 aureus	 by	 increasing	 the	 binding	 of	 daptomycin	 to	 the	
bacterial	 membrane413,418,502,526.	 Although	 the	 underlying	 mechanism	 is	 unclear,	 It	 has	 been	
		 195	
hypothesised	that	β-lactams	alter	the	staphylococcal	surface	charge,	enabling	more	daptomycin	to	
bind	 to	 the	membrane502.	Our	 data	 provide	 an	 alternative	 hypothesis,	 that	 β-lactam	 antibiotics	
promote	daptomycin	activity	by	preventing	its	inactivation	by	released	phospholipid.	
	 Regardless	of	the	molecular	mechanism	however,	the	data	from	murine	S.	aureus	infection	




































In	 previous	 chapters	 I	 described	 the	 identification	 and	 characterization	 of	 a	 novel	 daptomycin	






provides	 the	 precursor	 to	 all	membrane	 phospholipids	 such	 as	 phosphatidylglycerol,	 cardiolipin	





endogenous	 fatty	 acid	 synthesis,	S.	 aureus	 uses	 the	 Fatty	Acid	 Synthase	 II	 (FAS	 II)	 pathway	 (Fig	
6.1),	which	is	comprised	of	mono-functional	enzymes	and	is	broken	down	into	3	phases.	
Phase	1:	Initiation.	This	phase	is	catalyzed	by	2	enzymes	(Fig	6.2a).	
(i) The	 acetyl-CoA	 carboxylase	 (ACC)	 catalyzes	 the	 first	 step	 in	 the	 fatty	 acid	 biosynthesis	
pathway,	which	is	the	conversion	of	acetyl-CoA	to	Malonyl-CoA	by	the	addition	of	bicarbonate	
to	 acetyl-CoA.	 Thereafter,	 FabD	 catalyses	 the	 transfer	 of	 the	 malonyl	 group	 to	 acyl	 carrier	
protein	 (ACP)	 to	 yield	 Malonyl-ACP.	 Subsequently,	 Malonyl-ACP	 and	 the	 FabH	 enzyme	 are	
required	 to	 initiate	 the	 fatty	 acid	 biosynthesis	 by	 the	 formation	 of	 new	 acyl-chains	 (i.e.	
formation	of	new	fatty	acid	chains)	(Fig	6.2a)529,530.	
(ii) FabH	 is	 a	 condensing	 enzyme	 that	 catalyzes	 the	 first	 condensation	 step	 that	 results	 in	 the	
formation	of	new	acyl-chain,	β-ketoacyl-ACP	(Fig	6.2a).	This	is	the	first	intermediate	in	the	FAS	


























































































































































The	 endogenous	 pathway	 arrows	 are	 shown	 in	 black	 and	 the	 exogenous	 pathway	 arrows	 are	
shown	 in	 red.	 (a),	 Phase	 1:	 The	 initiation	 of	 the	 type	 II	 fatty	 acid	 synthesis.	 Acetyl-CoA	
carboxylase	(ACC)	is	composed	of	four	subunits	(ABCD)	and	provides	malonyl-CoA	elongation	units	
to	 the	elongation	 cycle.	 The	malonyl	 groups	are	 transferred	 to	 the	acyl	 carrier	protein	 (ACP)	by	
malonyl-CoA–ACP	transacylase	 (FadD).	β-ketoacyl-ACP	synthase	 III	 (FabH)	starts	a	new	fatty	acid	
by	 initiating	the	condensation	of	malonyl-ACP	and	an	acyl-CoA	primer	to	form	a	β-ketoacyl-ACP.	
(b),	Phase	2:	the	elongation	of	the	fatty	acid	chain:	The	β-ketoacyl-ACP	intermediate	is	reduced	
by	 the	 FabG	 β-ketoreductase,	 and	 the	 β-hydroxyacyl-ACP	 is	 dehydrated	 to	 enoyl-ACP	 by	 the	
dehydrase	 FabZ.	 FabI	 is	 an	 enoyl-ACP	 reductase	 that	 pulls	 the	 elongation	 cycle	 together.	 The	
saturated	acyl-ACP	is	a	substrate	for	FabF.	FabF	is	an	elongation	condensing	enzyme	and	initiates	
the	 additional	 rounds	 of	 elongation.	 (c),	 Transfer	 of	 fatty	 acids	 to	 glycerol-3-phosphate	 into	
membrane	phospholipids:	The	long-chain	acyl-ACP	end	products	are	recognized	as	substrates	by	
the	 acyltransferases.	 The	 peripheral	 membrane	 protein	 PlsX	 catalyses	 the	 formation	 of	 an	
acylphosphate(Acyl-P)	from	acyl-ACP,	and	PlsY	uses	this	unique	intermediate	to	acylate	glycerol-3-
phosphate	 to	 1-acyl-glycerol-3-phosphate	 (also	 known	 as	 lysophosphatidic	 acid	 (LPA)).	 PlsB	
acylates	glycerol-3-phosphate	using	either	acyl-ACP	or	acyl-CoA	as	the	acyl	donor.	PlsC	transfers	a	
fatty	 acid	 to	 the	 2-position	 of	 LPA	 to	 form	 phosphatidic	 acid	 (PA),	 the	 key	 intermediate	 in	 the	
synthesis	 of	 all	 membrane	 glycerolipids	 including	 phosphatidylglycerol,	 cardiolipin	 and	 lysyl-	
phosphatidylglycerol.	 (d),	 The	 incorporation	 of	 exogenous	 fatty	 acids	 into	 phospholipids	 in	 S.	
aureus:	Exogenous	fatty	acids	are	flipped	to	the	interior	of	the	cell	and	phosphorylated	by	Fak.	The	
acyl-PO4	 is	 either	 ligated	 to	 the	 1-position	 of	 sn-	 glycerol-3-phosphate	 by	 PlsY	 or	 converted	 to	
acyl-ACP	by	PlsX.	The	acyl-ACP	can	either	be	elongated	by	the	FASII	enzymes	or	ligated	into	the	2-
position	 of	 lysophosphatidic	 acid	 by	 PlsC,	 only	 if	 it	 is	 C15:0	 branched	 chain	 fatty	 acid.	 The	











S.	 aureus	 FabH	 prefers	 branched-chain	 acyl-CoAs,	 which	 yield	 branched-chain	 fatty	 acids.	 The	
branched-chain	primers	isobutyryl-CoA,	isovaleryl-CoA	and	2-methylbutyryl-CoA	are	derived	from	









































































Phase	 2.	 Elongation.	 This	 phase	 is	 catalyzed	 by	 4	 enzymatic	 reactions	 (Fig	 6.2b).	 Each	 of	 the	
reactions	are	 initiated	by	an	elongation-condensing	enzyme.	Enzymes	such	as	 (i)	FabG,	 (ii)	FabZ,	
(iii)	FabI	and	(iv)	FabF	enable	the	advancement	of	the	growing	acyl-chain	by	2	carbons.	In	brief,	the	
β-ketoacyl-ACP	 is	 converted	 to	enoyl-ACP	 (i.e.	 saturated	acyl-ACP)	by	 first	being	 reduced	by	 the	
NADPH	dependent	FabG	enzyme	and	 then	dehydrated	by	FabZ	and	FabI	ezymes	 to	yield	enoyl-
ACP.	Subsequently,	FabF	catalyses	the	condensation	reaction	by	using	enoyl-ACP	as	 its	substrate	
for	 the	 additional	 rounds	 of	 elongation.	 Finally,	 the	 cycle	 of	 the	 fatty	 acid	 chain	 elongation	 is	
brought	to	completion	by	the	FabI	(enoyl-ACP	reductase)	enzyme	(Fig	6.2b)529,531,536.	
Phase	3.	Transfer	to	the	membrane:	In	this	phase,	the	PlsX-PlsY	pathway	catalyzes	the	formation	
of	membrane	 phospholipids	 by	 the	 transfer	 of	 fatty	 acids	 to	 glycerol-3	 phosphate	 (Fig	 6.1	 and	
6.2c)529,531,537,538.	PlsX	 is	a	peripheral	membrane	protein	that	transfers	the	fatty	acid,	which	 is	an	
acyl-group	 that	 originated	 from	 the	 end-product	 of	 the	 elongation	 cycle	 to	 the	 inorganic	
phosphate	molecule	 to	 form	 a	 reactive	 acylphosphate	 intermediate.	 Thereafter,	 the	 transfer	 of	
this	activated	fatty	acid	to	the	1-position	of	glycerol-3	phosphate	can	be	performed	via	2	routes.	
(i) Via	PlsY,	which	is	an	integral	membrane	protein	that	uses	the	reactivate	fatty	acid	phosphate	














phospholipids	 at	 position	 1	 on	 the	 glycerol	 phosphate	 moiety	 (Fig	 6.1).	 Protonated	 fatty	 acids	
diffuse	 through	 the	cell	membrane	where	 they	are	processed	by	 the	 fatty	acid	kinase	 (FaK)	and	






3	phosphate	 (Fig	6.2d).	Only	 the	1-position	of	 the	glycerol-3	phosphate	 can	be	occupied	by	 the	
exogenous	fatty	acid	and	not	the	2-position	as	mentioned	above	(Fig	6.1)529,531,537,538,540.	
Overall,	 the	 FAS	 II	 pathway	 and	 the	 PlsX-PlsY	 pathway	 enable	 S.	 aureus	 to	 utilize	 both	





therapeutics.	 These	 next-generation	 antibiotics	 that	 inhibit	 the	 FAS	 II	 pathway	 predominantly	
target	the	fatty	acid	chain	elongation	and	completion	steps	in	the	pathway	such	as	the	FabF,	FabG,	
FabZ	 and	 FabI	 enzymes529,535,545–548.	 For	 example,	 platensimycin	 functions	 by	 blocking	 the	 FabF	
enzyme	which	is	a	fatty	acid	elongation	condensation	enzyme	(Fig	6.2b)549.	By	contrast,	AFN-1252	
functions	by	blocking	the	FabI	enzyme,	which	functions	by	bringing	the	fatty	acid	elongation	cycle	
to	 completion	 (Fig	 6.2b).	 This	 is	 the	 step	 that	 occurs	 immediately	 before	 the	 fatty	 acid	 is	
transferred	 to	 the	 glycerol-3	 phosphate	 to	 form	 a	 membrane	 phospholipid541,543,550.	 Whilst,	











Aim	 1	 of	 this	 chapter	 was	 to	 determine	 whether	 host-derived	 fatty	 acids	 contribute	 to	
daptomycin	induced	phospholipid	release.	
	
Furthermore,	 the	 ability	 of	 platensimycin	 to	 block	 daptomycin-induced	 phospholipid	
release	indicates	an	opportunity	to	use	inhibitors	of	fatty	acid	biosynthesis	to	enhance	daptomycin	
activity.	However,	 the	efficacy	of	such	 inhibitors	against	phospholipid	release	 in	 the	presence	of	
host-derived	fatty	acids	is	unclear529,535.	Therefore,		
	








The	host	environment	 is	 abundant	with	 free	and	protein-bound	 fatty	acids.	 The	most	abundant	
are	 listed	 in	 Table	 6.1,	 together	 with	 their	 concentrations	 in	 the	 serum	 or	 plasma	 of	 healthy	
humans553.	These	data	were	used	to	guide	the	concentrations	used	in	subsequent	experiments.		
Fatty	 acids	 are	 aliphatic	 monocarboxylic	 acids	 and	 commonly	 have	 a	 chain	 of	 4	 to	 28	
carbons,	which	may	be	saturated	or	unsaturated554.	Saturated	fatty	acids	do	not	contain	double	
bonds	 as	 all	 its	 carbon	 atoms	 (apart	 from	 the	 carboxylic	 acid	 group	 –	 COOH-)	 contain	 as	many	
hydrogen	atoms	it	can	bind	to554.	For	example,	the	carbon	atom	at	the	end	of	the	saturated	fatty	
acid	 chain	 holds	 3	 hydrogen	 atoms	 (CH3-)	 and	 each	 carbon	within	 the	 chain	 holds	 2	 hydrogen	













In	 addition	 to	 providing	 phospholipid	 precursors	 to	 bacteria,	 long	 chain	 fatty	 acids	 are	
potent	 antibacterials	 and	 are	 abundant	 on	 the	 skin,	 with	 sebum	 consisting	 of	 ~28%	 free	 fatty	





















Mean	 SD	 Mean	 SD	
C12:0	(lauric	acid)	 9.1-12	 2-37	 1.47	 +	0.68	
	
C14:0	(myrisGc	acid)	 15.46	 4.02	 7.16	 +	3	
	
C16:0	(palmiGc	acid)	 66.01	 9.88	 122	 +	48	
	
C18:1n9	(oleic	acid)	 49.24	 19.31	 122	 +	56	
	











































the	 lipid-reactive	 dye	 FM-4-64,	 using	 the	 same	 range	 of	 fatty	 acids	 at	 the	 same	 concentrations	
described	above.	These	data	indicated	that	the	presence	of	fatty	acids	had	no	significant	effect	on	

















TSB	 supplemented	 with	 or	 without	 C18:1,	 C16:0,	 C14:0,	 C12:0	 fatty	 acids	 at	 20	 µM	 (a)	 or	
increasing	concentrations	of	C18:1	(b)	were	incubated	with	daptomycin	over	8	h	before	reactivity	
with	the	lipid-dye	was	determined.	
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Previous	 studies	 have	 shown	 that	 the	 presence	 of	 free	 fatty	 acids	 results	 in	 altered	membrane	
fatty	 acid	 and	 staphyloxanthin	 content,	 which	 could,	 in	 turn	 affect	 bacterial	 susceptibility	 to	
daptomycin426.	Therefore,	the	daptomycin	MIC	of	the	ΔagrA	mutant	was	determined	in	TSB	alone	
or	 supplemented	with	various	 fatty	acids	at	20	µM.	For	most	of	 the	 fatty	acids	 tested	 including	
oleic	acid,	linoleic	acid,	palmitic	acid,	myristic	acid	or	lauric	acid	the	daptomycin	MIC	of	the	ΔagrA	





exponential	 phase	 growth556,560.	 In	 addition,	 previous	 studies	 have	 shown	 that	 antibacterial	
activity	 is	 restricted	 to	unsaturated	 fatty	acids	 including	 linoleic	acid.	 The	only	exception	 to	 this	
was	 the	 unsaturated	 fatty	 acid	 oleic	 acid,	 which	 was	 not	 growth	 inhibitory	 even	 at	 a	 supra-
physiological	concentration	of	500	µM556,561.		
	
6.4 Free	 fatty	 acids	 promote	 bacterial	 survival,	 phospholipid	 release	 and	
daptomycin	inactivation		
Having	established	that	fatty	acids	did	not	interfere	with	our	standard	daptomycin	challenge	assay	
protocols,	 it	 was	 then	 investigated	 whether	 free	 fatty	 acids	 modulated	 phospholipid	 release,	
daptomycin	inactivation	and	bacterial	survival.	S.	aureus	ΔagrA	was	added	to	TSB	containing	each	








of	 exogenous	 fatty	 acids	 on	 the	 survival	 of	 the	 ΔagrA	 mutant	 correlated	 with	 daptomycin	
inactivation,	the	activity	of	the	antibiotic	in	culture	supernatants	was	determined	(Fig	6.7b).	There	
were	 no	 significant	 differences	 observed	 between	 the	 inactivation	 of	 daptomycin	 by	 the	ΔagrA	
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mutant	 in	 TSB	 only	 or	 TSB	 supplemented	 with	 palmitic	 acid	 or	 myristic	 acid.	 The	 presence	 of	
linoleic	acid	caused	a	delay	in	the	inactivation	of	daptomycin	by	the	ΔagrA	mutant,	relative	to	TSB	
without	 fatty	 acids.	However,	 in	 keeping	with	our	 survival	 data,	we	 found	 that	 the	presence	of	
oleic	 acid	 or	 lauric	 acid	 increased	 the	 rate	 at	which	 the	 ΔagrA	mutant	 inactivated	 daptomycin,	
compared	to	fatty	acid-free	conditions	(Fig	6.7b).	Finally,	to	determine	whether	the	enhanced	rate	
of	 daptomycin	 inactivation	 was	 due	 to	 an	 increase	 in	 the	 rate	 or	 quantity	 of	 release	 of	
phospholipids,	 culture	 supernatants	 were	 examined	 for	 phospholipid	 content	 (Fig	 6.7c).	 As	
expected	 from	the	 survival	and	antibiotic	 inactivation	data,	 the	presence	of	 linoleic	acid	had	no	
effect	 on	 phospholipid	 release,	 relative	 to	 TSB	without	 fatty	 acids.	 The	 presence	 of	 palmitic	 or	




oleic	 and	 lauric	 acids,	 increased	 the	 rate	 and	 quantity	 of	 phospholipid	 release	 in	 response	 to	
daptomycin,	 which	 led	 to	 the	 accelerated	 inactivation	 of	 daptomycin	 and	 enhanced	 bacterial	
survival.	This	likely	reflects	preferential	use	of	these	fatty	acids	at	physiological	concentrations	(20	
µM)	by	S.	aureus	 in	phospholipid	biosynthesis.	By	contrast,	 lauric	acid	appeared	to	be	inhibitory.	
This	 is	 in	 keeping	with	 previous	 studies	 showing	 that	 oleic	 acid	 is	 an	 appropriate	 substrate	 for	


















































































































































		Having	established	 the	effect	of	 various	 free	 fatty	 acids	on	phospholipid	 release,	 it	was	
next	investigated	how	the	concentration	of	the	free	fatty	acid	modulated	this	process.	Since	oleic	






Next,	 the	effect	of	oleic	 acid	 concentration	on	 the	 survival	 kinetics	of	 the	ΔagrA	mutant	
exposed	 to	 daptomycin	 were	 determined	 over	 8	 h.	 The	 presence	 of	 oleic	 acid	 at	 any	 of	 the	
concentrations	 examined	 increased	 bacterial	 survival	 above	 that	 of	 bacteria	 exposed	 to	
daptomycin	in	the	absence	of	fatty	acid.	However,	at	the	highest	concentrations	of	oleic	acid	(50,	
100	 μM)	 there	 was	 slightly	 elevated	 CFU	 counts	 at	 the	 latest	 time	 point,	 relative	 to	 bacteria	
incubated	 with	 lower	 concentrations	 of	 the	 fatty	 acid	 (Fig	 6.8a).	 In	 keeping	 with	 the	 bacterial	
survival	data,	the	presence	of	oleic	acid	at	all	of	the	concentrations	examined	increased	the	rate	of	
daptomycin	 inactivation	 and	 the	 rate	 of	 phospholipid	 released	 above	 that	 of	 bacteria	 in	 TSB	
without	 fatty	 acid	 supplementation	 (Fig.	 6.8b,c).	 However,	 there	 was	 no	 significant	 effect	 of	
increasing	oleic	acid	concentration	above	10	µM.	





endogenous	 fatty	 acid	 biosynthesis	 required	 for	 the	 2-position	 of	 the	 glycerol	 phosphate	 head	











absence	of	a	 range	of	C18:1	 (µM)	concentrations	on	exposure	 to	20	µg	ml-1	daptomycin	 (Dapt).	
Data	 represent	 the	 mean	 of	 n=3	 in	 duplicate	 and	 were	 analysed	 by	 the	 two-way	 ANOVA	 and	
Dunnett’s	 post-hoc	 test.	 For	 bacteria	 treated	with	 C18:1	 +	 daptomycin	 vs	 bacteria	 treated	with	






























































































































Having	 established	 that	 de	 novo	 phospholipid	 biosynthesis	 is	 required	 for	 daptomycin-induced	
phospholipid	release	using	platensimycin	(Fig	4.8),	and	shown	that	the	presence	of	free	fatty	acids	
accelerates	 the	 rate	 of	 phospholipid	 release	 (Fig	 6.7	 and	 6.8),	 the	 next	 objective	 was	 to	
understand	 whether:	 (i)	 the	 ΔagrA	 mutant	 releases	 the	 newly	 synthesized	 phospholipids	 in	
response	 to	daptomycin,	or	 (ii)	 the	newly	synthesized	phospholipids	 facilitate	 the	 release	of	 the	
pre-existing	 phospholipids,	 or	 (iii)	 a	 combination	 of	 both	 newly-synthesised	 and	 pre-existing	
phospholipids	are	released	(Fig	6.9).	To	investigate	this,	phospholipids	of	the	ΔagrA	mutant	were	
labelled	by	incubating	the	bacterium	with	BoDipy-labelled	palmitic	acid	until	stationary	phase.	To	
confirm	 that	 S.	 aureus	 incorporated	 the	 BoDipy-labelled	 palmitic	 acid	 into	 membrane	
phospholipids,	TLC	was	performed	on	these	cells	(Fig	6.10a,b).	Total	lipids	were	extracted	from	the	
cells	of	the	ΔagrA	mutant	that	had	been	incubated	with	BoDipy-labelled	palmitic	acid	by	the	Bligh-
Dyer	 method	 (as	 described	 in	 chapter	 2).	 Thereafter,	 2D-TLC	 and	 iodine	 vapor	 was	 used	 to	
separate	and	identify	the	phospholipids	respectively	and	UV	light	to	 identify	the	BoDipy-labelled	
phospholipid.	 This	 confirmed	 that	 S.	 aureus	 incorporated	 the	 BoDipy-labelled	 palmitic	 acid	 into	
membrane	phospholipids.	This	is	in	agreement	with	previous	studies	which	have	shown	that	in	S.	
aureus	 almost	 all	 fatty	 acids	 either	 endogenously	 synthesized	 or	 acquired	 exogenously	 and	
activated	 by	 the	 FAS	 II	 pathway	 are	 converted	 to	 a	 phospholipid	 and	 incorporated	 into	 the	
membrane542,562.	 In	 addition,	 because	 S.	 aureus	 lacks	 the	 enzymes	 necessary	 for	 β-oxidation,	 it	
does	not	have	the	capacity	to	metabolize	fatty	acids	to	use	it	as	a	means	for	energy	by	breaking	it	
down	in	to	two-carbon	acetyl-CoA	molecules	by	β-oxidation	for	entrance	into	the	tricarboxylic	acid	
cycle556,563.	 After	 incubating	 the	 ΔagrA	 mutant	 with	 the	 BoDipy-labelled	 palmitic	 acid,	 the	 cells	
were	washed	to	remove	unincorporated	BoDipy-labelled	palmitic	acid	and	thereafter,	used	in	the	
subsequent	experiments	to	track	the	release	of	phospholipids.		
However,	 before	 starting	 assays,	 a	 standard	 plot	 of	 the	 relative	 fluorescence	 of	 BoDipy-
labelled	 palmitic	 acid	 was	 generated	 to	 enable	 correlation	 between	 the	 RFU	 values	 and	 the	
concentration	of	 the	BoDipy-labelled	palmitic	 acid	 (Fig	 6.10c).	 This	 revealed	 that	 the	 signal	was	
saturated	at	concentrations	>	3	µM.		






































Silica-based	 thin-layer	 chromatography	 (TLC)	 plate	 spotted	 with	 chloroform:methanol(2:1	 v/v)	
extracted	lipids	from	ΔagrA	cells	that	had	been	incubated	with	BoDipy-labelled	C16:0.	For	2D	TLC,	





and	 (b),	 imaged	 using	 the	 Biorad	 EZ	 imager	 (wavelength	 530	 nm)	 to	 detect	 the	 fluorescent	
molecule	 (BoDipy).	 The	 numbers	 denote	 the	 identified	 spots	 of	 phospholipid.	 All	 images	 are	

























































































a,	 To	 measure	 the	 concentration	 of	 Bodipy-labelled	 C16:0.	 a	 standard	 plot	 of	 the	 relative	
fluorescence	 was	 generated	 using	 increasing	 concentrations	 of	 BoDipy-labelled	 C16:0.	 b,	 The	



















































































Upon	 challenge	 with	 daptomycin,	 the	 RFU	 in	 the	 culture	 supernatant	 from	 the	 BoDipy-
labelled	 phospholipid	 rapidly	 increased	 to	 levels	 significantly	 higher	 than	 that	 of	 bacteria	 not	
exposed	to	daptomycin,	which	remained	at	basal	 levels	during	the	entire	8	h	growth	period	(Fig	
6.12a)	This	provided	evidence	that	daptomycin	triggered	the	release	of	pre-existing	phospholipids	
from	 the	 bacterial	 membrane.	 However,	 analysis	 of	 the	 BoDipy-mediated	 fluorescence	 of	 S.	
aureus	 cells	 found	 no	 difference	 between	 the	 RFU	 of	 the	 BoDipy-labelled	 ΔagrA	 mutant	 cell	
exposed	 to	 daptomycin	 compared	 to	 the	 BoDipy-labelled	 ΔagrA	 mutant	 cell	 not	 exposed	 to	
daptomycin	 (Fig	 6.12b).	 This	 indicated	 that	 although	 there	 is	 a	 release	 of	 BoDipy-labelled	
phospholipid	 into	 the	 culture	 supernatant,	 a	 large	 fraction	 of	 the	 pre-existing	 (BoDipy-labelled)	
phospholipid	 is	 retained	 in	 the	 membrane.	 i.e.	 only	 a	 relatively	 small	 fraction	 of	 pre-existing	








The	 data	 presented	 in	 Fig	 6.12	 indicated	 that	 upon	 daptomycin	 challenge	 pre-existing	
phospholipids	are	 released	 into	 the	culture	 supernatant.	To	confirm	 the	 findings	obtained	using	
fluorescent	dyes,	2D-TLC	was	used	to	separate	and	identify	 lipids.	After	separation,	 iodine	vapor	
was	 used	 to	 stain	 the	 phospholipids	 and	 UV	 light	 was	 used	 to	 detect	 lipids	 containing	 the	
fluorophore	BoDipy.	 The	 identity	 of	 each	 spot	was	 determined	by	 comparison	 to	 the	migration	
pattern	of	the	purified	phospholipid	standards	i.e.	PG,	LPG,	CL	and	BoDipy-labelled	palmitic	acid.	
As	 before,	 to	 ensure	 the	 correct	 identification	 of	 the	 phospholipids	 in	 the	 culture	 supernatant,	
purified	phospholipid	standards	were	mixed	with	TSB	at	100	μM	before	being	subjected	to	 lipid	
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extraction	 and	 TLC	 analysis	 to	 mimic	 the	 processing	 of	 staphylococcal	 lipids	 in	 culture	
supernatants	(Fig	6.13a,b,c,e).	As	expected,	staining	of	the	TLC	plate	by	iodine	vapour	revealed	the	
presence	of	 LPG,	PG	and	BoDipy-labelled	phospholipids	 in	 the	culture	supernatant	of	 the	ΔagrA	
mutant	exposed	to	daptomycin	(Fig	6.13d).	Visualization	of	the	TLC	plates	under	UV	light	revealed	
the	 presence	 of	 BoDipy-labelled	 phospholipids,	 confirming	 the	 incorporation	 of	 the	 BoDipy-








S.	aureus	was	 incubated	with	BoDipy-labelled	C16:0	 (20	µM)	until	 stationary	phase	and	washed	
before	being	exposed	or	not	exposed	to	daptomycin	for	8	h.	Presence	of	BoDipy-labelled	C16:0	in	
the	culture	supernatant	(a)	and	cells	(b)	of	the	USA300	ΔagrA	mutant	exposed	or	not	exposed	to	
20	 µg	ml-1	 daptomycin	 for	 8	 h.	 Total	 phospholipid	 release	 (c)	 from	 the	 USA300	 ΔagrA	 mutant	
exposed	or	not	exposed	to	daptomycin	was	also	measured.	Data	in	panels	a-c	represent	the	mean	
of	n=3	 in	duplicate	and	were	analysed	by	 the	 two-way	ANOVA	and	Dunnett’s	post-hoc	 test.	For	
bacteria	treated	with	daptomycin	vs	bacteria	not	treated	with	daptomycin	P	<0.001,	P	<0.00001	at	
the	 time	 points	 indicated	 (**),	 (****)	 respectively	 and	 ns	 =	 non-significant.	 For	 all	 panels	 error	
bars	represent	the	standard	deviation	of	the	mean.	
	





































































Silica-based	 thin-layer	 chromatography	 (TLC)	 plates	were	 spotted	with	 chloroform:methanol(2:1	
v/v)	 extracts	 from	 (a)	 purified	 phospholipid	 (PL)	 standards	 including	 phosphatidylglycerol	 (PG),	























































































labelled	 C16:0	 is	 denoted	 as	 BoDipy-labelled	 fatty	 acid	 (BoDipy-FA);	 (d,f)	 TSB,	 filtered	 culture	
supernatant	from	the	BoDipy-labelled	agrA	mutant	 	exposed	to	daptomycin	(ΔagrA	+	dapt.).	For	
2D	TLC,	the	TLC	plate	was	first	run	in	chloroform:methanol:ammonium	hydroxide	(65:30:4	v/v/v).	




the	 TLC	 plate	 to	 quantify	 the	 phosphate	 content	 in	 the	 phospholipid.	 The	migration	 of	 purified	
phospholipid	 (PL)	standards	CL,	LPG	or	PG	extracted	 in	the	absence	(a)	and	presence	of	TSB	(b);	
BoDipy-FA	(c)	match	those	generated	by	the	lipids	extracted	from	spent	culture	supernatant	which	
was	detected	by	 staining	with	 iodine	 vapour	 (d).	 In	 addition,	 TLC	plates	were	 imaged	using	 the	






phospholipid	 standards	 including	 PG,	 CL,	 LPG	 and	 BoDipy-labeled	 fatty	 acid.	 Therefore,	 as	 an	
additional	 confirmation	 that	 the	 spot	 identified	 as	 Bodipy-labelled	 phospholipid	 was	 a	
phospholipid,	iodine	stained	spots	were	scraped	and	subjected	to	a	colorimetric	assay	that	detects	
phosphate	 (Fig	 6.13).	 This	 assay	 confirmed	 the	 presence	 of	 a	 phosphate	 group	 attached	 to	 the	
identified	BoDipy-labelled	lipid	molecules	(Fig	6.14).	Thus,	this	finding	indicated	that	the	cells	pre-
labelled	 with	 BoDipy-labelled	 fatty	 acid	 is	 incorporated	 into	 a	 phospholipid	 and	 subsequently	
released	on	exposure	to	daptomycin,	but	the	precise	identity	of	the	phospholipid	species	remains	
to	be	confirmed	since	appropriate	standards	are	unavailable.		
Therefore,	 daptomycin	exposure	 triggers	 the	 release	of	phospholipids	 already	present	 in	









Figure	 6.14.	 Identification	 and	 quantification	 of	 pre-existing	 and	 newly-synthesised	
phospholipids	in	the	culture	supernatant	of	USA300	ΔagrA	strain	exposed	to	daptomycin	
	Lipids	were	 identified	by	 reference	 to	purified	 standards	and	quantified	as	described	 in	 section	
2.17.	 The	 numbers	 indicate	 the	 identity	 of	 the	 spots	 as	 denoted	 in	 Fig	 6.13	 and	 ΔagrA+Dapt	 =	
BoDipy-phospholipid	 labelled	ΔagrA	mutant	exposed	to	daptomycin,	PG	=	phosphatidyl	glycerol,	
LPG	 =	 Lysyl	 PG,	 BoDipy-PL	 =	 BoDipy	 phospholipid	 and	 BoDipy-FA	 =	 BoDipy	 fatty	 acid.	 Data	 are	
presented	 as	 the	 relative	 proportions	 of	 each	 phospholipid,	 fatty	 acid	 standards	 and	 each	
phospholipid	 in	 the	 spent	 culture	 supernatant	 (relative	 absorbance	 values	 of	 the	 phosphate	
content).	Data	represent	the	mean	of	n=3	in	duplicate	and	were	analysed	by	the	one-way	ANOVA	
and	 Tukey’s	 post-hoc	 test.	 For	 BoDipy-PL	 vs	 BoDipy-FA	 standard	P	<0.00001	 at	 the	 time	 points	








Figure	 6.14.	 Identification	 and	 quantification	 of	 pre-existing	 and	 newly-synthesised	
phospholipids	in	the	culture	supernatant	of	USA300	ΔagrA	strain	exposed	to	daptomycin	
	Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	 quantified	 as	 described	 in	 the	
methods	 section.	 The	 numbers	 indicate	 the	 identity	 of	 the	 spots	 as	 denoted	 in	 Fig	 6.13	 and	
ΔagrA+Dapt	 =	 BoDipy-phospholipid	 labelled	 ΔagrA	 mutant	 exposed	 to	 daptomycin,	 PG	 =	
phosphatidyl	glycerol,	LPG	=	Lysyl	PG,	BoDipy-PL	=	BoDipy	phospholipid	and	BoDipy-FA	=	BoDipy	












Figure	 6.14.	 Identification	 and	 quantification	 of	 pre-existing	 and	 newly-synthesised	
phospholipids	in	 he	culture	supernatan 	 f	USA300	ΔagrA	strain	exposed	to	dap omycin.	
	Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	 quantified	 as	 described	 in	 the	
methods	 section.	 Th 	 numbers	 indicate	 the	 identity	 of	 the	 spots	 as	 denoted	 in	 Fig	 6.13	 and	
ΔagrA+Dapt	 =	 BoDipy	 C16:0	 labeled	 ΔagrA	mutant	 exposed	 to	 daptomycin,	 PG	 =	 phosphatidyl	
glycerol,	LPG	=	Lysyl	PG,	BoDipy-PL	=	BoDipy	ph spholipid	and	BoDipy-FA	=	BoDipy	fatty	acid.	Data	
are	 presented	 as	 the	 relative	 pro ortions	 of	 each	 phospholipid,	 fatty	 acid	 standards	 and	 each	
phospholipid	 in	 the	 spent	 culture	 supernatant	 (relative	 absorbance	 values	 of	 the	 p osphate	
content).	Data	r present	the	mean	of	n=3	in	duplicate	and	were	analysed	by	the	one-way	ANOVA	















































The	 first	 assay	 was	 to	 determine	 the	 daptomycin	 MIC	 in	 serum.	 Using	 a	 checkerboard	
method,	it	was	found	that	the	susceptibility	of	S.	aureus	to	daptomycin	was	reduced	slightly	with	
increasing	concentrations	of	human	serum	for	both	wild-type	and	ΔagrA	strains	(Table	6.2).	This	
indicated	that	daptomycin	was	 likely	binding	to	serum	proteins,	which	resulted	 in	an	 increase	 in	
the	MIC	of	daptomycin	compared	to	TSB	only.	This	 is	 in	keeping	with	previous	studies	that	have	
shown	 that	 ~90%	 of	 daptomycin	 binds	 to	 proteins	 in	 serum,	 independent	 of	 the	 drug	
concentration131,184,581–584.	 However,	 in	 agreement	 with	 our	 data,	 several	 studies	 have	
demonstrated	that	human	serum	only	moderately	reduces	the	bactericidal	activity	of	daptomycin	
(i.e.	 2-4	 fold	 increase),	 presumably	 because	 daptomycin	 binding	 to	 serum	proteins	 is	weak	 and	
reversible185,569,570.	
To	 investigate	 the	 role	 of	 fatty	 acids	 in	 serum	 towards	 the	 survival	 of	 S.	 aureus	when	





type	 strain	 survived	 daptomycin	 challenge	 and	 completely	 inactivated	 daptomycin	 by	 4	 h	 (Fig	
6.15a,c).	This	phenotype	was	similar	 to	 the	survival	phenotype	of	 the	ΔagrA	mutant	exposed	to	
daptomycin	in	TSB	only	(Fig	6.15b,c).		
Because	 serum	 suppresses	 Agr	 activity	 and	 sequesters	 PSMs185,524,	 the	 greatly	 increased	
survival	of	wild-type	bacteria	in	serum	was	likely	due	to	the	absence	of	PSMα1,	which	inhibits	the	
inactivation	 of	 daptomycin	 by	 released	 phospholipids.	 However,	 of	 note,	 there	 was	 a	 4-fold	








Taken	 together,	 these	data	 indicated	 that	 serum	promotes	 the	survival	of	both	 the	wild-
type	and	the	ΔagrA	mutant	when	exposed	to	daptomycin.	The	fact	that	there	is	a	difference	in	the	
survival	 of	 the	 ΔagrA	 mutant	 with	 serum	 compared	 with	 the	 ΔagrA	 mutant	 without	 serum	
suggests	the	availability	of	nutrients	such	as	fatty	acids	may	play	a	role	in	promoting	the	survival	of	
















Table	6.2.	 The	 susceptibility	of	S.	aureus	 to	daptomycin	 is	 reduced	 in	 the	presence	of	Human	
serum		
The	checkerboard	plate	 contains	a	 range	of	 concentrations	of	daptomycin	and	human	 serum	 in	
TSB	(50:50)	determined	by	broth	microdilution	as	described	previously,	with	microtitre	wells	that	
contain	the	highest	concentration	of	daptomycin	(μg	ml-1)	and	human	serum	in	the	same	well.	All	
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of	n=3	 in	duplicate	and	were	analysed	by	 the	 two-way	ANOVA	and	Dunnett’s	post-hoc	 test.	For	
bacteria	treated	with	daptomycin	inTSB	+	serum	vs	bacteria	treated	with	daptomycin	in	TSB	only	P	
<0.01,	P	<0.00001	at	 the	time	points	 indicated	(*),	 (****)	respectively.	 	For	all	panels	error	bars	
represent	the	standard	deviation	of	the	mean.	
	 	

















































































6.7 Serum	 albumin	 prevents	 the	 utilization	 of	 exogenous	 fatty	 acids	 in	
phospholipid	release	




transport	 the	 high	 concentrations	 of	 free	 fatty	 acids	 to	 vital	 organs	 and	 to	 increase	 the	

















To	 understand	whether	 the	differences	 seen	between	 TSB	 and	 serum	were	due	 to	 fatty	
acid	 binding	 by	HSA,	 assays	were	 repeated	 in	 TSB	 supplemented	with	 the	 serum	protein.	 Fatty	
acid-free	HSA	was	supplemented	with	or	without	oleic	acid	(20	µM)	before	being	added	to	ΔagrA	
mutant	 cultures,	which	were	 then	 exposed	 to	 daptomycin.	 Similar	 to	 the	 results	 obtained	with	
DLS,	 no	 significant	 differences	 in	 bacterial	 survival	 or	 daptomycin	 inactivation	 was	 observed	







the	phospholipids	 in	 response	 to	daptomycin	 (Fig	6.7	and	6.8).	This	 result	was	a	 little	 surprising	
since	 previous	 work	 has	 shown	 that	 S.	 aureus	 can	 utilize	 fatty	 acids	 in	 the	 presence	 of	 HSA.	
However,	whilst	this	study	used	a	similar	HSA	concentration	to	that	used	here,	the	concentration	
of	fatty	acids	used	 in	previous	work	were	far	 in	excess	of	the	physiological	range,	which	may	be	



































































































































































































AFN-1252	 is	 an	 inhibitor	 of	 the	 FabI	 enzyme	 involved	 in	 staphylococcal	 fatty	 acid	 biosynthesis,	
which	 appears	 to	 be	 essential	 for	 daptomycin-induced	 phospholipid	 release.	 This	 suggests	 that	
combination	 therapy	 using	 AFN-1252	 and	 daptomycin	 could	 significantly	 improve	 treatment	
outcomes.	However,	there	is	some	evidence	that	the	presence	of	exogenous	fatty	acids,	as	occurs	






























study.	 Data	 show	 the	MIC	 (μg	ml-1)	 for	 Platensimycin	 (a)	 and	AFN-125	 (b)	 in	 TSB	 (TrypGc	 Soy	 Broth)	
determined	 by	 broth	 microdiluGon	 as	 described	 previously.	 The	 MIC	 was	 determined	 a_er	 24	 h	





To	 test	whether	 AFN-1252	 could	 block	 phospholipid	 release	 in	 response	 to	 daptomycin,	
assays	were	first	done	without	fatty	acids	to	establish	appropriate	AFN-1252	concentrations.	TSB	
was	supplemented	with	AFN-1252	at	1x,	5x,	10x,	30x	or	60x	the	MIC	in	the	presence	or	absence	of	
a	 single	 concentration	 of	 daptomycin	 (20	 µg	 ml-1)	 before	 the	 addition	 of	 the	 ΔagrA	 mutant.	
Bacterial	 survival	 and	 phospholipid	 release	 were	 then	 measured	 over	 time	 (Fig	 6.19a,b).	 As	
expected,	 in	 the	 absence	 of	 daptomycin,	 increasing	 concentrations	 of	 AFN-1252	 resulted	 in	
bacteriostatic	 activity.	 Also,	 as	 expected,	 daptomycin	 alone	 failed	 to	 kill	 the	 ΔagrA	mutant	 and	
there	was	a	 significant	quantity	of	phospholipid	 released	 into	 the	culture	 supernatant.	 This	was	













Figure	 6.19.	 AFN-1252	 prevents	 phospholipid	 release	 and	 promotes	 bacterial	 killing	 by	
daptomycin			






















































































































pass	AFN-1252	mediated	 inhibition	of	 FabI	 and	 release	phospholipids.	 To	 test	 this,	 the	previous	
experiment	described	in	Fig	6.19	was	repeated	in	the	presence	of	20	μM	oleic	acid	(Fig	6.20a,b).		
As	 expected,	 the	 ΔagrA	 mutant	 was	 able	 to	 survive	 daptomycin	 exposure	 by	 releasing	
phospholipids	 (Fig	 6.20a,b).	 By	 contrast,	 the	 ΔagrA	mutant	was	 killed	 and	 phospholipid	 release	
completely	inhibited	when	AFN-1252	was	present	at	10x,	MIC	or	greater.	
Therefore,	 regardless	 of	 the	 availability	 of	 exogenous	 fatty	 acids,	 AFN-1252/daptomycin	
combination	 therapy	was	 significantly	more	effective	 than	daptomycin	 alone.	 These	 findings	do	
not	rule	out	the	possibility	that	exogenous	fatty	acids	enable	by-pass	of	FabI.	However,	if	this	does	



















Figure	6.20.	Regardless	of	the	presence	of	 free	C18:1	the	 lipid	biosynthesis	 inhibitor	AFN-1252	
prevents	phospholipid	release	and	promotes	bacterial	killing	by	daptomycin		












































when 2way - ANOVA  was performed just between between dapt  and 
dapt afn 10 30 60 and not all 12  significance was observed - Post hoc 
test- Dunette’s multiple comparison test










































































environment	 are	 likely	 to	 affect	 phospholipid	 release	 and	 whether	 a	 FabI	 inhibitor	 in	 clinical	
development	 could	 provide	 a	 useful	 adjunctive	 to	 daptomycin	 therapy.	 These	 experiments	
revealed	that	fatty	acid	utilization	during	daptomycin	exposure	is	complex,	but	provided	evidence	
that	 AFN-1252	 has	 the	 potential	 to	 improve	 daptomycin	 treatment	 outcomes	 by	 suppressing	
phospholipid	release.				
6.9.1 Certain	exogenous	fatty	acids	promote	daptomycin-induced	phospholipid	release		
In	 chapter	 4,	 it	 was	 shown	 that	 daptomycin-induced	 phospholipid	 release	 was	 blocked	 by	
platensimicin,	 demonstrating	 that	 this	 process	 is	 dependent	 upon	 de	 novo	 phospholipid	
production.	 Since	 S.	 aureus	 phospholipid	 biosynthesis	 can	 utilise	 exogenous	 fatty	 acids,	 it	 was	
explored	whether	these	enhanced	phospholipid	release529,531,540.	The	experiments	done	with	free	
fatty	acids	 in	TSB	demonstrated	 that,	 in	principle,	 the	presence	of	 specific	exogenous	 free	 fatty	
acids	 significantly	 enhance	 phospholipid	 release	 in	 response	 to	 daptomycin.	 However,	 the	
presence	 of	 some	 fatty	 acids	 inhibited	 phospholipid	 release,	 which	 reflects	 the	 high	 degree	 of	
specificity	in	the	staphylococcal	FASII	system.		
	 During	 growth,	 95%	 of	 the	 cell’s	 energy	 is	 spent	 on	 re-generating	 the	 phospholipid	
membrane529,	 which	 suggests	 that	 phospholipid	 release	 is	 a	 very	 costly	 process.	 However,	 S.	
aureus	 cannot	 divert	 the	 fatty	 acids	 to	 energy	 production	 since	 S.	 aureus	 lacks	 the	 β-oxidation	




branched	 chain	 amino	 acids,	 to	 build	 phospholipids426.	 For	 example,	 isoleucine	 is	 needed	 to	
synthesize	 anteiso	 odd-numbered	 fatty	 acids	 and	 leucine	 is	 needed	 for	 iso	 odd-numbered	 fatty	
acids535,562	(Fig	6.3).	Thus,	although	the	availability	of	particular	fatty	acids	appars	to	enhance	the	
efficiency	 of	 phospholipid	 release,	 S.	 aureus	must	 also	 acquire	 other	 nutrients	 from	within	 the	




membrane,	 but	 has	 limited	 means	 to	 eject	 those	 fatty	 acids	 that	 cannot	 be	 incorporated	 into	
		 243	
phospholipids.	Thus,	host	derived	fatty	acids	which	are	toxic	to	S.	aureus	such	as	16:1Δ9	and	found	
on	 the	 skin	 cause	 membrane	 disruption	 and	 growth	 inhibition562.	 We	 do	 not	 yet	 know	 the	





A	total	of	3381	types	of	 lipids	are	 found	 in	 the	human	serum	metabolome	of	which	27	types	of	
lipids	are	found	as	free	fatty	acids	(the	upper	limit	of	the	concentration	range	can	be	as	high	as	66	
μM)	574.	Fatty	acids	are	important	substrates	for	the	synthesis	of	membrane	phospholipids	in	host	
cells	 and	 an	 important	 source	 of	 energy572.	 Fatty	 acids	 exist	 in	 the	 plasma	 as	 anions	 and	 the	
aqueous	solubility	of	the	monomeric	forms	of	fatty	acids	including	oleic	acid	and	palmitic	acid	are	
~10-20	 μM	 575,576.	 To	 enable	 the	 transport	 of	 fatty	 acids	 via	 the	 bloodstream,	 these	 lipids	 are	
carried	and	delivered	to	the	cells	by	the	serum	albumin	protein,	which	is	the	key	carrier	of	fatty	
acids577,578,575.			







for	S.	 aureus	 to	 rapidly	 release	 phospholipids	 to	 inactivate	 the	 antibiotic	 as	 quickly	 as	 possible.	
Therefore,	 the	 fact	 that	 HSA	 simply	 reduces	 the	 efficiency	 of	 staphylococcal	 utilization	 of	 fatty	
acids	 to	 generate	 phospholipids	 for	 release,	 is	 sufficient	 to	 prevent	 their	 contribution	 to	
daptomycin	inactivation.	What	is	unknown,	and	warrants	investigation,	is	whether	cells	lysed	by	S.	




6.9.3 Serum-protein	 sequestration	 of	 AIP	 and	 PSM	 enable	 daptomycin	 survival	 by	 the	
wild-type	
An	interesting	observation	was	made	when	serum	dramatically	improved	the	survival	of	the	wild-
type	 in	 the	 presence	 of	 daptomycin.	 However,	 the	 findings	 suggest	 that	 this	 is	 due	 to	 the	
suppression	of	the	Agr	quorum-sensing	system	and/or	sequestration	of	PSMs	since	serum	had	a	
very	 modest	 effect	 on	 the	 survival	 of	 the	 ΔagrA	 mutant	 exposed	 to	 daptomycin.	 It	 is	 well	
established	 that	 serum	 contains	 lipoproteins	 which	 sequesters	 the	 AIP	 molecule	 required	 to	







AFN-1252	 inhibits	 the	 FabI	 enzyme	 in	 the	 FAS	 II	 pathway,	 which	 blocks	 the	 endogenously	
synthesized	fatty	acids	required	to	form	phospholipids	542,550,541,543.	The	FabI	enzyme	is	an	essential	
enzyme	 in	S.	 aureus	 as	 it	 is	 the	 sole	 form	of	 the	enoyl-ACP	 reductase	enzyme	 in	S.	 aureus	 that	
catalyses	 the	completion	of	 the	elongation	cycle	of	 the	 fatty	acids,	which	 is	 the	step	before	 the	
fatty	 acid	 becomes	 a	 phospholipid550,541.	 	 AFN-1252,	which	 is	 the	 first	 antibiotic	 in	 its	 class	 has	








531,542,543.	However,	despite	 the	 fact	 that	S.	aureus	FAS	 II	 is	essential	 for	 the	 fatty	acid	synthesis,	
even	 in	 the	presence	of	host-derived	 fatty	acids,	 it	 is	unclear	whether	AFN-1252	 is	viable	 in	 the	





in	 the	 presence	 of	 host-derived	 fatty	 acids	 by	 completely	 shutting	 down	 daptomycin-induced	
phospholipid	 release	 and	 thereby	 enhancing	 daptomycin	 activity.	 Thus,	 the	 use	 of	 AFN-1252	
alongside	daptomycin	provides	a	viable	dual	therapeutic	approach	with	the	potential	to	improve	
daptomycin	 treatment	 outcomes.	 However,	 further	 studies	 on	 how	 this	 combination	 therapy	
would	 work	 in	 the	 host	 remains	 to	 be	 addressed,	 in	 particular	 using	 appropriate	 mammalian	
infection	models	 to	 test	 the	efficiency	of	 the	dual	 therapy.	 In	addition,	 since	 resistance	 to	both	












There	 is	 a	 growing	 body	 of	 evidence	 that	 persistent	 and	 invasive	 staphylococcal	 infections	 are	
caused	by	 strains	 defective	 for	Agr	 function.	However,	 it	 is	 not	 clear	what,	 if	 any,	 advantage	S.	
aureus	 gains	 from	 losing	 Agr	 activity.	 S.	 aureus	 faces	 two	 major	 threats	 during	 infection:	 host	
immunity	 and	 antibiotics.	 Since	 we	 have	 shown	 previously	 that	 loss	 of	 Agr	 function	 does	 not	
promote	staphylococcal	survival	in	blood183,385,	the	hypothesis	for	this	project	was	that	loss	of	Agr	
function	 reduced	 antibiotic	 susceptibility.	 This	 was	 supported	 by	 several	 reports	 linking	 Agr-
dysfunction	 to	 chronic	 infection	 and	 the	 emergence	 of	 antibiotic	 resistance183,368,377,389,425.	
However,	 a	 direct,	 mechanistic,	 link	 between	 Agr	 and	 antibiotic	 susceptibility	 had	 not	 been	
investigated.	Using	a	panel	of	well-defined	mutants	and	standard	antibiotic	susceptibility	testing	
protocols,	 it	 was	 found	 that	 there	was	 no	 link	 between	 Agr	 activity	 and	 drug	 susceptibility	 for	
several	 clinically-relevant	 antibiotics.	 There	 was,	 however,	 one	 notable	 exception	 to	 this.	
Daptomycin,	a	lipopeptide	antibiotic	of	last	resort	for	MRSA	and	VISA	infections,	was	significantly	
more	active	against	wild-type	than	Agr-defective	S.	aureus.	This	finding	 led	to	the	discovery	of	a	






host	 apolipoproteins14,183,375,377,378,389,399.	 For	 example,	 a	 large	proportion	of	MRSA	 strains	 in	 the	
UK	 have	 reduced	 or	 absent	 Agr	 activity	 due	 to	 the	 action	 of	 the	 alternative	 penicillin-binding	
protein	2a375,438.	
Using	 a	 combination	 of	 agr	 mutant	 strains	 and	 clinical	 isolates	 with	 Agr-functional	 or	
dysfunctional	 phenotypes,	 it	was	 observed	 that	 the	 absence	 of	 Agr	 activity	 enabled	 bacteria	 to	
survive	daptomycin	more	efficiently	than	bacteria	with	functional	Agr	systems.	Subsequent	work	






and	 antibiotic	 resistance,	 this	 may	 be	 the	 only	 case	 of	 a	 virulence	 factor	 directly	 sensitizing	 a	
pathogen	 to	 an	 antibiotic375,377,378,380.	 Therefore,	whilst	 the	 initial	 hypothesis	 of	 this	 project	was	
that	 loss	 of	 Agr	 function	 reduces	 susceptibility,	 it	may	 be	more	 correct	 to	 say	 that	 Agr	 activity	
increases	susceptibility	by	compromising	the	phospholipid-release	defence	mechanism.	
The	finding	that	phospholipid-mediated	inactivation	of	daptomycin	is	compromised	by	the	
Agr-dependent	 secretion	 of	 PSMs	 may	 appear	 paradoxical.	 However,	 whilst	 Agr	 is	 certainly	
required	during	the	early	stages	of	acute	infection,	it	appears	dispensable	for	invasive	or	chronic	
infection	 in	 humans,	 from	 which	 agr-mutants	 are	 frequently	 isolated115,368,380,387,388,425.	
Furthermore,	 even	when	 the	Agr	 system	 is	 functional,	Agr	 is	 active	 in	only	 a	 subset	of	 bacteria	
during	acute	infection,	whether	in	tissue	or	biofilm507,509,518.	Therefore,	as	infection	progresses,	the	
staphylococcal	population	consists	of	a	mixture	of	Agr	active	and	Agr	inactive	cells,	meaning	that	
PSMs	are	not	 expressed	by	 all	 or	 even	most	bacteria.	 Since	daptomycin	 is	 often	not	 a	 first	 line	
therapeutic,	it	is	typically	used	to	treat	established	infection,	when	Agr	activity	is	most	likely	to	be	
variable	or	absent,	 rather	than	during	the	early	stages	of	 infection	when	Agr	activity	 is	greatest.	
Heterogeneity	 in	 Agr	 activity	 within	 S.	 aureus	 populations	 may	 therefore	 enable	 S.	 aureus	 to	
effectively	balance	virulence	and	daptomycin	susceptibility	by	producing	enough	toxins	to	sustain	
infection	but	without	significantly	 impairing	 the	 lipid-release	defence	mechanism.	This	 is	akin	 to	








inactivated	 by	 enzymes	 produced	 by	 various	 environmental	 organisms,	 as	 well	 as	 mammalian	
proteases434.	 However,	 whilst	 S.	 aureus	 produces	 several	 proteases,	 it	 does	 not	 hydrolyse	
daptomycin.	Instead,	the	data	presented	here	reveal	that	S.	aureus	can	inactivate	daptomycin	via	
an	 enzyme-independent	 mechanism,	 by	 showing	 that	 membrane	 phospholipid	 released	 by	 S.	
aureus	 sequesters	 and	 inactivates	 the	 antibiotic.	 In	 addition,	 recent	 work	 from	 our	 group	 has	




The	 release	 of	 phospholipid,	 it	 appears	 is	 a	 specific	 response	 to	 the	 presence	 of	
daptomycin,	and	results	in	the	release	of	all	membrane	phospholipids	at	approximately	the	same	
relative	abundances	found	in	the	membrane.	However,	despite	similarities	in	the	structure	of	the	
major	 staphylococcal	 phospholipids,	 the	 data	 show	 that	 PG	 was	 significantly	 more	 efficient	 at	
inactivating	 daptomycin	 than	 LPG.	 This	 suggests	 that	 S.	 aureus	 releases	 phospholipids	 directly	
from	 the	membrane,	 rather	 than	 employ	 a	 dedicated	 release	mechanism	 such	 as	 a	 pump	 that	







moderate	 increases	 in	 the	 MIC	 (2-4-fold),	 but	 these	 are	 often	 sufficient	 to	 enable	 growth	 at	
clinically-achievable	 daptomycin	 concentrations132,440.	 However,	 the	 emergence	 of	 these	
‘daptomycin	non-susceptible’	 strains	 is	a	 relatively	 rare	event	and	do	not	 therefore	explain	why	
daptomycin	treatment	failure	occurs	in	up	to	30	%	of	cases136.	
The	data	presented	in	this	thesis	provides	evidence	that	Agr	status	influences	daptomycin	
treatment	 outcomes	 but	 does	 not	 directly	 demonstrate	 that	 phospholipid	 release	 influences	
therapeutic	 outcomes.	 Evidence	 is	 also	 provided	 that	 combining	 the	 β-lactam	 antibiotic	 with	
daptomycin	 improved	 daptomycin	 efficacy	 in	 a	 murine	 model.	 This	 is	 agreement	 with	 other	
studies	 showing	 synergistic	 activity	 of	 daptomycin	 and	 β-lactam	 antibiotics	 and	 the	 CAMERA2	
clinical	trial	is	currently	underway	to	determine	if	this	constitutes	a	clinically	efficacious	approach	
in	 humans587.	 However,	 whilst	 the	 data	 presented	 here	 indicate	 that	 the	 β-lactam	 oxacillin	
promotes	daptomycin	efficacy	by	 inhibiting	phospholipid	release,	additional	mechanisms	for	this	











of	 the	 range	 of	 different	 mechanisms	 by	 which	 bacteria	 can	 withstand	 antibiotic	 exposure.	 In	
general,	there	are	4	well-described	mechanisms	by	which	bacteria	can	resistant	antibiotics,	which	
require	 the	 acquisition	 of	 genes	 or	 mutations.	 Resistance	 enables	 bacteria	 to	 replicate	 in	
concentrations	of	antibiotic	that	would	otherwise	be	inhibitory	and	typically	occurs	via	four	main	
mechanisms446,590,591:	 (i)	 enzyme-mediated	 antibiotic	 hydrolysis	 or	 modification;	 (ii)	 antibiotic	
efflux	 pumps,	 which	 results	 in	 the	 reduction	 of	 the	 intracellular	 antibiotic	 concentration;	 (iii)	
altered	target	site	i.e.	genetic	mutation	or	post-translational	modification	of	the	antibiotic	target	
site,	 and	 (iv)	 target	 over-expression446.	 In	 addition	 to	 these	 dedicated	 resistance	 mechanisms,	








In	 addition	 to	 these	well-described	phenomena	of	 resistance,	 persistence	 and	 tolerance,	
there	 is	an	 increasing	recognition	of	extracellular	mechanisms	by	which	bacteria	can	survive	the	
exposure	to	antibiotics,	which	our	group	have	termed	‘antibiotic	interceptors'.	The	inactivation	of	
antibiotics	 before	 they	 engage	with	 the	 organism	 enables	 bacteria	 to	 evade	 killing,	 akin	 to	 the	
ability	 of	 S.	 aureus	 to	 evade	 complement	 deposition	 by	 releasing	 inhibitors	 of	 complement	
activation271–273.		
These	 antibiotic	 interception	mechanisms	 involve	 diverse	mechanisms	 but	 share	 several	
similarities	 with	 the	 phospholipid	 release	 mechanism	 described	 in	 this	 thesis	 (Fig	 7.1).	 For	
example,	antibiotic	interceptors	include	the	release	of	molecules	that	mimic	the	intended	target,	
such	as	outer	membrane	vesicles	(OMVs),	which	act	as	decoys	for	membrane-targeting	antibiotics	
such	 as	 colistin594,595.	 Other	 interceptors	 do	 not	 appear	 to	 act	 as	 decoys.	 For	 example,	 the	
		 251	
lipochalins	 are	 secreted	 proteins,	 which	 bind	 multiple	 classes	 of	 antibiotics	 and	 CAMPs	 via	 a	
hydrophobic	pocket.	As	for	phospholipid	release	in	S.	aureus,	lipocalins	are	produced	in	response	
to	antibiotic	exposure,	indicating	they	form	part	of	a	dedicated	defence	mechanism.	Furthermore,	





of	 the	 antibiotic.	 Similarly,	 the	 exposure	 of	 Accinetobacter	 baumannii	 to	 sub-inhibitory	
concentrations	 of	 chloramphenicol	 or	 erythromycin	 resulted	 in	 the	 hyperproduction	 of	 the	

















A.	 baumanii	 increases	 the	 production	 of	 the	 extracellular	 polysaccharide	 capsule	 that	 can	 be	









Many	 of	 the	 antibiotic	 interception	 mechanisms	 described	 above	 provide	 protection	 from	




important	 colonization	 sites602,604–606.	During	 infection,	 S.	 aureus	 will	 also	 be	 exposed	 to	 AMPs	
produced	by	neutrophils	and	other	immune	cells	including	the	cationic	peptides	cathelicidin	LL-37,	
human	 β-defensin,	 protegrin	 and	 human	 neutrophil	 peptide	 α-defensin275,607.	 All	 of	 these	
contribute	 to	 innate	 immunity	 and	 derivatives	 of	 these	 have	 been	 developed	 as	 topical	
bactericidal	agents	to	treat	infections608.	For	example,	OP-145	(P60.4AC)	is	derived	from	LL-37	and	
is	under	phase	2	clinical	trial	for	treating	chronic	ear	infections602,609,610.		
In	 this	 thesis,	 it	 was	 shown	 that	 the	 S.	 aureus	ΔagrA	 mutant	 released	 phospholipids	 in	
response	to	the	CAMPs	melittin	and	nisin	(Fig	7.2).	It	is	not	yet	known	whether	mammalian	host	
defence	peptides	such	as	β-defensins,	cathelicidin	LL-37,	gramicidin	or	PR-39	induce	phospholipid	
release	 in	 S.	 aureus.	However,	 since	 colistin	 and	 daptomycin	 are	 used	 rarely	 in	 humans,	whilst	
bacteria	 frequently	 encounter	 antimicrobial	 peptides	 from	 host	 defences	 and/or	 competitor	
species,	 it	 appears	 much	 more	 likely	 that	 peptides	 provided	 the	 selection	 pressure	 for	 these	





In	 summary,	 this	 thesis	 describes	 the	 discovery	 and	 characterization	 of	 a	 novel	 mechanism	 of	
antibiotic	inactivation,	whereby	S.	aureus	releases	phospholipids,	which	sequester	daptomycin	(Fig	
7.3).	 This	 system	 is	 compromised	 by	 the	 Agr-triggered	 secretion	 of	 PSMα	 toxins,	 but	 the	 host	
environment	may	enhance	the	efficiency	of	this	system	by	suppressing	Agr	activity	and	providing	
phospholipid	precursors	 in	the	form	of	fatty	acids.	However,	additional	work	 identified	potential	













On	exposure	 to	nisin	or	melittin,	S.	aureus	 releases	phospholipids,	which	protect	 the	bacterium	
from	 the	 respective	 CAMPs.	 However,	 a	 major	 question	 is	 whether	 S.	 aureus	 releases	
phospholipids	in	response	to	host	defences	AMPs	such	as	LL-37	and	defensins,	and	does	released	
phospholipid	 inactivate	 these	 AMPs?	 It	 also	 remains	 to	 be	 determined	 whether	 host	 defence	



















inactivate	 daptomycin.	 This	 enables	 the	 agrA	 mutant	 to	 survive	 daptomycin	 exposure	 and	

















4. Is	 phospholipid	 release	 heterogeneous	 at	 the	 population	 level	 and	 how	 does	 this	 affect	
bacterial	survival?		





induced	 phospholipid-release	 (Fig	 4.11)	 and	 (Fig	 7.4).	 This	 is	 in	 agreement	 with	 previous	
transcriptomic	profiling	of	S.	 aureus,	which	 revealed	 that	daptomycin	 induces	 the	expression	of	
genes	associated	with	the	cell	wall	stress	stimulon,	regulated	by	VraUTRS111.		VraUTRS	is	activated	
in	response	to	damage	caused	by	cell	wall	and	cell	membrane	acting	antibiotics	and	antimicrobial	
peptides,	 including	 daptomycin,	 vancomycin,	 oxacillin	 and	 nisin611.	 Therefore,	 it	 is	 hypothesized	
that	 the	 VraUTRS	 system	 detects	 the	 presence	 of	 daptomycin	 and	 signals	 the	 release	 of	
membrane	 phospholipids.	 To	 test	 this	 hypothesis,	 and	 determine	 how	 VraUTRS	 modulates	
phospholipid	release,	the	following	experiments	are	proposed:	
a. The	 first	 objective	 would	 be	 to	 determine	 which	 components	 of	 the	 VraUTRS	 system	
contribute	 to	 daptomycin-induced	 phospholipid-release	 and	 the	 effects	 of	 clinically-relevant	
mutations	in	the	vra	operon.	For	example,	VISA	isolates	often	have	gain	of	function	mutations	
in	vraS	 or	vraR,	 leading	 to	 a	 constitutively	 active	 phenotype	 and	decreased	 susceptibility	 to	
vancomycin	 and	 daptomycin	 612.	 However,	 the	 effect	 of	 these	 mutations	 on	 phospholipid	
release	is	unclear.	The	USA300	ΔvraUTRS	mutant	would	be	complemented	with	plasmid	pCL55	
containing	either	 the	entire	vraUTRS	 operon,	or	mutated	versions	 lacking	each	of	 the	genes	
(ΔvraU,	ΔvraT,	ΔvraR,	ΔvraS),	under	the	control	of	the	native	promoter.	This	vector	inserts	as	a	
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single	 stable	 copy	 on	 the	 chromosome	 at	 the	 geh	 locus,	 removing	 the	 requirement	 for	
antibiotic	 selection	 that	 might	 confound	 subsequent	 experiments613,614.	 To	 determine	 the	
contribution	of	each	gene	within	the	vra	operon,	each	of	the	complemented	strains	would	be	
subjected	 to	 daptomycin-challenge	 and	 bacterial	 survival,	 phospholipid	 release	 and	
daptomycin	 inactivation	measured.	 Experiments	would	 be	 repeated	 in	 the	 SH1000	 strain	 to	
account	for	any	regulatory	variations	between	strains.		
b. If	 the	 Vra	 system	 is	 responsible	 for	 triggering	 phospholipid	 release,	 then	 activation	 of	 the	
CWSS	 should	 lead	 to	 phospholipid	 release.	 Therefore,	 the	 temporal	 relationship	 between	
induction	of	the	CWSS	by	daptomycin	and	phospholipid	release	would	be	determined.	CWSS	
induction	could	be	quantified	by	measuring	transcription	of	vraR	and/or	vraS	using	RT-PCR	at	
various	 times	 after	 exposure	 to	 daptomycin,	 and	 compared	 with	 measurements	 of	
phospholipid	in	the	culture	supernatant	at	identical	time	points111,612.			
c. Next,	 it	 would	 be	 determined	 whether	 activation	 of	 VraUTRS	 alone	 is	 sufficient	 for	
phospholipid	 release.	 As	 described	 above,	 several	 mutations	 in	 vraR	 or	 vraS	 have	 been	
identified	in	clinical	isolates	that	confer	a	constitutively	active	CWSS	phenotype	and	decreased	
susceptibility	to	daptomycin612.	Strains	containing	these	mutations	will	be	generated	and	used	






these	 could	 be	 placed	 under	 the	 control	 of	 an	 inducible	 promoter	 to	 enable	 them	 to	 be	
switched	off	during	assays.	For	example,	a	copy	of	the	respective	essential	gene	will	be	placed	






























The	 results	 in	 chapters	4	and	6	 show	 that	blocking	 lipid	metabolism	also	blocks	 lipid	 release.	 In	
addition,	 experiments	 indicated	 that	 S.	 aureus	 utilizes	 host-associated	 fatty	 acids	 to	 promote	
phospholipid	release	in	response	to	daptomycin	(chapter	6).	However,	it	is	not	clear	whether	the	
newly	synthesized	phospholipids	are	released.	The	data	do	show	that	at	least	some	of	the	released	
phospholipids	 existed	 prior	 to	 daptomycin	 challenge.	 However,	 this	 does	 not	 rule	 out	 the	
possibility	that	newly	synthesized	phospholipids	are	also	released	and	additional	experiments	are	
therefore	 needed	 to	 understand	 how	 phospholipids	 are	 released	 from	 the	 membrane.	 In	
particular,	
a. To	 determine	 whether	 any	 of	 the	 released	 phospholipid	 is	 newly	 synthesized,	 radiolabeled	
(C14)	oleic	acid	could	be	used	to	track	phospholipid	biogenesis	and	release.	Bacteria	could	be	





very	 little	 daptomycin.	 Future	 experiments	 will	 identify	 whether	 individual	 monomeric	
phospholipids	 are	 directly	 released	 or	 whether	 phospholipids	 are	 released	 as	 membrane	
vesicles	 that	 subsequently	 lyse	 (Fig	 7.5).	 This	 could	 be	 determined	 by	 performing	 the	 same	
daptomycin-induced	phospholipid	release	assay	(as	described	in	chapter	2)	but	in	in	hypertonic	
spheroplasting	buffer,	which	is	expected	to	prevent	lysis	of	vesicles.		
c. The	determination	of	whether	 phospholipids	 are	 released	 from	 the	membrane	 as	 individual	
phospholipids	or	as	vesicles	will	be	an	important	step	in	our	understanding	of	the	requirement	
of	 cell	wall	 rearrangement.	 If	 the	phospholipids	are	 released	 in	 the	 form	of	vesicles	 it	must,	
presumably,	 require	 either	 a	 pore	 (opening)	 in	 the	peptidoglycan	big	 enough	 for	 the	MV	 to	
pass	 through	 or	 change	 in	 cell	 wall	 thickness,	 both	 of	 which	 then	 requires	 cell	 wall	
rearrangement11	.	To	explore	this	further,	the	architecture	of	the	cell	wall,	and	the	emergence	






































Two	 key	 findings	 presented	 in	 this	 thesis	 indicate	 that	 cell	 wall	 biosynthesis	 modulates	
phospholipid	release:	 inhibition	of	phospholipid	release	by	oxacillin	and	the	requirement	for	the	
VraUTRS	system	for	maximal	phospholipid	release.	
a. Therefore,	 future	 work	 will	 determine	 whether	 VraUTSR/CWSS	 contributes	 to	 phospholipid	
release	 via	 its	 role	 in	 regulating	 cell	 wall	 biosynthesis.	 However,	 many	 VraUTSR-regulated	
genes	 are	 essential	 and	 cell	wall	 biosynthesis	 is	 complex.	 To	 untangle	 this,	 a	 large	 panel	 of	
specific	inhibitors	of	individual	PBPs	and	other	enzymes	involved	in	peptidoglycan	biosynthesis	
would	be	employed	525,618.	For	example,	we	will	use	a	panel	of	commercially	available	β-lactam	
antibiotics	 with	 specificity	 for	 each	 of	 the	 4	 PBPs	 to	 determine	 which	 are	 required	 for	
phospholipid-release619.	 Next,	 various	 inhibitors	 of	 other	 steps	 in	 cell	 wall	 biosynthesis,	
including	 fosfomycin,	 D-cycloserine,	 tunicamycin,	 bacitracin,	 flavomycin,	 vancomycin	 and	
teicoplanin	 could	 be	 used	 to	 identify	 the	 various	 stages	 of	 the	 cell	 wall	 synthesis	 that	 are	
required	 to	 enable	phospholipid	 release	 (Fig	 7.6)611,620.	 For	 this	 the	ΔagrA	mutant	would	be	
exposed	 to	 sub-inhibitory	 concentrations	 of	 the	 respective	 cell-wall	 inhibitors	 along	 with	
daptomycin	 for	 8	 h,	 as	 described	 for	 oxacillin,	 and	 the	 same	 phospholipid	 release	 assay	 (as	
described	in	chapter	2)	used	to	measure	phospholipid	release	in	response	to	daptomycin.	
b. In	addition	to	cell	wall	biosynthesis,	it	is	also	possible	that	cell	wall	is	degraded.	For	example,	












Together,	 these	 experiments	 will	 provide	 an	 understanding	 of	 how	 S.	 aureus	 detects	
daptomycin	through	the	CWSS	and	how	cell	wall	remodelling	contributes	to	phospholipid	release	
from	 the	membrane	 and	 through	 the	 cell	 wall	 in	 S.	 aureus.	 Studies	 with	 inhibitors	 of	 cell	 wall	
biosynthesis	 will	 provide	 mechanistic	 insight	 and	 may	 identify	 therapeutic	 approaches	 that	






Figure	 7.6.	 Schematic	 representation	 of	 the	 enzymatic	 steps	 involved	 in	 S.	 aureus	 cell	 wall	
synthesis	and	the	targets	of	cell	wall	active	antibiotics	
	(Adapted	 from	N	McCallum	2011	and	Pinho	2013)	 611,623.	Fosfomycin	 inhibits	 the	enzyme	MurA	
(UDP-N-acetylglucosamine-3-enolpyruvyl	 transferase)	 that	 catalyses	 the	 addition	 of	
phosphoenolpyruvate	(PEP)	to	UDP-N-acetyl-glucosamine	(GlcNAc)	to	form	UDP-N-acetyl-muramic	
acid	 (UDP-MurNAc).	 D-cycloserine	 prevents	 the	 addition	 of	 D-alanine	 to	 the	 peptidoglycan	
precursor	 by	 inhibiting	 D-alanine:D-alanine	 ligase	 A	 and	 alanine	 racemase.	 Tunicamycin	 is	 a	





the	 lipid	 carrier	 undecaprenyl	 pyrophosphate,	 thereby	 preventing	 dephosphorylation	 and	 the	
recycling	of	the	lipid	carrier	required	for	cell	wall	synthesis.	Flavomycin	(a	moenomycin	complex)	is	
a	 phosphoglycolipid	 antibiotic	 that	 inhibits	 transglycosylation	 through	 binding	 of	 the	
transglycosylase	 domain	of	 penicillin-binding	 protein	 2	 (PBP2).	Glycopeptide	 antibiotics,	 such	 as	
vancomycin	and	teicoplanin,	inhibit	cell	wall	synthesis	by	binding	the	D-ala-D-ala	of	the	lipid	II	and	
sterically	 hindering	 transglycosylation	 and	 transpeptidation.	 Teicoplanin	 activity	 is	 enhanced	
through	 its	 interaction	 with	 the	 cytoplasmic	 membrane.	 β-lactam	 antibiotics,	 such	 as	 oxacillin,	
bind	 the	 transpeptidase	 active	domain	of	 penicillin-binding	proteins	 (PBPs)	 by	mimicking	 the	D-






Upon	daptomycin	exposure,	>90%	of	 the	ΔagrA	bacterial	population	 is	killed,	but	 the	 remaining	






Similar	 to	 Silverman	 et	 al.,	 2011	 and	 Chen	 et	 al.,	 2014	 single	 cell	 time-lapse	
microscopy125,121,462	could	be	used	in	conjunction	with	a	microfluidic	system	(Zeiss	Axio	Observer,	
cell	asic	ONIX	available	at	the	FILM	facility,	Imperial	College).	Specifically,	the	S.	aureus	membrane	
will	 be	 stained	 with	 FM4-64	 (lipophilic	 dye),	 whilst	 fluorescently	 tagged	 fatty	 acids	 (Life	
Technologies)	could	be	used	to	track	lipid	metabolism.	Fluorescently	(BoDipy)	labeled	daptomycin	
could	be	used	to	detect	insertion	of	the	antibiotic	into	the	membrane	and	a	live/dead	stain	(Sytox	
green)	 could	be	used	 to	detect	which	bacteria	are	dead	or	alive.	 These	 techniques	and	kits	will	
















7.3.5 Can	 the	 information	 generated	 in	 this	 and	 future	 studies	 improve	 daptomycin	
treatment	outcomes?	
The	 mechanism	 by	 which	 phospholipid-release	 occurs	 provides	 opportunities	 for	 interventions	
that	 enhance	 the	 efficacy	 of	 daptomycin	 therapy.	 The	 data	 presented	 in	 this	 thesis	 support	
previous	 reports	 demonstrating	 synergy	 between	 daptomycin	 and	 β-lactam	 antibiotics,	 which	
target	 penicillin-binding	 proteins	 (PBPs)413,418.	 S.	 aureus	 encodes	 4	 PBPs,	 with	 MRSA	 strains	
additionally	 encoding	 PBP2a	 which	 has	 low	 affinity	 for	 β-lactam	 antibiotics24.	 Our	 experiments	
revealed	 an	 important	 role	 for	 PBP3,	 but	 not	 PBP4,	 in	 daptomycin-triggered	 lipid	 release.	 This	
explains	 why	 oxacillin,	 which	 inhibits	 the	 function	 of	 PBPs	 1-4	 (but	 not	 PBP2a),	 inhibits	
daptomycin-triggered	 phospholipid-release	 in	 MRSA,	 even	 though	 it	 cannot	 inhibit	 MRSA	
replication.	 The	 role	 of	 PBP3	 in	 phospholipid-release	 could	 be	 confirmed	 using	 clean	 deletion	
mutants	in	the	USA300	and	SH1000	strains,	and	complemented	strains	expressing	PBP3.		
Previous	work	 has	 implicated	 a	 role	 for	 PBP1	 in	 the	 synergistic	 action	 of	 β-lactams	 and	
daptomycin,	 which,	 together	 with	 our	 data	 showing	 a	 role	 for	 PBP3,	 indicate	 that	 cell	 wall	
remodeling	 is	 part	 of	 the	 staphylococcal	 response	 to	 daptomycin	 exposure35.	 This	 is	 in	 keeping	
with	a	study	of	the	transcriptional	response	of	S.	aureus	to	daptomycin,	which	showed	increased	
expression	of	several	genes	involved	in	peptidoglycan	biosynthesis135.		
β-lactam	 antibiotics	 appear	 to	 promote	 daptomycin	 activity	 by	 increasing	 the	 binding	 of	
the	 lipopetide	antibiotic	 to	the	staphylococcal	membrane413,418,502,526.	This	has	been	proposed	to	
occur	 via	 the	 modulation	 of	 surface	 charge	 by	 the	 β-lactam,	 enabling	 greater	 binding	 of	




An	 additional	 potential	 therapeutic	 approach	 arises	 from	 the	 growing	 interest	 in	








showing	that	phospholipid	release	 is	an	active	process	that	 is	 triggered	by	daptomycin	exposure	
and	 explains	 why	 it	 was	 completely	 inhibited	 by	 blocking	 protein	 synthesis	 or	 respiration.	
Therefore,	 the	 release	 of	 membrane	 lipid	 is	 not	 simply	 due	 to	 membrane	 disruption	 by	
daptomycin	 but	 the	 result	 of	 a	 complex	 and	 coordinated	 response	 by	 the	 bacterium	 to	 survive	
exposure	to	an	otherwise	lethal	antibiotic	challenge.		
In	summary	(Fig	7.8),	by	identifying	and	elucidating	this	phospholipid-release	response	to	














Figure	 7.8.	 S.	 aureus	 PBPs	 and	 the	 FAS	 II	 pathway	 are	 potential	 targets	 for	 adjunctive	
therapeutic	approaches	that	improve	daptomycin	efficacy		
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